[["index.html", "Rat DCIS study Chapter 1 Prerequisites 1.1 Packages and Software 1.2 External software 1.3 Annotations", " Rat DCIS study Anne Trinh 2020-12-30 Chapter 1 Prerequisites 1.1 Packages and Software The following packages are required to conduct the analyses described below. In house scripts are deposited in the rscript folder. library(AnnotationHub) library(biomaRt) library(Biostrings) library(colorspace) library(DESeq2) library(dplyr) library(DT) library(ensembldb) library(EnsDb.Hsapiens.v86) library(GenVisR) library(GenomicFeatures) library(ggplot2) library(gplots) library(GSEABase) library(GSVA) library(heatmap.plus) library(HTSanalyzeR2) library(kableExtra) library(limma) library(matrixStats) library(pamr) library(reshape2) library(RColorBrewer) library(scales) library(spatstat) library(tcR) library(vcfR) library(xlsx) library(writexl) DiffCols=hue_pal()(8) palette(brewer.pal(9, &quot;Set1&quot;)) RdBu=brewer.pal(11, &quot;RdBu&quot;) SetCols=brewer.pal(12, &quot;Set3&quot;) source(&quot;../rscript/cnFreq_fn.R&quot;) #modified version of GenVisR source(&quot;../rscript/merge_contig.R&quot;) source(&quot;../rscript/gseaCode.R&quot;) source(&quot;../rscript/ContingencyTable.R&quot;) source(&quot;../rscript/PvalueHeatMap.R&quot;) source(&quot;../rscript/BootstrapShannonIdx.R&quot;) #source(&quot;../rscript/CreateRnor87db.R&quot;) source(&quot;../rscript/FindRatAAHomolog.R&quot;) source(&quot;../rscript/OutputplotFun.R&quot;) firstup &lt;- function(x) { substr(x, 1, 1) &lt;- toupper(substr(x, 1, 1)) x } ColMerge=matrix(c(&quot;#FFC82F&quot;, &quot;#FFEDBC&quot;, &quot;#73FDFE&quot;,&quot;#D2FFFF&quot;, &quot;#FF41FF&quot;, &quot;#FECAFF&quot;, &quot;#5D5D5D&quot;, &quot;#BEBEBE&quot;), ncol=2, byrow = T) rownames(ColMerge)=c(&quot;LY&quot;,&quot;PDL1&quot;, &quot;PDL1+LY&quot;,&quot;Vehicle&quot;) ColSize=c(&quot;#008E00&quot;, &quot;#FF9300&quot;) names(ColSize)=c(&quot;small&quot;, &quot;big&quot;) ColSizeb=ColSize[2:1] Hsedb&lt;-EnsDb.Hsapiens.v86 1.2 External software The following external software was utilised: Software Function bwa Alignment of WGS data to reference GATK4 Mutation calling, done by NYGC. Mutation calling from RNA (Haplotype caller) strelka Mutation calling, done by NYGC BICseq CNV calling GEM3 create mappability files for CNV calling STAR Alignment of RNAseq data RSEM Calculate RSEM, TPM, FPKM from RNAseq data TRUST4 assignment of T and B cell clonotypes from RNA-seq data Oncotator Annotation of genetic variants QuPath Tool for cell segmentation and extraction of features from IF images samtools, bcftools querying and dispalying information from bam files, extracting allelic depth at specific genomic locations CIBERSORT inferring immune composition from RNA lumpy structural variants PAM50 code from parker et al 2009 to infer PAM50 subtypes 1.3 Annotations 1.3.1 Genomic properties Information on chromosome sizes, cytobands and centromere locations were obtained from the UCSC genome browser. The following annotation data for the hg19/b37/GRCh37 genome is required: Data Type Download link ref. genome http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/rn6.fa.gz refSeq annot http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/genes/rn6.refGene.gtf.gz refSeq annot http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/genes/rn6.ncbiRefSeq.gtf.gz gff3 file for TRUST4 (ftp://ftp.ensembl.org/pub/release-100/gff3/rattus_norvegicus/Rattus_norvegicus.Rnor_6.0.100.gff3.gz) gene lengths Extracted from GRCh37.75.gtf file from ensembl hg19cytoBand ucsc server of all cytoband locations chromosome sizes uscs genome browser biomart conversion between gene symbol, ensbl and entrez was faciliated using biomart package Below is the summary of chromosome sizes and centromere locations: ## chrom chromStart chromEnd name gieStain ## 1 chr1 0 10704345 p13 gneg ## 2 chr1 10704345 25618263 p12 gvar ## 3 chr1 25618263 40652454 p11 gneg ## 4 chr1 40652454 51356799 q11 gpos ## 5 chr1 51356799 73607402 q12 gneg ## 6 chr1 73607402 95016091 q21 gpos Create a TxDb object from a gtf file and save information: Not sure which version to use?? Below is an example of the gene annotation files ## GRanges object with 6 ranges and 2 metadata columns: ## seqnames ranges strand | gene_id gene_width ## &lt;Rle&gt; &lt;IRanges&gt; &lt;Rle&gt; | &lt;character&gt; &lt;integer&gt; ## Vom2r3 chr1 396700-409676 + | Vom2r3 12977 ## Lrp11 chr1 1702696-1731210 + | Lrp11 28515 ## Nup43 chr1 1771721-1781554 + | Nup43 9834 ## Lats1 chr1 1784078-1817310 + | Lats1 33233 ## Katna1 chr1 1826170-1867786 + | Katna1 41617 ## Ppil4 chr1 1897350-1930311 + | Ppil4 32962 ## ------- ## seqinfo: 22 sequences from an unspecified genome; no seqlengths 1.3.2 Gene name homologs between organisms Biomart was used to convert between rat, mouse and human gene symbols and ensembl ids. Below is an example of the human gene names mapped to the rat homolog Figure out what is required here for later analysis ## HGNC.symbol RGD.symbol ## 1 TAB1 Tab1 ## 2 PHF1 Phf1 ## 3 RNF39 Rnf39 ## 4 IGSF10 Igsf10 ## 5 TMEM130 Tmem130 ## 6 EFNB1 Efnb1 1.3.3 Gene signatures and data-bases Gene sets/signatures were obtained from the following sources: Source Description IEDB database of immune epitopes MsigDB c2, c5, hallmark set of curated pathway gene sets Metacore Process Networks and Pathway Maps data bases COSMIC database of concensus oncogenes ImmPort List of immune related genes InnateDB List of genes associated with innate immune system Rosenthal 2019 genes associated with MHC-I presentation Thorsson 2018 Immune gene signatures curated from studies by Wolf, Calabro, Teschendorff, Beck, Chang Pardoll, Wykes Immune checkpoint genes gil del alcazar 2017 Supplementary table 5: list of activation, dysfunction gene signatures Bailey 2018 List of 10 most comon tumor pathways Chang 2018 Common mutation locations in cancer The PAM50 signature was implemented using the scripts provided in supplementary from Parker et al 2010. These gene lists can be found in the annotations folder 1.3.3.1 Human gene homologs Below, lists of common mutations in cancer are loaded and the “homolog” in rat is determined using an in-house script. The steps involved are: determine the amino acid context in human (find 5 a.a. prior and after) find the region with most amino acid homology in rat (2 or less differences) check whether the amino acid of interest is present in rat An example of the output is shown ## Gene AAno AA1 Variant RatGene Sequence HumProt RatProt ## 1 NRAS 61 Q R Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 2 NRAS 61 Q K Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 3 NRAS 61 Q L Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 4 NRAS 61 Q H Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 5 NRAS 61 Q P Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 6 NRAS 61 Q * Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## RatAAno RatSequence ## 1 61 LDTAGQEEYSA ## 2 61 LDTAGQEEYSA ## 3 61 LDTAGQEEYSA ## 4 61 LDTAGQEEYSA ## 5 61 LDTAGQEEYSA ## 6 61 LDTAGQEEYSA 1.3.3.2 GSEA compendiums For pathway analysis, the c2 (pathway), Hallmark and c5 (Gene Ontology). In addition, metacore pathways (pathway maps and process networks) were obtained and loaded below. This gives a list of 7 different data-sets to interrogate CHECK: When GSVA is run, which input is required?? "],["cohort-summary.html", "Chapter 2 Cohort summary 2.1 Size information 2.2 Calculating growth rates 2.3 FACS data 2.4 Summary Table", " Chapter 2 Cohort summary Below we assess summary statistics on clinico-pathological features of this data set. This includes information on: treatment tumor size growth rates (mm/week) number of tumors per rat TumorID Rat_ID Batch Location Cohort Treatment Age.at.injection..days. Date.of.NMU.injection Date.when.tumor.was.first.palpated Date.Sacrificed Tumor.growth.status Time.NMU2Tumor Time.Tumor2Sac Time.NMU2Sac Tumor.dia..sac..mm. Growth2 Tumor.Histology X..CD45..by.FACS. X..DN..by.FACS. X..EpCAM..by.FACS. X..TILs..Histology. Intermixing.with.leukocytes PgR..IF. ER..IF. Nick.s.calls.Basal.Luminal DN.PgR_clust Ep.PgR_clust CD45.ER_clust DN.ER_clust Ep.ER_clust CD45.Ki67_clust DN.Ki67_clust Ep.Ki67_clust WGS CD45.RNA EpCAM.RNA DN.RNA RNA.seqSampleID FqFile.CD45 TRUSTName.CD45 AnyRNAdata starSampleName.CD45 FqFile.Ep TRUSTName.Ep starSampleName.Ep FqFile.DN TRUSTName.DN starSampleName.DN DN.PgRvsd Ep.PgRvsd DN.ERvsd Ep.ERvsd DN.Ki67vsd Ep.Ki67vsd DN.PAM50 Ep.PAM50 Image.Name Image.converted.for.qupath Matrix.available Comments.about.matrix CD8.are…Tumor.infiltrating.vs..stroma.restricted. InfiltratingVsRestricted GrowthRate CD8Fraction EpCAMFraction DPFraction SMAFraction UnclassFraction knnEpDist knnEpstrRatio knnEpAntstrRatio knnSMADist IFEpstrRatio IFEpAntstrRatio IFEpcam IFSMA MHEpstrRatio MHEpAntstrRatio MHEpcam MHSMA 10L_B 10L 2 B Progression PDL1 32-36 2018-02-14 2018-03-29 2018-05-04 growing 43 36 79 35.0 growing well differentiated mammary solid adenocarcinoma 15.2 75.7 8.59 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No Yes 10L_B_DN NA NA yes NA NA NA NA 20190213_47_CGDA6432-3of3_S1_R1_001.fastq.gz 20190213_47_CGDA6432-3of3_S1_R1_001_report.tsv DN_10L_B NA NA NA NA NA NA NA NA 10L PT B 5 HPC18-0971.mrxs 4channel_23samples YES NA Tumor infiltrating Infiltrating 6.2285714 0.0216413 0.2433985 0.1050166 0.3553565 0.2745871 47.98343 0.5529532 2.6586734 18.04789 0.2929498 0.3027004 0.0398611 0.1316849 0.4380387 0.7610091 0.4984859 0.6550328 10L_C 10L 3 C Progression PDL1 32-36 2018-02-14 2018-04-12 2018-05-04 growing 57 22 79 25.0 growing well differentiated mammary solid adenocarcinoma 51.4 35.6 12 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 10L_C_CD45 20191030_CD45_10LC_CGDA7427_S25_R1_001.fastq.gz 20191030_CD4510LC_report.tsv yes CD45_10LC NA NA NA 20191030_DN_10LC_CGDA7428_S8_R1_001.fastq.gz NA DN_10LC 7.117009 NA 7.187085 NA 7.857674 NA Normal NA 10L PT C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 5.3571429 0.0097353 0.2839173 0.1607107 0.3132420 0.2323947 35.79494 0.6400629 1.9373690 18.47606 0.5069034 0.6408978 0.0729492 0.1138234 0.4584403 0.9208043 0.5219795 0.5668735 10L_D 10L 2 D Progression PDL1 32-36 2018-02-14 2018-03-29 2018-05-04 stable 43 36 79 10.0 stable well differentiated mammary solid adenocarcinoma 49.8 39 13.5 NA NA Mod Neg B NA 3 NA NA 1 NA NA 1 No yes yes No 10L_D_CD45 20190213_25_CGDA6432-2of3_S1_R1_001.fastq.gz 20190213_25_CGDA6432-2of3_S1_R1_001_report.tsv yes CD45_10L_D 20190213_2_CGDA6432-1of3_S1_R1_001.fastq.gz 20190213_2_CGDA6432-1of3_S1_R1_001_report.tsv Ep_10L_D NA NA NA NA 10.582811 NA 9.189996 NA 7.256776 NA Normal 10L PT D-R+P.mrxs 2 halves: ?? Yes NA Tumor infiltrating Infiltrating 1.9729730 0.0655979 0.1706167 0.1711310 0.3895102 0.2031443 48.71052 0.7327214 2.8050670 17.36519 0.3019387 0.3560023 0.0541387 0.1520740 0.4949588 0.9038839 0.6730006 0.7445653 10N_A 10N NA A Progression PDL1 32-36 2018-02-14 2018-11-08 2018-11-15 no data (big) 267 7 274 12.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N A 1.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA stroma restricted and very few restricted NA 0.0459678 0.5442790 0.0000000 0.2818107 0.1279424 23.93511 0.8744548 0.8744548 27.37146 2.6345083 2.6345083 0.1028948 0.0390566 0.9265348 0.9265348 0.4968038 0.5361955 10N_D 10N NA D Progression PDL1 32-36 2018-02-14 2018-04-05 2018-11-15 stable 50 224 274 15.0 stable mucinous carcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N D-R+P.mrxs 2+3channel_57samples YES Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 0.3930533 0.0230218 0.4361433 0.0000000 0.3140889 0.2267460 138.52158 4.6320759 4.6320759 29.90486 2.0450368 2.0450368 0.0902820 0.0441469 1.1186318 1.1186318 0.4217567 0.3770291 10N3 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? FIBROADENOMA? NA NA NA 0.0829106 0.1239425 0.0580833 0.2563836 0.4786800 154.15707 0.4900419 2.5398923 60.69433 1.1238938 1.1651376 0.0118992 0.0102127 1.0178861 1.4905845 0.0720883 0.0483625 10R_BL 10R 2 BL Progression PDL1 32-36 2018-02-14 2018-04-02 2018-05-23 growing 47 51 98 40.0 growing well differentiated mammary solid adenocarcinoma 14.5 19.4 66.6 NA NA Not done Not done L 2 4 NA 1 2 NA 1 1 No yes yes Yes 10R_B_CD45 NA NA yes CD45_10R_B 20190213_3_CGDA6432-1of3_S2_R1_001.fastq.gz 20190213_3_CGDA6432-1of3_S2_R1_001_report.tsv Ep_10R_B 20190213_49_CGDA6432-3of3_S2_R1_001.fastq.gz 20190213_49_CGDA6432-3of3_S2_R1_001_report.tsv DN_10R_B 8.613963 12.034954 8.432534 10.180611 8.327953 7.376086 Basal LumA 10R PT -B4-R+P.mrxs NA Yes, named 10RB4 NA stroma restricted restricted 4.9761905 0.0193134 0.3240520 0.1402713 0.2479772 0.2683861 56.50503 0.5629225 2.7269413 20.72103 0.2613909 0.3191801 0.0627699 0.1966599 0.4976627 0.8998152 0.6177975 0.6865826 10R_BU 10R 3 BU Progression PDL1 32-36 2018-02-14 2018-04-02 2018-05-23 no data 47 51 98 12.0 NA well differentiated mammary solid adenocarcinoma 31.7 40.2 28.2 NA NA Not done Not done NA 2 4 NA 1 2 NA 2 2 No Yes No No 10R_BU_CD45 20191030_CD45_10RBU_CGDA7427_S26_R1_001.fastq.gz 20191030_CD4510RBU_report.tsv yes CD45_10RBU 20191030_Ep_10RBU_CGDA7428_S5_R1_001.fastq.gz NA Ep_10RBU 20191030_DN_10RBU_CGDA7428_S9_R1_001.fastq.gz NA DN_10RBU 9.329606 11.774760 7.241326 9.600055 9.275112 9.422135 Basal LumB 10R PT-B-R+P.mrxs 2+3channel_57samples Yes, named 10RB NA stroma restricted restricted NA 0.0642329 0.1525813 0.3099870 0.2752306 0.1979682 105.58406 0.8967735 4.8631868 21.71088 0.0749408 0.1209147 0.0134511 0.1112444 0.3812351 0.6630232 0.4059670 0.6122968 10R_C 10R NA C Progression PDL1 32-36 2018-02-14 2018-05-23 2018-05-23 no data (tiny) 98 0 98 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10R PT-C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” inflitrating Infiltrating NA 0.0384560 0.2909336 0.0262298 0.1399282 0.5044524 40.44271 0.2704214 0.9304911 43.46383 4.6458333 5.3095238 0.1041083 0.0196078 0.6639194 1.1406866 0.7291189 0.6391930 11L_B 11L 3 B Progression PDL1 32-36 2018-02-14 2018-04-19 2018-06-06 growing 64 48 112 25.0 growing well differentiated mammary solid adenocarcinoma 37.3 46.9 11.6 NA NA Not done Not done NA 4 4 NA 2 2 NA 1 1 No No No No 11L_B_CD45 20191030_CD45_11LB_CGDA7427_S27_R1_001.fastq.gz 20191030_CD4511LB_report.tsv yes CD45_11LB 20191030_Ep_11LB_CGDA7428_S6_R1_001.fastq.gz NA Ep_11LB 20191030_DN_11LB_CGDA7428_S10_R1_001.fastq.gz NA DN_11LB 11.344689 12.176955 9.049246 10.539352 8.293527 7.513111 LumA LumA 11L PT B-R+P.mrxs 2+3channel_57samples Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. No SMA Most are Stroma restricted but there are so many that a significant number still infiltrating NA 3.7857143 0.1491413 0.4449584 0.0000098 0.0001400 0.4057505 69.84563 0.0051785 0.0125865 5549.23417 NA NA 0.0464376 0.0000000 192.6326449 607.5145074 0.3284619 0.0005407 11N_D 11N 2 D Progression PDL1 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 3.0 stable well differentiated mammary solid adenocarcinoma 70.3 13.2 10.4 NA NA Mod Pos B NA 3 NA NA 2 NA NA 2 No yes yes No 11N_D_CD45 20190213_27_CGDA6432-2of3_S3_R1_001.fastq.gz 20190213_27_CGDA6432-2of3_S3_R1_001_report.tsv yes CD45_11N_D 20190213_4_CGDA6432-1of3_S3_R1_001.fastq.gz 20190213_4_CGDA6432-1of3_S3_R1_001_report.tsv Ep_11N_D NA NA NA NA 10.143842 NA 9.745793 NA 8.934701 NA Her2 11N Tumor B-R+P.mrxs pyramid Yes, labeled 11NB Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 0.1065574 0.3186158 0.3397687 0.0162144 0.0219573 0.3034436 31.54256 0.1502491 0.3503607 90.02883 61.3033708 136.4000000 0.1197831 0.0008782 0.8228057 1.8422338 0.7552033 0.4099389 11R_C 11R 3 C Progression PDL1 32-36 2018-02-14 2018-04-26 2018-06-06 growing 71 41 112 19.0 growing well differentiated mammary solid adenocarcinoma 23.8 32.5 42.3 NA NA Not done Not done NA 1 3 NA 1 2 NA 2 2 No No No No 11R_C_CD45 20191030_CD45_11RC_CGDA7427_S28_R1_001.fastq.gz 20191030_CD4511RC_report.tsv yes CD45_11RC 20191030_Ep_11RC_CGDA7428_S7_R1_001.fastq.gz NA Ep_11RC 20191030_DN_11RC_CGDA7428_S11_R1_001.fastq.gz NA DN_11RC 6.999032 10.625153 6.817717 8.839119 9.038043 8.565420 Basal Her2 11R PT C-R+P.mrxs NA Yes NA stroma restricted restricted 2.6785714 0.0508051 0.2919956 0.1634848 0.2119945 0.2817199 165.76133 0.6670125 2.4621673 67.32334 0.4583942 0.5395189 0.0072790 0.0134916 0.3825126 0.6480545 0.0493837 0.0762029 11R_D 11R 2 D Progression PDL1 32-36 2018-02-14 2018-04-26 2018-06-06 growing 71 41 112 25.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Pos Neg L 2 4 NA 1 2 NA 1 1 No yes yes Yes 11R_D_CD45 20190213_28_CGDA6432-2of3_S4_R1_001.fastq.gz 20190213_28_CGDA6432-2of3_S4_R1_001_report.tsv yes CD45_11R_D 20190213_5_CGDA6432-1of3_S4_R1_001.fastq.gz 20190213_5_CGDA6432-1of3_S4_R1_001_report.tsv Ep_11R_D 20190213_51_CGDA6432-3of3_S3_R1_001.fastq.gz 20190213_51_CGDA6432-3of3_S3_R1_001_report.tsv DN_11R_D 8.530865 11.988115 8.044929 9.983751 8.717588 7.792052 Her2 LumA 11R PT D-G.mrxs NA Yes NA stroma restricted restricted 3.6428571 0.0308077 0.2501905 0.1422258 0.2913907 0.2853853 156.56719 0.7624120 3.7083404 42.22028 0.4764464 0.5648426 0.0347075 0.0614463 0.4781256 0.8850004 0.1586241 0.1792362 12L_C 12L NA C Progression PDL1 32-36 2018-02-14 2018-05-14 2018-06-21 no data (tiny) 89 38 127 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12L Tumor C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” infiltrating Infiltrating NA 0.0846821 0.4423354 0.0120046 0.0102534 0.4507245 25.78770 0.0824443 0.1607888 160.38243 50.1250000 401.0000000 0.1337558 0.0003336 0.7834229 2.0172677 0.5858494 0.2904173 12L_D 12L 2 D Progression PDL1 32-36 2018-02-14 2018-05-14 2018-06-21 stable 89 38 127 6.0 stable well differentiated mammary solid adenocarcinoma 11.2 52 32.9 NA NA Mod Neg B 1 2 NA 1 2 NA 1 1 No No yes Yes 12L_D_DN NA NA yes NA 20190213_6_CGDA6432-1of3_S5_R1_001.fastq.gz 20190213_6_CGDA6432-1of3_S5_R1_001_report.tsv Ep_12L_D 20190213_52_CGDA6432-3of3_S4_R1_001.fastq.gz 20190213_52_CGDA6432-3of3_S4_R1_001_report.tsv DN_12L_D 6.662938 8.412817 7.735980 8.666475 7.050137 6.970116 Normal LumA 12L Tumor D-G.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 0.7702703 0.0214899 0.7100194 0.0107209 0.0020876 0.2556823 12.95364 0.0201820 0.0363766 356.09812 85.8571429 1202.0000000 0.3365062 0.0002800 2.2281795 4.2922100 0.8515853 0.1984025 12R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Stroma restricted restricted NA 0.0099449 0.0882340 0.0443608 0.1261992 0.7312612 392.54901 0.9521448 11.9409693 32.87413 0.5566038 0.6276596 0.0672748 0.1071836 0.3325371 0.5017665 0.2641628 0.5264656 12R3 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R 3.mrxs 4channel_23samples YES Normal? Fibroadenoma? NA NA NA 0.0205554 0.0373773 0.0240700 0.5097667 0.4082305 126.86753 0.7843815 8.4113651 15.08287 0.1322115 0.1348039 0.0279046 0.2070015 0.4508201 0.7568310 0.3490011 0.4611348 12N NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.0205510 0.0057682 0.2500734 0.5798918 0.1437157 619.20691 5.5566377 35.4889967 17.44786 0.0020619 0.0036145 0.0005422 0.1500090 0.1702894 0.3065013 0.0523020 0.1706420 13L NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.0180710 0.0042113 0.0960432 0.5240580 0.3576165 735.85177 1.6743701 38.6692751 19.02937 0.0000000 0.0000000 0.0000000 0.1843478 0.1783751 0.3611975 0.1248313 0.3456039 13R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.1387644 0.0038132 0.0644568 0.2184573 0.5745083 818.46797 1.0186965 2.9375809 278.61972 0.0031746 0.0041841 0.0001205 0.0288056 0.2855829 0.4521210 0.0702582 0.1553968 13N_A 13N NA A Progression Vehicle 32-36 2018-02-14 2018-06-22 2018-07-27 growing 128 35 163 35.0 growing well differentiated mammary solid adenocarcinoma 18.4 36.3 37.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13N Tumor A-R+P.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM Stroma restricted restricted 6.2000000 0.0446357 0.3224974 0.0000000 0.3481243 0.2847427 93.50342 3.8593214 3.8593214 24.22794 0.1822103 0.1822103 0.0228302 0.1252959 0.7305441 0.7305441 0.1996603 0.2733036 14L_A 14L NA A Progression PDL1+LY 32-36 2018-02-14 2018-03-29 2018-10-10 stable 43 195 238 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.4044118 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_B 14L NA B Progression PDL1+LY 32-36 2018-02-14 2018-07-26 2018-10-10 growing 162 76 238 40.0 stable well differentiated mammary solid adenocarcinoma 12.1 32.6 30 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.5062500 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_C 14L NA C Progression PDL1+LY 32-36 2018-02-14 2018-07-12 2018-10-10 stable 148 90 238 2.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.1111111 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_D 14L NA D Progression PDL1+LY 32-36 2018-02-14 2018-08-16 2018-10-10 growing 183 55 238 40.0 growing fibroadenoma 9.74 52.8 38 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5.9615385 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14N_B 14N 2 B Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-05-04 growing 78 1 79 23.0 growing well differentiated mammary solid adenocarcinoma 19.6 19.9 59.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 14N_B_CD45 20190213_30_CGDA6432-2of3_S5_R1_001.fastq.gz 20190213_30_CGDA6432-2of3_S5_R1_001_report.tsv yes CD45_14N_B NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14N PT-B-R+P.mrxs NA Yes NA stroma restricted restricted 3.3150685 0.1060734 0.2986938 0.0531320 0.1553705 0.3867304 122.53225 0.4386699 3.2716092 37.45320 1.2652266 1.3606245 0.0573083 0.0421191 0.5479543 0.8810063 0.4353135 0.4941094 14N_C 14N 2 C Progression PDL1+LY 32-36 2018-02-14 2018-04-05 2018-05-04 stable 50 29 79 6.0 stable well differentiated mammary solid adenocarcinoma 36.9 50.1 11.3 NA NA Pos Neg L 3 4 NA 1 2 NA 1 1 No yes yes Yes 14N_C_CD45 20190213_32_CGDA6432-2of3_S7_R1_001.fastq.gz 20190213_32_CGDA6432-2of3_S7_R1_001_report.tsv yes CD45_14N_C 20190213_9_CGDA6432-1of3_S7_R1_001.fastq.gz 20190213_9_CGDA6432-1of3_S7_R1_001_report.tsv Ep_14N_C 20190213_55_CGDA6432-3of3_S6_R1_001.fastq.gz 20190213_55_CGDA6432-3of3_S6_R1_001_report.tsv DN_14N_C 9.965040 11.775665 8.106844 9.947588 7.471002 6.942936 Normal LumA 14N PT C-G.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” mostly stroma restricted restricted 0.5595238 0.0541714 0.5292786 0.1241025 0.0824713 0.2099763 46.46409 0.3846863 1.0479289 44.33897 2.8177677 4.6856061 0.1044322 0.0222879 0.5104408 0.8515194 0.3279479 0.3851326 14N_D 14N 2 D Progression PDL1+LY 32-36 2018-02-14 2018-04-19 2018-05-04 stable 64 15 79 5.0 stable well differentiated mammary solid adenocarcinoma 25.3 49 24.8 NA NA Mod Neg L 2 3 NA 1 1 NA 1 1 No yes yes yes 14N_D_CD45 20190213_31_CGDA6432-2of3_S6_R1_001.fastq.gz 20190213_31_CGDA6432-2of3_S6_R1_001_report.tsv yes CD45_14N_D 20190213_8_CGDA6432-1of3_S6_R1_001.fastq.gz 20190213_8_CGDA6432-1of3_S6_R1_001_report.tsv Ep_14N_D 20190213_54_CGDA6432-3of3_S5_R1_001.fastq.gz 20190213_54_CGDA6432-3of3_S5_R1_001_report.tsv DN_14N_D 8.820322 10.143147 6.791405 8.714452 8.189546 7.545576 Normal Normal NA NA NA NA NA NA 0.7621622 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R_B 14R 2 B Progression PDL1+LY 32-36 2018-02-14 2018-05-07 2018-05-23 growing 82 16 98 35.0 growing well differentiated mammary solid adenocarcinoma 6.16 38.8 50.4 NA NA Pos Neg L 3 4 NA 1 2 NA 1 1 No No yes Yes 14R_B_DN NA NA yes NA 20190213_10_CGDA6432-1of3_S8_R1_001.fastq.gz 20190213_10_CGDA6432-1of3_S8_R1_001_report.tsv Ep_14R_B 20190213_56_CGDA6432-3of3_S7_R1_001.fastq.gz 20190213_56_CGDA6432-3of3_S7_R1_001_report.tsv DN_14R_B 10.204521 11.881851 8.644201 10.405372 8.056755 7.073204 Normal LumA NA NA NA NA NA NA 4.3298969 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R_D 14R NA D Progression PDL1+LY 32-36 2018-02-14 2018-04-02 2018-05-23 stable 47 51 98 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R PT D-r+p.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating but not many in general Infiltrating -0.1666667 0.0117970 0.4017020 0.0916170 0.1187684 0.3761156 48.85005 0.3375567 1.0789635 45.27498 2.9379310 5.7567568 0.1134790 0.0197123 0.8034234 1.6428080 0.6796239 0.4136965 15L_B 15L 3 B Progression PDL1+LY 32-36 2018-02-14 2018-04-19 2018-05-04 growing 64 15 79 10.0 growing well differentiated mammary solid adenocarcinoma 45.5 32.7 18.7 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 15L_B_CD45 20191030_CD45_15LB_CGDA7427_S29_R1_001.fastq.gz 20191030_CD4515LB_report.tsv yes CD45_15LB NA NA NA 20191030_DN_15LB_CGDA7428_S12_R1_001.fastq.gz NA DN_15LB 7.751602 NA 7.813059 NA 7.924340 NA Normal NA 15L PT-R+P.mrxs NA ? Maybe Yes? NA stroma restricted restricted 3.5000000 0.0111370 0.1847646 0.0390109 0.2710420 0.4940455 38.26745 0.3955776 1.8111846 21.12841 0.3194131 0.3286876 0.0397919 0.1210630 0.5137634 0.9076574 0.4808783 0.5298016 15N_C 15N 2 C Progression PDL1+LY 32-36 2018-02-14 2018-05-24 2018-06-06 growing 99 13 112 30.0 growing well differentiated mammary solid adenocarcinoma 14.8 39.9 44 NA NA Mod Neg B 1 2 NA 1 1 NA 2 2 No yes yes Yes 15N_C_CD45 20190213_34_CGDA6432-2of3_S8_R1_001.fastq.gz 20190213_34_CGDA6432-2of3_S8_R1_001_report.tsv yes CD45_15N_C 20190213_11_CGDA6432-1of3_S9_R1_001.fastq.gz 20190213_11_CGDA6432-1of3_S9_R1_001_report.tsv Ep_15N_C 20190213_57_CGDA6432-3of3_S8_R1_001.fastq.gz 20190213_57_CGDA6432-3of3_S8_R1_001_report.tsv DN_15N_C 7.547977 7.900689 6.751697 7.319210 9.623160 9.621462 Basal Basal NA NA NA NA NA NA 5.7142857 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N_C-D 15N NA C-D Progression PDL1+LY 32-36 2018-02-14 2018-05-17 2018-06-06 growing 92 20 112 22.0 growing fibroadenoma 7.25 65.1 26.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N PT C-D 1.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA Very few CD8. Stroma restricted. Fibroadenoma? restricted 2.6857143 0.0103478 0.2080159 0.0000000 0.2845617 0.4970746 50.23737 2.0409443 2.0409443 24.61477 0.2707581 0.2707581 0.0180375 0.0666186 0.9185654 0.9185654 0.5431117 0.5912608 15N_D 15N NA D Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-06-06 stable 78 34 112 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N PT D 7.mrxs 4channel_23samples YES NA infiltrating Infiltrating -0.2285714 0.0099611 0.3821704 0.0524684 0.1032245 0.4521756 16.37622 0.1782979 0.4342034 37.71556 4.1355932 4.5185185 0.1446354 0.0320095 0.4508831 0.9408380 0.6456409 0.6862402 15R_D 15R 3 D Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-06-06 growing 78 34 112 17.0 growing well differentiated mammary solid adenocarcinoma 27.4 42 29.8 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 15R_D_CD45 20191030_CD45_15RD_CGDA7427_S30_R1_001.fastq.gz 20191030_CD4515RD_report.tsv yes CD45_15RD NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15R PT D-R+P.mrxs NA Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. NA stroma restricted restricted 3.5000000 0.0323480 0.1453377 0.0000000 0.0000000 0.8223143 94.84958 NA NA NA NA NA 0.0363265 NA NA NA 0.4108967 NA 16L_A 16L NA A Progression PDL1+LY 32-36 2018-02-14 2018-07-24 2018-07-27 no data 160 3 163 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16L Tumor A-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Mostly stroma, few infiltrated Infiltrating NA 0.0166398 0.4115991 0.0000000 0.3636697 0.2080914 31.42735 1.6330629 1.6330629 19.24442 0.6585839 0.6585839 0.0553879 0.0841015 1.0170047 1.0170047 0.4230694 0.4159955 16L_C 16L 2 C Progression PDL1+LY 32-36 2018-02-14 2018-06-26 2018-07-27 stable 132 31 163 7.0 stable well differentiated mammary solid adenocarcinoma 61.7 23.1 13.7 NA NA Mod Neg L 3 3 NA 2 2 NA 1 2 No No yes Yes 16L_C_DN NA NA yes NA 20190213_12_CGDA6432-1of3_S10_R1_001.fastq.gz 20190213_12_CGDA6432-1of3_S10_R1_001_report.tsv Ep_16L_C 20190213_58_CGDA6432-3of3_S9_R1_001.fastq.gz 20190213_58_CGDA6432-3of3_S9_R1_001_report.tsv DN_16L_C 10.091019 10.755017 9.538591 9.806592 8.394353 8.999201 Basal LumB 16L Tumor C 8.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just EpCAM Infiltrating but not many Infiltrating 0.6475410 0.0469600 0.4689090 0.0000000 0.2466732 0.2374578 68.89330 1.0930529 1.0930529 63.02833 2.0740741 2.0740741 0.0580094 0.0279688 1.0344293 1.0344293 0.0707065 0.0683532 16L_D 16L 3 D Progression PDL1+LY 32-36 2018-02-14 2018-05-15 2018-07-27 stable 90 73 163 24.0 stable well differentiated mammary solid adenocarcinoma 40.5 27.1 30.7 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No Yes No No 16L_D_CD45 20191030_CD45_16LD_CGDA7427_S31_R1_001.fastq.gz 20191030_CD45_16LD_report.tsv yes CD45_16LD NA NA NA 20191030_DN_16LD_CGDA7428_S13_R1_001.fastq.gz NA DN_16LD 8.821280 NA 7.921996 NA 8.357876 NA LumB NA 16L Tumor D-P+R.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating 1.9151786 0.0316745 0.3473600 0.0000000 0.4037981 0.2171674 41.66245 2.0765619 2.0765619 20.06319 0.5758169 0.5758169 0.0535965 0.0930790 0.9892534 0.9892534 0.6194852 0.6262148 16N_D 16N NA D Progression PDL1 32-36 2018-02-14 2018-06-21 2018-10-04 stable 127 105 232 25.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16N D 2.mrxs 4channel_23samples YES NA infiltrating but not many Infiltrating 1.0745763 0.0739084 0.3661758 0.1285033 0.3156246 0.1157879 30.67905 0.4503144 1.1615878 26.41131 1.0666667 1.1207037 0.0490696 0.0437846 0.4746967 0.9025683 0.5277804 0.5847540 16R_C 16R NA C Progression PDL1 32-36 2018-02-14 2018-06-21 2018-08-16 growing 127 56 183 25.0 growing well differentiated mammary solid adenocarcinoma 9.83 47.7 36.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16R TC-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just EpCAM Infiltrating Infiltrating 2.4571429 0.1170018 0.3159351 0.0000000 0.1917937 0.3752694 221.63698 3.2526256 3.2526256 68.14094 3.5719844 3.5719844 0.0608229 0.0170278 0.6129173 0.6129173 0.0906911 0.1479662 16R_D 16R 3 D Progression PDL1 32-36 2018-02-14 2018-06-21 2018-08-16 stable 127 56 183 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 16R_D_DN NA NA yes NA NA NA NA 20191030_DN_16RD_CGDA7428_S14_R1_001.fastq.gz NA DN_16RD 7.072540 NA 6.593111 NA 6.844678 NA Normal NA 16R TD-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating -0.1027397 0.0286946 0.1882468 0.0000000 0.4877710 0.2952876 82.67478 4.7255313 4.7255313 17.49534 0.2398635 0.2398635 0.0417292 0.1739707 0.7958084 0.7958084 0.4223919 0.5307709 17N_A 17N 3 A Progression Vehicle 32-36 2018-02-14 2018-07-05 2018-08-02 growing 141 28 169 28.0 growing mucinous carcinoma 20.4 29.3 50 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 17N_A_CD45 20191030_CD45_17NA_CGDA7427_S32_R1_001.fastq.gz 20191030_CD4517NA_report.tsv yes CD45_17NA NA NA NA 20191030_DN_17NA_CGDA7428_S15_R1_001.fastq.gz NA DN_17NA 8.674888 NA 8.698166 NA 8.616739 NA Her2 NA 17N Tumor A-R+P.mrxs 2+3channel_57samples Yes Most double labeled are just SMA stroma restricted restricted 6.8000000 0.0472524 0.1755227 0.0000000 0.4965940 0.2806309 84.19668 3.6028136 3.6028136 23.36970 0.1795486 0.1795486 0.0130866 0.0728862 0.9607334 0.9607334 0.3762539 0.3916320 17N_B 17N NA B Progression Vehicle 32-36 2018-02-14 2018-05-31 2018-08-02 stable 106 63 169 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 17N_D 17N 2 D Progression Vehicle 32-36 2018-02-14 2018-08-02 2018-08-02 stable 169 0 169 4.0 stable well differentiated mammary solid adenocarcinoma 6.88 46.3 44.8 NA NA Mod Neg L 1 2 NA 1 2 NA 1 1 No No Yes Yes 17N_D_DN NA NA yes NA 20190213_13_CGDA6432-1of3_S11_R1_001.fastq.gz 20190213_13_CGDA6432-1of3_S11_R1_001_report.tsv Ep_17N_D 20190213_59_CGDA6432-3of3_S10_R1_001.fastq.gz 20190213_59_CGDA6432-3of3_S10_R1_001_report.tsv DN_17N_D 7.591882 9.226168 7.962199 9.216738 7.804626 8.113343 Normal LumB 17N Tumor D-R+P.mrxs 2+3channel_57samples Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating -0.3846154 0.0777472 0.3783436 0.0021022 0.0201337 0.5216733 20.41543 0.0608049 0.2082690 98.02435 58.5897436 63.4722222 0.1243131 0.0019585 0.9749741 1.6472614 0.8238693 0.5001448 17R_B 17R NA B Progression Vehicle 32-36 2018-02-14 2018-05-31 2018-06-21 growing 106 21 127 35.0 growing well differentiated mammary solid adenocarcinoma 4.35 18.4 67.1 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 17R tumor B 4 HPC18-1274.mrxs 4channel_23samples YES NA infiltrating Infiltrating 8.2142857 0.0420434 0.6431048 0.1132436 0.0512089 0.1503993 16.71597 0.0840295 0.1541792 108.41913 14.2179342 27.9598214 0.1334114 0.0047715 0.7859833 1.7123368 0.5027943 0.2936305 18LN2 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 18N 2.mrxs 4channel_23samples YES Normal? FIBROADENOMA? MOST DOUBLE LABELED IS EPCAM NA NA NA 0.0053220 0.3526985 0.0000000 0.3067915 0.3351880 21.58353 1.1172725 1.1172725 19.31805 1.5517241 1.5517241 0.2097902 0.1351981 0.9501550 0.9501550 0.4201287 0.4421686 18R4 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 18R 4.mrxs 4channel_23samples Yes Normal? Fibroadenoma? NA NA NA 0.0115088 0.1597988 0.1223603 0.3364584 0.3698738 41.14848 0.5683999 2.2633170 18.18061 0.3462604 0.3834356 0.0563825 0.1470456 0.5118961 0.9717001 0.4683674 0.4820081 1L_A 1L NA A Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-11-29 stable 169 119 288 17.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LA-R+P.mrxs NA Not done. No image found NA NA NA 0.9440338 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1N_A 1N NA A Progression PDL1+LY 32-36 2018-02-14 2018-09-20 2018-10-25 stable 218 35 253 10.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1.0571429 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1N_D 1N NA D Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-10-25 growing 169 84 253 29.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1.6774892 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1R_B 1R NA B Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-10-13 stable 169 72 241 15.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.7597403 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2N_ 2N 2 D Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-02 growing 47 30 77 47.0 growing well differentiated mammary solid adenocarcinoma 21.8 61.6 16.6 NA NA Not done Not done B 2 2 NA 1 2 NA 2 2 No yes yes Yes 2N__CD45 20190213_37_CGDA6432-2of3_S10_R1_001.fastq.gz 20190213_37_CGDA6432-2of3_S10_R1_001_report.tsv yes CD45_2N 20190213_14_CGDA6432-1of3_S12_R1_001.fastq.gz 20190213_14_CGDA6432-1of3_S12_R1_001_report.tsv Ep_2N 20190213_60_CGDA6432-3of3_S11_R1_001.fastq.gz 20190213_60_CGDA6432-3of3_S11_R1_001_report.tsv DN_2N 8.066863 9.152129 7.996903 9.590791 9.632986 9.256976 Basal Her2 2N PT-R+P.mrxs 4 parts: pyra, Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Stroma restricted restricted 11.7000000 0.0302046 0.3111043 0.0913614 0.1954502 0.3718795 50.57317 0.3958040 1.3934420 36.29371 1.0607350 1.2720703 0.0808353 0.0635462 0.6639386 1.1954598 0.4691640 0.3924548 2R_A 2R 3 A Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 20.0 growing well differentiated mammary solid adenocarcinoma 70.7 21.9 6.23 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 2R_A_CD45 20191030_CD45_2RA_CGDA7427_S33_R1_001.fastq.gz 20191030_CD452RA_report.tsv yes CD45_2RA NA NA NA 20191030_DN_2RA_CGDA7428_S16_R1_001.fastq.gz NA DN_2RA 8.797113 NA 8.326194 NA 7.149784 NA LumA NA 2R A Tumor-G-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Mostly stroma restricted restricted 3.5428571 0.0792751 0.3913913 0.0023491 0.0461938 0.4807907 46.05918 0.0711163 0.3568518 129.07088 16.0205128 16.1865285 0.1252656 0.0077389 1.6375694 1.8864816 0.6503756 0.3447559 2R_C 2R 3 C Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 15.0 growing well differentiated mammary solid adenocarcinoma 73.5 19.2 5.23 NA NA Not done Not done NA 3 NA NA 2 NA NA 2 NA No No No No 2R_C_CD45 20191030_CD45_2RC_CGDA7427_S34_R1_001.fastq.gz 20191030_CD452RC_report.tsv yes CD45_2RC NA NA NA 20191030_DN_2RC_CGDA7428_S17_R1_001.fastq.gz NA DN_2RC 9.942308 NA 8.425529 NA 9.122072 NA Normal NA NA NA NA NA NA NA 15.0000000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2R_D 2R 3 D Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA 1 NA NA 1 NA NA 2 NA No No No No 2R_D_CD45 20191030_CD45_2RD_CGDA7427_S35_R1_001.fastq.gz 20191030_CD452RD_report.tsv yes CD45_2RD NA NA NA 20191030_DN_2RD_CGDA7428_S18_R1_001.fastq.gz NA DN_2RD 5.350711 NA 5.009788 NA 9.397333 NA LumB NA 2R D Tumor-R+P.mrxs 1 Yes NA stroma restricted restricted 20.0000000 0.0679470 0.2390803 0.1098166 0.1748265 0.4083295 44.01575 0.4204195 1.5995029 27.51839 0.5629272 1.0971787 0.0440127 0.0401144 0.6003194 1.0687599 0.6926679 0.6481043 3L_A 3L 3 A Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-05-09 growing 78 6 84 12.0 growing well differentiated mammary solid adenocarcinoma 12.5 80.9 4.21 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 3L_A_CD45 20191030_CD45_3LA_CGDA7427_S36_R1_001.fastq.gz 20191030_CD453LA_report.tsv yes CD45_3LA NA NA NA 20191030_DN_3LA_CGDA7428_S19_R1_001.fastq.gz NA DN_3LA 9.096221 NA 8.344281 NA 7.622097 NA LumB NA 3L A Tumor-R+P.mrxs ROItoobig Yes NA stroma restricted restricted 3.0000000 0.0534346 0.3906121 0.1457996 0.0987689 0.3113848 50.81349 0.2904539 0.7622396 66.66341 4.3657787 14.2508361 0.0498829 0.0035004 0.5568064 1.1134545 0.4487909 0.4030617 3L_D 3L 2 D Progression Vehicle 32-36 2018-02-14 2018-04-05 2018-05-09 growing 50 34 84 30.0 growing fibroadenoma 26.2 69.6 2.55 NA NA Not done Not done NA 1 NA NA 1 NA NA 2 NA No yes No Yes 3L_D_CD45 20190213_38_CGDA6432-2of3_S11_R1_001.fastq.gz 20190213_38_CGDA6432-2of3_S11_R1_001_report.tsv yes CD45_3L_D NA NA NA 20190213_61_CGDA6432-3of3_S12_R1_001.fastq.gz 20190213_61_CGDA6432-3of3_S12_R1_001_report.tsv DN_3L_D 5.440199 NA 9.034759 NA 9.112564 NA LumB NA 3L D Tumor-R+P.mrxs 1 Yes weird. Fibroadenoma? stroma restricted restricted 5.8000000 0.1693800 0.0011329 0.0035403 0.0894314 0.7365153 1469.94759 1.0674643 18.5061923 79.43004 0.0000000 0.0000000 0.0000000 0.0021676 0.0560487 0.0631333 0.0299087 0.4737395 3N_B 3N 2 B Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 6.0 stable well differentiated mammary solid adenocarcinoma 24.4 44.5 25.3 NA NA Mod Positive B 1 3 NA 1 2 NA 1 1 No yes yes Yes 3N_B_CD45 20190213_39_CGDA6432-2of3_S12_R1_001.fastq.gz 20190213_39_CGDA6432-2of3_S12_R1_001_report.tsv yes CD45_3N_B 20190213_16_CGDA6432-1of3_S13_R1_001.fastq.gz 20190213_16_CGDA6432-1of3_S13_R1_001_report.tsv Ep_3N_B 20190213_62_CGDA6432-3of3_S13_R1_001.fastq.gz 20190213_62_CGDA6432-3of3_S13_R1_001_report.tsv DN_3N_B 6.153223 9.699559 6.446680 9.988743 6.908861 8.314425 Normal LumA 3N Tumor B-R+P.mrxs 1 Yes Most double labeled SMA:EpCAM is really just EpCAM Infiltrating Infiltrating 0.0245902 0.2436148 0.4279583 0.0000000 0.0430856 0.2853413 35.85117 0.5736141 0.5736141 62.50051 32.4685714 32.4685714 0.1089340 0.0033551 1.1898543 1.1898543 0.7272775 0.6112324 3N_D 3N NA D Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 3N Tumor D 1.mrxs 4channel_23samples Yes NA Tumor infiltrating Infiltrating -0.1516393 0.0275129 0.4057772 0.1214179 0.1169171 0.3283749 14.88177 0.2404611 0.4350742 34.20513 6.7187500 8.6000000 0.1987061 0.0231054 0.6448255 1.4608243 0.8101682 0.5545966 3R_B 3R 3 B Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-09 growing 47 37 84 35.0 growing well differentiated mammary solid adenocarcinoma 29.7 65.2 3.17 NA NA Not done Not done NA 2 NA NA 2 NA NA 1 NA No No No No 3R_B_CD45 20191030_CD45_3RB_CGDA7427_S37_R1_001.fastq.gz 20191030_CD453RB_report.tsv yes CD45_3RB NA NA NA 20191030_DN_3RB_CGDA7428_S20_R1_001.fastq.gz NA DN_3RB 9.076911 NA 10.222521 NA 7.726099 NA LumA NA 3R B.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just SMA Stroma restricted restricted 7.6857143 0.0271596 0.4290121 0.0000000 0.3780280 0.1658003 45.06497 1.5134520 1.5134520 29.77628 0.8008086 0.8008086 0.0650665 0.0812510 0.8697861 0.8697861 0.4830709 0.5553905 3R_C 3R 2 C Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-09 growing 47 37 84 32.0 growing well differentiated mammary solid adenocarcinoma 39.4 40.2 17 NA NA Pos Pos L 2 3 NA 2 2 NA 1 1 No yes yes Yes 3R_C_CD45 20190213_40_CGDA6432-2of3_S13_R1_001.fastq.gz 20190213_40_CGDA6432-2of3_S13_R1_001_report.tsv yes CD45_3R_C 20190213_17_CGDA6432-1of3_S14_R1_001.fastq.gz 20190213_17_CGDA6432-1of3_S14_R1_001_report.tsv Ep_3R_C 20190213_63_CGDA6432-3of3_S14_R1_001.fastq.gz 20190213_63_CGDA6432-3of3_S14_R1_001_report.tsv DN_3R_C 9.008625 10.467371 10.300376 12.200748 6.971775 7.061798 LumA LumA 3R C Tumor-r+p.mrxs 4channel_23samples Yes NA Tumor infiltrating but not many in general Infiltrating 5.5428571 0.0213619 0.3557497 0.1060803 0.1396821 0.3771261 34.19778 0.3536028 0.8841226 38.67991 1.3763636 1.7811765 0.0642778 0.0360873 0.4779858 0.8983180 0.5405923 0.6017828 4L2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4L_2.mrxs 4channel_23samples Yes normal? Fibroadenoma? NA NA NA 0.0107261 0.0949610 0.0413567 0.3647135 0.4882427 61.55198 0.3730199 2.8810690 21.36429 0.4808081 0.5207877 0.0827538 0.1589013 0.5017400 0.9985155 0.5085118 0.5092678 4L_B 4L 3 B Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 35.0 growing well differentiated mammary solid adenocarcinoma 1.64 11.5 81.6 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 4L_B_CD45 20191030_CD45_4LB_CGDA7427_S38_R1_001.fastq.gz 20191030_CD454LB_report.tsv yes CD45_4LB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4L Tumor-R+P.mrxs Too large Yes NA Infiltrating Infiltrating 6.8783784 0.0231318 0.2915087 0.0843215 0.1479126 0.4531254 64.74914 0.4531535 2.0830003 31.08456 1.0044357 1.2923272 0.0439035 0.0339724 0.5341282 0.9817225 0.5635765 0.5740691 4N_C 4N 3 C Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 15.0 growing well differentiated mammary solid adenocarcinoma 4.86 41.3 51.2 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 4N_C_DN NA NA yes NA NA NA NA 20191030_DN_4NC_CGDA7428_S21_R1_001.fastq.gz NA DN_4NC 7.450232 NA 6.897643 NA 6.834431 NA Normal NA 4N T C-R+P.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM stroma restricted and very few restricted 3.0000000 0.0082696 0.6904486 0.0000000 0.1998705 0.1014113 17.41818 0.5857194 0.5857194 29.73810 5.6067416 5.6067416 0.1988048 0.0354582 1.1566551 1.1566551 0.1225326 0.1059371 4N_D 4N NA D Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4N Tumor D-R+P.mrxs 2+3channel_57samples Yes Most double labeled are just SMA Infiltrated but very few Infiltrating 4.3000000 0.0075226 0.3686144 0.0000000 0.4966413 0.1272217 19.31346 1.4696949 1.4696949 13.14114 0.6537143 0.6537143 0.2808740 0.4296587 0.9496026 0.9496026 0.6621314 0.6972721 4R_B 4R NA B Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 40.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4R Tumor B-R+P.mrxs NA Yes NA stroma restricted and very few restricted 7.8108108 0.0264206 0.2628547 0.1375470 0.2123231 0.3608546 77.05475 0.6163713 3.0155708 25.55229 0.3088124 0.3725370 0.0303672 0.0815145 0.4637185 0.7595255 0.3659895 0.4818660 4R_C 4R NA C Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 15.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4.0000000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5L_A 5L NA A Progression Vehicle 32-36 2018-02-14 2018-10-03 2018-10-24 no data 231 21 252 6.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLA-R+P.pyramid.ome.tif 2+3channel_57samples Yes Most double labeled are just SMA. Use bottom half Infiltrating Infiltrating 0.5000000 0.0499837 0.3211756 0.0000000 0.4594575 0.1693832 88.34088 5.1585539 5.1585539 17.12513 0.3129039 0.3129039 0.0410479 0.1311839 0.7586228 0.7586228 0.3676234 0.4845931 5L_B 5L NA B Progression Vehicle 32-36 2018-02-14 2018-10-17 2018-10-24 no data 245 7 252 4.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLB-R+P.pyramid.ome.tif 2+3channel_57samples Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. Use bottom half Stroma restricted restricted 4.0000000 0.0264844 0.4379465 0.0000000 0.0000000 0.5355691 49.82563 NA NA NA NA NA 0.0764733 NA NA NA 0.5132992 NA 5L_C 5L NA C Progression Vehicle 32-36 2018-02-14 2018-10-03 2018-10-24 growing 231 21 252 22.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLC-R+P.pyramid.ome.tif 2+3channel_57samples Yes Most double labeled are just SMA. There is potentially bleached area on top third. Best to ignore stroma restricted restricted 3.5000000 0.0534633 0.2774943 0.0000000 0.4679598 0.2010826 69.06072 2.9381168 2.9381168 23.50510 0.2242609 0.2242609 0.0236657 0.1055275 0.5228379 0.5228379 0.2228294 0.4261921 5L_D 5L NA D Progression Vehicle 32-36 2018-02-14 2018-06-06 2018-10-24 stable 112 140 252 15.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLD 8.mrxs 4channel_23samples: currently converting Yes Bad fragmentation and classification. Avoid if possible stroma restricted restricted 0.9299769 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5N_A 5N 3 A Progression Vehicle 32-36 2018-02-14 2018-06-07 2018-06-29 growing 113 22 135 26.0 growing mucinous carcinoma 31 24.1 42.2 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 5N_A_CD45 20191030_CD45_5NA_CGDA7427_S39_R1_001.fastq.gz 20191030_CD455NA_report.tsv yes CD45_5NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5N-A Tumor 4.mrxs 4channel_23samples Yes Most double labeled are just Epcam stroma restricted restricted 5.4285714 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5R_B 5R 3 B Progression Vehicle 32-36 2018-02-14 2018-06-07 2018-06-29 growing 113 22 135 35.0 growing well differentiated mammary solid adenocarcinoma 8.93 20.2 65.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 5R_B_CD45 20191030_CD45_5RB_CGDA7427_S40_R1_001.fastq.gz 20191030_CD455RB_report.tsv yes CD45_5RB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5R-B tumor 6 HPC18-1644.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 10.3571429 0.0606622 0.3335444 0.0000000 0.4396765 0.1661169 42.71834 1.8873247 1.8873247 22.63434 0.2646211 0.2646211 0.0250896 0.0948132 0.8555603 0.8555603 0.4794061 0.5603418 6L_DL 6L NA DL Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-06-29 stable 43 92 135 0.0 stable NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.2374720 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6L_DU 6L NA DU Progression LY 32-36 2018-02-14 2018-03-29 2018-06-29 growing 43 92 135 32.0 growing well differentiated mammary solid adenocarcinoma 12.3 34.1 46.6 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6L-D Tumor-R+P.mrxs NA Yes? Maybe? Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 2.1974522 0.0564756 0.2536569 0.0000000 0.6390098 0.0508577 113.21745 5.2279784 5.2279784 21.65607 0.1039889 0.1039889 0.0228854 0.2200758 0.5244385 0.5244385 0.2875550 0.5483102 6N_D 6N 2 D Progression LY 32-36 2018-02-14 2018-04-02 2018-04-10 growing 47 8 55 40.0 growing well differentiated mammary solid adenocarcinoma 6.85 41 54.1 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 6N_D_CD45 20190213_41_CGDA6432-2of3_S14_R1_001.fastq.gz 20190213_41_CGDA6432-2of3_S14_R1_001_report.tsv yes CD45_6N_D NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6N tumor 4 HPC18-0751.mrxs 4channel_23samples Done. Raw matrix saved NA stroma restricted NA 30.0000000 0.0993318 0.4011496 0.0890823 0.2404363 0.1700000 121.66730 0.4694938 2.8771741 42.28708 1.4519153 1.5049422 0.0355995 0.0236551 0.4830465 0.9118512 0.3459035 0.3793420 6R_B 6R 2 B Progression LY 32-36 2018-02-14 2018-03-29 2018-05-04 stable 43 36 79 18.0 growing well differentiated mammary solid adenocarcinoma 61.1 31.1 6.12 NA NA Pos Pos B 3 3 NA 2 2 NA 1 1 No No yes Yes 6R_B_DN NA NA yes NA 20190213_20_CGDA6432-1of3_S15_R1_001.fastq.gz 20190213_20_CGDA6432-1of3_S15_R1_001_report.tsv Ep_6R_B 20190213_66_CGDA6432-3of3_S15_R1_001.fastq.gz 20190213_66_CGDA6432-3of3_S15_R1_001_report.tsv DN_6R_B 10.169492 10.344437 8.781685 8.969722 7.522004 6.177675 LumA LumA 6R PT B-G.mrxs extract error? Yes, did this matrix disappear? Resaved Most double labeled are just Epcam inflitrating Infiltrating 2.8000000 0.1333593 0.1493153 0.0000000 0.4420708 0.2752545 91.50034 5.5053405 5.5053405 16.62029 0.1220465 0.1220465 0.0299516 0.2454114 0.7830649 0.7830649 0.6100782 0.7790902 6R_C 6R 2 C Progression LY 32-36 2018-02-14 2018-04-19 2018-05-04 growing 64 15 79 40.0 growing well differentiated mammary solid adenocarcinoma 27.2 63.7 11.9 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 6R_C_CD45 20190213_42_CGDA6432-2of3_S15_R1_001.fastq.gz 20190213_42_CGDA6432-2of3_S15_R1_001_report.tsv yes CD45_6R_C NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6R PT C 5.mrxs 4channel_23samples YES NA Stroma restricted restricted 8.2142857 0.0864989 0.2319101 0.1109560 0.3706485 0.1999864 72.49339 0.6029672 2.4881180 29.13583 0.2374418 0.2434573 0.0258498 0.1061780 0.4298154 0.7701881 0.5206863 0.6760508 6R_D 6R 3 D Progression LY 32-36 2018-02-14 2018-04-20 2018-05-04 stable 65 14 79 6.0 stable well differentiated mammary solid adenocarcinoma 80.8 11.1 6.61 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No Yes No Yes 6R_D_CD45 20191030_CD45_6RD_CGDA7427_S41_R1_001.fastq.gz 20191030_CD456RD_report.tsv yes CD45_6RD NA NA NA 20191030_DN_6RD_CGDA7428_S22_R1_001.fastq.gz NA DN_6RD 8.417325 NA 7.236626 NA 6.312630 NA Normal NA NA NA NA NA NA NA 1.2857143 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7L_C 7L NA C Progression LY 32-36 2018-02-14 2018-06-14 2018-10-10 growing 120 118 238 40.0 growing fibroadenoma 4.66 72.3 20.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4.7750000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7L_D 7L NA D Progression LY 32-36 2018-02-14 2018-04-05 2018-10-10 stable 50 188 238 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.1235236 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N_A 7N 2 A Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 stable 120 43 163 30.0 growing well differentiated mammary solid adenocarcinoma 23.7 33.2 40 NA NA Mod Neg B NA 3 NA NA 2 NA NA 1 No yes yes No 7N_A_CD45 20190213_44_CGDA6432-2of3_S16_R1_001.fastq.gz 20190213_44_CGDA6432-2of3_S16_R1_001_report.tsv yes CD45_7N_A 20190213_21_CGDA6432-1of3_S16_R1_001.fastq.gz 20190213_21_CGDA6432-1of3_S16_R1_001_report.tsv Ep_7N_A NA NA NA NA 9.661717 NA 10.411145 NA 7.660148 NA Her2 NA NA NA NA NA NA 2.3555556 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N_B 7N 3 B Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 growing 120 43 163 31.0 growing well differentiated mammary solid adenocarcinoma 30.4 49.4 14.9 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No Yes No No 7N_B_CD45 20191030_CD45_7NB_CGDA7427_S42_R1_001.fastq.gz 20191030_CD457NB_report.tsv yes CD45_7NB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N tumor B-P+R.mrxs ROItoobig Yes Most double labeled are SMA stroma restricted restricted 2.8878505 0.0197097 0.2490162 0.0000000 0.3294001 0.4018740 84.92436 3.6566527 3.6566527 23.22462 0.1224769 0.1224769 0.0107935 0.0881271 0.5880665 0.5880665 0.2129967 0.3621983 7N_C 7N NA C Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 growing 120 43 163 40.0 growing well differentiated mammary solid adenocarcinoma 13.2 40 43.5 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N tumor C-R+P.mrxs NA Yes Most double labeled are SMA stroma restricted restricted 3.4444444 0.0463236 0.1346398 0.0000000 0.7110174 0.1080192 92.31737 4.9228872 4.9228872 18.75269 0.0537130 0.0537130 0.0072339 0.1346774 0.6417327 0.6417327 0.2326071 0.3624673 7N_D 7N NA D Progression LY 32-36 2018-02-14 2018-05-03 2018-07-27 stable 78 85 163 0.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N Tumor D-R+P.mrxs NA QC fail Poor fragmentation. No matrix. Fibroadenoma? NA NA -0.4041667 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7R_A 7R NA A Progression LY 32-36 2018-02-14 2018-09-06 2018-10-04 stable 204 28 232 8.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RA 1.mrxs 4channel_23samples YES NA Stroma restricted. restricted 1.1153846 0.0317495 0.2214839 0.1816895 0.3343786 0.2306985 39.38134 0.6286412 2.2497090 17.50508 0.2502672 0.2841323 0.0233445 0.0821607 0.4579687 0.8736315 0.4487517 0.5136625 7R_B 7R NA B Progression LY 32-36 2018-02-14 2018-09-06 2018-10-04 growing 204 28 232 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RB-R+P.mrxs NA Yes NA No leukocytes NA 3.9615385 0.0166350 0.1950950 0.5054210 0.1375849 0.1452641 43.57347 0.9030164 1.5733647 27.69445 0.0894722 0.7731707 0.0130378 0.0168627 0.5098294 1.1129001 0.7558650 0.6791850 7R_D 7R NA D Progression LY 32-36 2018-02-14 2018-04-26 2018-10-04 stable 71 161 232 20.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RD-R+P.mrxs NA Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating 0.9966997 0.0323655 0.2446566 0.0000000 0.5631544 0.1598235 50.83112 3.5481404 3.5481404 14.32613 0.2462187 0.2462187 0.0444639 0.1805868 0.7886489 0.7886489 0.4171900 0.5289933 8L_D 8L 2 D Progression LY 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 6.0 stable well differentiated mammary solid adenocarcinoma 34.6 43.4 16.5 NA NA Pos Pos B NA 3 NA NA 2 NA NA 1 No yes yes No 8L_D_CD45 20190213_45_CGDA6432-2of3_S17_R1_001.fastq.gz 20190213_45_CGDA6432-2of3_S17_R1_001_report.tsv yes CD45_8L_D 20190213_22_CGDA6432-1of3_S17_R1_001.fastq.gz 20190213_22_CGDA6432-1of3_S17_R1_001_report.tsv Ep_8L_D NA NA NA NA 10.122925 NA 9.544170 NA 3.153971 NA LumA 8L Tumor D-R+P.mrxs extract error? Yes USE bottom half Infiltrating Infiltrating 0.2418033 0.0538574 0.5599011 0.0020168 0.0043954 0.3798293 17.23622 0.0274629 0.0602517 286.07024 749.5000000 749.5000000 0.1864892 0.0002488 1.4730487 2.9839286 0.7792160 0.2611376 8R_CL 8R 3 CL Progression LY 32-36 2018-02-14 2018-06-20 2018-06-21 growing 126 1 127 12.0 growing well differentiated mammary solid adenocarcinoma 31.8 32.3 29.8 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No Yes No Yes 8R_CL_CD45 20191030_CD45_8RCL_CGDA7427_S43_R1_001.fastq.gz 20191030_CD458RCL_report.tsv yes CD45_8RCL NA NA NA 20191030_DN_8RCL_CGDA7428_S23_R1_001.fastq.gz NA DN_8RCL 7.489866 NA 6.690138 NA 7.658753 NA Normal NA 8R Tumor CL-1 5.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA stroma restricted restricted 12.0000000 0.0161679 0.5067175 0.0000000 0.2719489 0.2051657 15.61440 0.4269370 0.4269370 36.57309 1.7398649 1.7398649 0.1124700 0.0646429 1.3216443 1.3216443 0.8006283 0.6057820 8R_CU 8R 2 CU Progression LY 32-36 2018-02-14 2018-05-14 2018-06-21 growing 89 38 127 27.0 growing well differentiated mammary solid adenocarcinoma 9.79 29.7 55.7 NA NA Pos Pos B 2 2 NA 1 1 NA 2 2 No yes yes Yes 8R_CU_CD45 20190213_46_CGDA6432-2of3_S18_R1_001.fastq.gz 20190213_46_CGDA6432-2of3_S18_R1_001_report.tsv yes CD45_8R_CU 20190213_23_CGDA6432-1of3_S18_R1_001.fastq.gz 20190213_23_CGDA6432-1of3_S18_R1_001_report.tsv Ep_8R_CU 20190213_69_CGDA6432-3of3_S16_R1_001.fastq.gz 20190213_69_CGDA6432-3of3_S16_R1_001_report.tsv DN_8R_CU 8.636364 9.218367 7.482100 8.499153 9.396025 9.515202 Basal Basal 8R Tumor CU-R+P.mrxs ROItoobig Yes Most double labeled SMA:EpCAM is really just SMA stroma restricted restricted 5.5142857 0.0285043 0.2510430 0.0000000 0.5074442 0.2130085 57.96393 2.3659458 2.3659458 24.49926 0.3686127 0.3686127 0.0355496 0.0964415 1.0299044 1.0299044 0.5045609 0.4899104 9N NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9N-R+P.pyramid.ome.tif 2+3channel_57samples Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples infiltrating Infiltrating NA 0.0281318 0.0527279 0.2718778 0.3041077 0.3431548 122.14151 1.6230379 4.6141243 26.47122 0.0257210 0.0633397 0.0045181 0.0713308 0.3342252 0.6758403 0.2248600 0.3327118 9R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9R-R+P.pyramid.ome.tif 2+3channel_57samples Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples stroma NA NA 0.0264824 0.1126289 0.0427425 0.0579105 0.7602357 116.40815 0.6781596 1.8294927 63.62865 2.5185185 3.6266667 0.0790009 0.0217833 0.4442082 0.7932739 0.4431065 0.5585794 9L_A 9L 3 A Progression PDL1+LY 32-36 2018-02-14 2018-08-29 2018-10-10 growing 196 42 238 45.0 growing well differentiated mammary solid adenocarcinoma 13 21 61.1 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No Yes 9L_A_DN NA NA yes NA NA NA NA 20191030_DN_9LA_CGDA7428_S24_R1_001.fastq.gz NA DN_9LA 8.216490 NA 8.028715 NA 8.016124 NA Basal NA NA NA NA NA NA NA 5.8504673 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9L_B 9L 3 B Progression PDL1+LY 32-36 2018-02-14 2018-08-15 2018-10-10 growing 182 56 238 35.0 growing well differentiated mammary solid adenocarcinoma 15.8 15.7 57.4 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No Yes No No 9L_B_CD45 20191030_CD45_9LB_CGDA7427_S44_R1_001.fastq.gz 20191030_CD45_9LB_CGDA7427_S44_R1_001_report.tsv yes CD45_9LB NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 3.2597403 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C1R_ C1R NA NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C1R-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2N_ C2N 1 NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 19.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 C2N-tumor.final.bam Yes Yes No C2N__CD45 20180119_C2N_Tumor_CD45plus_LD5110-5of6_S16_R1_001.fastq.gz 20180119_C2N_Tumor_CD45plus_LD5110-5of6_S16_R1_001_report.tsv yes C2N_Tumor_CD45plus 20180119_C2N_Tumor_Epcamplus_LD5110-5of6_S4_R1_001.fastq.gz 20180119_C2N_Tumor_Epcamplus_LD5110-5of6_S4_R1_001_report.tsv C2N_Tumor_Epcamplus NA NA NA NA 7.043804 NA 6.648735 NA 6.648735 NA Normal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R_ C2R 1 NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 21.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No C2R__CD45 20180119_C2R_Tumor_CD45plus_LD5110-5of6_S17_R1_001.fastq.gz 20180119_C2R_Tumor_CD45plus_LD5110-5of6_S17_R1_001_report.tsv yes C2R_Tumor_CD45plus 20180119_C2R_Tumor_Epcamplus_LD5110-5of6_S5_R1_001.fastq.gz 20180119_C2R_Tumor_Epcamplus_LD5110-5of6_S5_R1_001_report.tsv C2R_Tumor_Epcamplus NA NA NA NA 7.541335 NA 7.367312 NA 5.727280 NA Normal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R1_ C2R1 NA NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 15.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R1-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R2_ C2R2 NA NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 7.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R2-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R3_ C2R3 NA NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 3.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R3-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C4P_ C4P NA NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 25.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C4P-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C5R_ C5R 1 NA Prevention Vehicle 32-36 2017-05-26 NA 2017-08-21 no data NA NA 87 9.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 1 No Yes Yes No C5R__CD45 20180119_C5R_Tumor_CD45plus_LD5110-5of6_S18_R1_001.fastq.gz 20180119_C5R_Tumor_CD45plus_LD5110-5of6_S18_R1_001_report.tsv yes C5R_Tumor_CD45plus 20180119_C5R_Tumor_Epcamplus_LD5110-5of6_S6_R1_001.fastq.gz 20180119_C5R_Tumor_Epcamplus_LD5110-5of6_S6_R1_001_report.tsv C5R_Tumor_Epcamplus NA NA NA NA 8.606440 NA 8.355635 NA 8.470766 NA LumA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control1_ Control1 NA NA Characterisation Untreated 49 2016-10-11 NA 2017-01-07 no data NA NA 88 NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control2_ Control2 NA NA Characterisation Untreated 49 2016-10-11 NA 2017-01-10 no data NA NA 91 NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control3_ Control3 NA NA Characterisation Untreated 35 2017-01-06 NA NA no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control4_ Control4 1 NA Characterisation Untreated 35 2017-01-06 NA NA no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA control4-liver.final.bam Yes Yes No control__Ep NA NA yes Mammarygland_leukocyte_control 20170125_Control4_Mammarygland__EpCAM_CGDA5146_S16_R1_001.fastq.gz NA Mammarygland_epithelial_control NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU1_LL NMU1 3 LL Characterisation Vehicle 49 2016-10-11 NA 2017-01-07 no data NA NA 88 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU1-tumor.final.bam No Yes No NMU1_LL_Ep NA NA yes NA 20191030_Ep_NMU1_CGDA7428_S1_R1_001.fastq.gz NA Ep_NMU1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU10_LL NMU10 1 LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-08 no data NA NA 61 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 2 No Yes Yes No NMU10_LL_Ep 20170125_NMU10_Tumor_LL_CD45_CGDA5146_S2_R1_001.fastq.gz 20170125_NMU10_Tumor_LL_CD45_CGDA5146_S2_R1_001_report.tsv yes Tumor_leukocyte_NMU10_LL 20170125_NMU10_Tumor_LL_EpCAM_CGDA5146_S10_R1_001.fastq.gz NA Tumor_epithelial_NMU10_LL NA NA NA NA 8.493266 NA 7.983543 NA 9.754247 NA LumB NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU11_LA NMU11 NA LA Characterisation Vehicle 49 2016-10-11 NA 2017-04-26 no data NA NA 197 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU12_LA NMU12 1 LA Characterisation Vehicle 35 2017-01-06 NA 2017-04-26 no data NA NA 110 12.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 2 NMU12-tumor-LA.final.bam Yes Yes No NMU12_LA_Ep 20170125_NMU12_Tumor_LA_CD45_CGDA5146_S3_R1_001.fastq.gz 20170125_NMU12_Tumor_LA_CD45_CGDA5146_S3_R1_001_report.tsv yes Tumor_leukocyte_NMU12_LA 20170125_NMU12_Tumor_LA_EpCAM_CGDA5146_S11_R1_001.fastq.gz NA Tumor_epithelial_NMU12_LA NA NA NA NA 8.811266 NA 9.083968 NA 9.537113 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU12_RL NMU12 3 RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-08 no data NA NA 61 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 3 NA NA 2 NA NA 2 NMU12-tumor-RL.final.bam No Yes No NMU12_RL_Ep NA NA yes NA 20191030_Ep_NMU12RL_CGDA7428_S2_R1_001.fastq.gz NA Ep_NMU12RL NA NA NA NA 9.963973 NA 9.911103 NA 9.937780 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LAL NMU13 NA LAL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 8.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-LAL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LAU NMU13 1 LAU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 14.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No NMU13_LAU_Ep 20170125_NMU13_Tumor_LAU_CD45_CGDA5146_S5_R1_001.fastq.gz 20170125_NMU13_Tumor_LAU_CD45_CGDA5146_S5_R1_001_report.tsv yes Tumor_leukocyte_NMU13_LAU 20170125_NMU13_Tumor_LAU_EpCAM_CGDA5146_S13_R1_001.fastq.gz NA Tumor_epithelial_NMU13_LAU NA NA NA NA 3.153971 NA 10.644107 NA 4.569700 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LLL NMU13 NA LLL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LLU NMU13 1 LLU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 2 No Yes Yes No NMU13_LLU_Ep 20170125_NMU13_Tumor_LLU_CD45_CGDA5146_S4_R1_001.fastq.gz 20170125_NMU13_Tumor_LLU_CD45_CGDA5146_S4_R1_001_report.tsv yes Tumor_leukocyte_NMU13_LLU 20170125_NMU13_Tumor_LLU_EpCAM_CGDA5146_S12_R1_001.fastq.gz NA Tumor_epithelial_NMU13_LLU NA NA NA NA 8.086132 NA 8.643148 NA 9.408074 NA Basal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RAL NMU13 NA RAL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 20.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RAU NMU13 1 RAU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 8.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-RAU.final.bam Yes Yes No NMU13_RAU_Ep 20170125_NMU13_Tumor_RAU_CD45_CGDA5146_S6_R1_001.fastq.gz 20170125_NMU13_Tumor_RAU_CD45_CGDA5146_S6_R1_001_report.tsv yes Tumor_leukocyte_NMU13_RAU 20170125_NMU13_Tumor_RAU_EpCAM_CGDA5146_S14_R1_001.fastq.gz NA Tumor_epithelial_NMU13_RAU NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RLL NMU13 NA RLL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 7.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-RLL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RLU NMU13 NA RLU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 20.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU14_ NMU14 1 NA Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 3 NA NA 1 NA NA 1 NMU14-tumor.final.bam Yes Yes No NMU14__Ep 20170125_NMU14_Tumor__CD45_CGDA5146_S7_R1_001.fastq.gz 20170125_NMU14_Tumor__CD45_CGDA5146_S7_R1_001_report.tsv yes Tumor_leukocyte_NMU14 20170125_NMU14_Tumor__EpCAM_CGDA5146_S15_R1_001.fastq.gz NA Tumor_epithelial_NMU14 NA NA NA NA 11.059146 NA 9.399838 NA 8.236589 NA LumA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU2_RL NMU2 NA RL Characterisation Vehicle 49 2016-10-11 NA 2017-01-07 no data NA NA 88 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU2-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU3_LA NMU3 NA LA Characterisation Vehicle 49 2016-10-11 NA 2017-01-10 no data NA NA 91 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU4_RA NMU4 NA RA Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU4_RL NMU4 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 1.5 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU5_LA NMU5 3 LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 3.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU5-tumor-LA.final.bam No Yes No NMU5_LA_Ep NA NA yes NA 20191030_Ep_NMU5LA_CGDA7428_S3_R1_001.fastq.gz NA Ep_NMU5LA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU5_LL NMU5 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU6_LA NMU6 NA LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU6_RL NMU6 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_LA NMU7 NA LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 2.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_LL NMU7 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_RL lower x2 NMU7 NA RL lower x2 Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 2.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_RLU NMU7 1 RLU Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No NMU7_RLU_Ep 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001.fastq.gz 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001_report.tsv yes Tumor_leukocyte_NMU7_RLU 20170125_NMU7_Tumor_RLU_EpCAM_CGDA5146_S9_R1_001.fastq.gz NA Tumor_epithelial_NMU7_RLU NA NA NA NA 6.746370 NA 3.561978 NA 8.172066 NA Basal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU8_RA NMU8 NA RA Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU8_RL NMU8 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU9_LL NMU9 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU9-tumor-LL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LB2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LB 2.mrxs 4channel_23samples: NOT CONVERTED NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LD2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LD 2.mrxs 4channel_23samples: NOT CONVERTED NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N_3 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N_3.mrxs 4channel_23samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12N NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12N-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13L NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13L-P+R.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13R NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13R-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2.1 Size information We have two cohorts, the characterisation and progression cohorts. Below is a plot of the size distribution in these two cohorts: Note that in the characterisation cohort, samples are selected for SAC at different time points: 2.2 Calculating growth rates In this section, we estimate the growth rates of the samples: Below is a plot of the tumor size per week for each recorded tumor, color-coded according to treatment. Time is measured at the first time point at which a tumor is palpated. Spontaneous large tumors are assumed to have a tumor size of 0 or 1 one week prior to palpating. Plot the growth of tumours which u-turn: ## quartz_off_screen ## 2 These tumors doesn’t have growth rate data: 17N_B. We can then compute the growth rate for the above samples by considering the change in size over a given period of time using a linear regression model. Below is the histogram of growth rates: Based on the above distribution, a cut-off of 2mm/week may be an optimal cut-off to separate growing and stable tumors. Below are growth rates of tumors under different treatments: We can calculate the p.values below, using a t.test. The growth rates comparing the treatment to the controls are: ## [1] &quot;LY samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;LY&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 165.5, p-value = 0.1718 ## alternative hypothesis: true location shift is not equal to 0 ## [1] &quot;PDL1 samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;PDL1&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 103, p-value = 0.051 ## alternative hypothesis: true location shift is not equal to 0 ## [1] &quot;PDL1+LY samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;PDL1+LY&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 154.5, p-value = 0.006713 ## alternative hypothesis: true location shift is not equal to 0 This shows a smaller growth-rate in PDL1 single and double treated cases compared to the vehicles. Overall the distribution of growing vs stable tumors is shown below: ## ## grow stable ## 47 31 We can replot the previous graphs according to growth, and color code according to whether it is a fast or slow growing tumor ## quartz_off_screen ## 2 As a sanity check, compare these growth rates with differences in tumour size at different time points: comparing the growth rate according to classifications (growing, stable) tumor size at time of sacrifice rate of tumor development from the time of NMU injection ## Warning in wilcox.test.default(x = c(3.54285714285714, 15, 20, 11.7, 5.8, : ## cannot compute exact p-value with ties ## Warning in wilcox.test.default(x = c(20, 15, 20, 47, 30, 12, 32, 35, 4, : cannot ## compute exact p-value with ties ## Warning in wilcox.test.default(x = c(0.238095238095238, 0.178571428571429, : ## cannot compute exact p-value with ties Is there an association with treatment? Calculate below using chi-squared test: ## ## Pearson&#39;s Chi-squared test ## ## data: table(factor(d1$treatment), d1$growthrate_cutoff2) ## X-squared = 6.8181, df = 3, p-value = 0.07793 ## quartz_off_screen ## 2 Overall, it appears that there is an association between growth rate and treatment 2.3 FACS data The immune (CD45) fractions from a number of samples were collected, and assessed using FACs. The major cell types detected are: Leukocytes: Tregs CD8 T cells Thelper cells B cells NK T cells gamma delta T cells Myeloid cells: Macrophages M1 Macrophages M2 Dendritic cells Monocytes Neutrophils We can look at the: types of cells distributions Note that in a number of samples the leukocyte population could not be inferred with confidence, and proportions are normalised to the myeloid population type 11ND 8LD 8RCU 12LD 6RB 11RD 14ND 14NC 3NB 3RC 10LC 10RB 11LB 11RC 15LB 15NC 15RD 16LD 2RA 2RC 5NA 6RD 8RCL Leukocytes 913.8400000 379.5600000 829.5700000 298.8300000 NA NA 291.4300000 576.7400000 1118.8200000 616.3800000 414.7500000 899.6000000 1243.7900000 204.8900000 NA NA NA NA NA NA NA NA NA leukocytes NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Th 0.1823733 0.1223259 0.1239799 0.0542784 NA NA 0.1503277 0.1370462 0.0964141 0.0980077 0.0832309 0.1489996 0.0910604 0.0454390 NA NA NA NA NA NA NA NA NA Tregs 0.1020748 0.3822584 0.0570175 0.0703075 NA NA 0.0703085 0.0438673 0.1722261 0.1392972 0.1607233 0.1387394 0.0263389 0.0292352 NA NA NA NA NA NA NA NA NA CD8 T cells 0.0558632 0.0329329 0.0248804 0.0239936 NA NA 0.0681124 0.0403648 0.0628966 0.0438204 0.0201326 0.0435749 0.0088681 0.0188394 NA NA NA NA NA NA NA NA NA gd T cells 0.0057231 0.0029508 0.0048338 0.0051869 NA NA 0.0052843 0.0034851 0.0054343 0.0099614 0.0108981 0.0039573 0.0023155 0.0078091 NA NA NA NA NA NA NA NA NA NK cells 0.0081852 0.0023975 0.0086430 0.0082321 NA NA 0.0024706 0.0033984 0.0057471 0.0130277 0.0073056 0.0078924 0.0047355 0.0009273 NA NA NA NA NA NA NA NA NA B cells 0.0320297 0.0259774 0.1150958 0.3691731 NA NA 0.0552105 0.1627076 0.1690978 0.1648821 0.0852803 0.1415963 0.1131783 0.5891942 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA DC 0.0847253 0.0099781 0.0240649 0.0937623 0.0796767 0.0904331 0.0210829 0.0866281 0.1246231 0.2439219 0.0338069 0.0087373 0.0787654 0.0441001 0.0782997 0.1614173 0.0582119 0.0529557 0.0371143 0.0034515 0.0605741 0.0224583 0.0656124 Monocytes 0.0869640 0.0992694 0.1052141 0.1075509 0.0750577 0.0896695 0.1671775 0.0227902 0.0658291 0.0406536 0.0388811 0.0573525 0.0550409 0.0607867 0.0630813 0.0921618 0.1345743 0.2219148 0.0818758 0.0326953 0.1337320 0.0871336 0.0882122 Neutrophils 0.1195109 0.0713534 0.0989646 0.0961261 0.1039261 0.0484346 0.0821956 0.0795769 0.1165829 0.0390594 0.2022707 0.0442465 0.1378131 0.0369487 0.0839361 0.0629921 0.1058862 0.0959791 0.1177103 0.0213367 0.1875633 0.0681735 0.0702109 MHCII-hi Macro 0.0079215 0.0188760 0.0327395 0.0978332 0.0254042 0.1052689 0.1015139 0.0328633 0.0341709 0.0462336 0.0260688 0.0224593 0.0856493 0.0309893 0.0660404 0.0758769 0.0283632 0.1103736 0.0456621 0.0460621 0.0757107 0.1725741 0.0463399 MHCII-lo Macro 0.0451180 0.2975240 0.2654603 0.1099146 0.0542725 0.0976328 0.1608619 0.0690003 0.0894472 0.0278996 0.0253711 0.2559019 0.0511094 0.0536353 0.0862846 0.0606657 0.0647108 0.1009692 0.2576354 0.2502040 0.0721728 0.1834358 0.0866607 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Total 0.7304889 1.0658438 0.8608938 1.0363587 0.3383372 0.4314389 0.8845458 0.6817281 0.9424693 0.8667644 0.6939694 0.8734574 0.6548747 0.9179043 0.3776421 0.4531138 0.3917464 0.5821924 0.5399978 0.3537496 0.5297529 0.5337753 0.3570360 Lin- 0.2695111 -0.0658438 0.1391062 -0.0363587 0.6616628 0.5685611 0.1154542 0.3182719 0.0575307 0.1332356 0.3060306 0.1265426 0.3451253 0.0820957 0.6223579 0.5468862 0.6082536 0.4178076 0.4600022 0.6462504 0.4702471 0.4662247 0.6429640 We can look solely at the myeloid population (and normalise to this total), and color according to growth Similarly, we can look at the leukocyte population. Note that the Treg population in some of these samples is very high. 2.4 Summary Table Firstly, look at the total number of samples: Feature Levels N Total No Tumors All 143 - Characterisation 33 - Prevention 8 - Progression 84 Total No Rats All 69 - Characterisation 18 - Prevention 8 - Progression 42 No tumours per rat 1.84 ( 1, 3) 2.4.1 Compare the characterisation vs progression cohort Feature Levels Characterisation Progression Total No tumours 59 102 Treatments Vehicle 64 27 - Untreated 4 - LY 17 - PDL1 17 - PDL1+LY 23 - NA 18 18 Histology diff. adenocarcinomas 41 76 - mucinous carcinoma 0 3 - Fibroadenoma 0 4 - NA 18 19 Age Injection 32-36 8 84 - 35 27 0 - 49 6 0 - NA 18 18 Time (days) NMU 2 Sac 95.74 (54.8, 160) 149.37 (79, 248.7) - Cases with NA 20 18 - NMU 2 Tumor 100.62 (44.2, 182.7) - Cases with NA 59 18 - Tum Spec Surv 48.75 (9.5, 92) - Cases with NA 59 18 Growth Rate/Size (mm) overall size @ sac 8.07 (1.8, 19.4) 19.52 (3, 40) - Growing No. 47 - Growing size @ sac 27.7 15, 28, 40 - Stable 31 - Stable size @ sac 9.58 (1, 6, 24) - NA 59 24 Spatial Pattern - Infiltrating 0 26 - Restricted 0 33 - NA 59 43 RNA samples any fraction 14 46 - Ep 14 21 - DN 0 33 - CD45 10 36 Imaging Data No tumors 64 - No tumors with RNA 38 FACS data Comprehensive 22 - EpCAM/CD45 0 82 TO INCLUDE: - trichrome data? 2.4.2 Summary of the RNA data Below is a table of the samples with RNA information Feature Levels Characterisation Progression RNA samples any fraction 14 46 - Ep 14 21 - DN 0 33 - CD45 10 36 Treatments Char/Prev Vehicle 13 15 - Untreat (char) 1 - LY 9 - PDL1 11 - PDL1+LY 11 - NA 0 0 Time NMU 2 Sac 102.31 (56.2, 160) 113.85 (79, 166) Growth Rate/Size (mm) overall size @ sac 9.23 (4, 18) 21.96 (6, 37.5) - Growing No. 33 - Growing size @ sac 27.64 15, 28, 40 - Stable 12 - Stable size @ sac 7.17 (3.1, 6, 9.7) - NA 14 1 Growth and Treatment: comparing small/stable vs large/growing Vehicle N s/l 2, 13 LY N s/l 2, 7 PDL1 and Treatment N s/l 4, 6 PDL1+LY N s/l 4, 7 "],["whole-slide-imaging.html", "Chapter 3 Whole-slide imaging 3.1 Associate the frequencies with other data types 3.2 Cellular composition 3.3 Associate composition with other covariates 3.4 Estimate tumor size 3.5 Correlations between different subpopulations 3.6 Associations between CD8 counts with other clinical variables", " Chapter 3 Whole-slide imaging In this section, we will be looking at the composition and spatial distribution of cells in whole slide images. These sections have previously been assessed using an external script. Save this somewhere The following markers have been used: EpCAM (tumor cells) SMA (fibroblasts or myeopithelial cells) CD8 (T cells) Note that in some images a double positive EpCAM+/SMA+ population exists. Some CD8 cells have Epcam+ or SMA+ staining, however, we consider all of these to be simply CD8+ 3.1 Associate the frequencies with other data types Note there are 47 samples with imaging data. 33 of these samples have FACS data, manual counts and TIMER scores Correlate the following information: “CD8.WSI”: CD8 total counts “CD8Frac.WSI”: CD8 fraction (normalised by cell count) “CD8_EPorSMARatio.WSI”: CD8/EP+SMA ratio (any EpCAM or SMA + cell) “CD8_AnySMARatio.WSI”: CD8/Any EPcam+ cell “CD8_EPRatio.WSI”: CD8 to EpCAM+SMA- ratio “CD8normTumSize”: normalised CD8 counts per mm of tumor size at sac “CD8.EpBoundingBox”: approx area per CD8 cell (density) UPDATE THE CIBERSORT INFORMATION. Below are heatmaps which show the correlation between two variables (red is correlated and blue is anti-correlated), and the p.value is indicated in the middle of the square. It appears that CD8 whole-slide imaging associates well with: FACS data (both CD8 and CD45) Manual scoring (Fig 4) of CD8 cells Some CD8 gene signature scores (mainly in EPC, TIMER) 3.2 Cellular composition Here, we look at the raw distributions of the different cell types and see if there are associations with: tumor size growth rate growth rate (categorical) treatment stromal restricted or infiltrating Below are the total cell counts: Here, the same data is shown and normalised according to total cell count: ## quartz_off_screen ## 2 3.3 Associate composition with other covariates Boxplots of the above data: ## quartz_off_screen ## 2 P values when comparing to the vehicle for each comparison: Treatment values LY 0.8630663, 0.0323942, 0.9495167, 0.0437861, 0.04824 PDL1 0.9624018, 0.6258328, 0.0255031, 0.9373764, 0.3049106 PDL1+LY 0.2307253, 1, 1, 0.9298782, 0.4479729 Is there a difference if we normalise to tumor size: ## quartz_off_screen ## 2 P values when comparing to the vehicle for each comparison: Treatment values LY 0.7737063, 0.1820997, 0.9495167, 0.1159333, 0.209251 PDL1 1, 0.4035605, 0.0869047, 0.9373764, 0.2233681 PDL1+LY 0.4479729, 0.9827602, 0.8692811, 0.7917844, 0.2307253 We can collapse the above data into boxplots to see if there is an association with treatments, performed using non-parametric wilcoxon test. Compared to the vehicle, LY treated samples have a lower “stromal” fraction (unclassed DAPI+ cells) and PDL1 treated samples are more likely to have a EpCAM+SMA+ double positive fraction When comparing these fractions to growth, there is no association: ## Warning in wilcox.test.default(Cdata[Cdata$Growth2 == &quot;growing&quot;, i], ## Cdata[Cdata$Growth2 == : cannot compute exact p-value with ties ## Warning in wilcox.test.default(Cdata[Cdata$Growth2 == &quot;growing&quot;, i], ## Cdata[Cdata$Growth2 == : cannot compute exact p-value with ties Nor is there any association with whether a sample is “immune infiltrated” or not (by manual inspection) ## Warning in wilcox.test.default(Cdata[Cdata$InfiltratingVsRestricted == ## &quot;Infiltrating&quot;, : cannot compute exact p-value with ties ## Warning in wilcox.test.default(Cdata[Cdata$InfiltratingVsRestricted == ## &quot;Infiltrating&quot;, : cannot compute exact p-value with ties We can also use linear regression models to assess: correlation between growth rate and cell fractions (no associations) correlation between final tumor size and cell fractions (no association) 3.4 Estimate tumor size Using WSI data, we can estimate a tumor size for each tissue sample and compare to the final tumor sizes. This will be based on the distribution of EpCAM+ cells. This estimate is also used to normalise CD8 counts earlier on. ## ## Pearson&#39;s product-moment correlation ## ## data: TareaSum and Tdiameter ## t = 1.8547, df = 56, p-value = 0.06891 ## alternative hypothesis: true correlation is not equal to 0 ## 95 percent confidence interval: ## -0.01890939 0.46967349 ## sample estimates: ## cor ## 0.2405613 3.5 Correlations between different subpopulations Look for correlates between different subpopulations: Naturally, we would expect a negative correlation since this should sum to 1. Below are heatmaps showing correlations between different cell types, and significant associations are linearly shown. Note the following negative correlations: epcam and SMA SMA+ and Unclass ## CD8 EpCAM EpCAM: SMA SMA Unclass ## CD8 1.00000000 0.08959405 -0.1323142 -0.2522840 -0.1089706 ## EpCAM 0.08959405 1.00000000 -0.2653483 -0.5437439 -0.1515598 ## EpCAM: SMA -0.13231419 -0.26534834 1.0000000 -0.1339415 -0.1861942 ## SMA -0.25228404 -0.54374393 -0.1339415 1.0000000 -0.5356891 ## Unclass -0.10897063 -0.15155976 -0.1861942 -0.5356891 1.0000000 ## [,1] [,2] [,3] [,4] [,5] ## [1,] 0.00000000 5.036094e-01 0.32212484 5.606335e-02 0.4154967834 ## [2,] 0.50360935 0.000000e+00 0.04410552 1.028296e-05 0.2560848075 ## [3,] 0.32212484 4.410552e-02 0.00000000 3.161560e-01 0.1616883575 ## [4,] 0.05606335 1.028296e-05 0.31615604 0.000000e+00 0.0000146942 ## [5,] 0.41549678 2.560848e-01 0.16168836 1.469420e-05 0.0000000000 3.6 Associations between CD8 counts with other clinical variables Below we assess whether any of the CD8-variables described in section 3.1 is associated with treatment growth spatial pattern Note that CD8 normalised by tumor size is associated with growth (but this could a reflection of the size of the tumor), and there is a borderline difference once normalised by epithelial content. In addition the CD8 total count is associated with pdl1+ly treatment. Note that p=0.05 is designated by a value of 1.3 "],["spatial-statistics.html", "Chapter 4 Spatial statistics 4.1 knn-Distances: 4.2 The interacting fraction 4.3 M-H distances 4.4 Comparison between metrics 4.5 Other cell types", " Chapter 4 Spatial statistics Below, we use three different metrics to compare spatial distributions: k-nearest neighbour distances the interacting fraction morisita-horn distances These are compared to manual inspection of the result 4.1 knn-Distances: The k-nearest neighbour distances looks at the average distance from a given cell type of class A to a cell type of class B. In this section, the reference class A is the CD8 T cell, and we will look at the mean distance to SMA, Epcam, double positive and unclassified cells in each image. To account for potential fluctuations due to misclassified cells, or isolated single cells, k values of 1, 3, 5 will be used. I.e. for each cell, we will compute the mean distance from each Cd8Tcell to its 1, 3, and 5 nearest neighbours. 4.1.1 Comparison to manual classification, treatment, growth Overall, we see that the differences in infiltrating vs restricted are similar. We see statistical differences (using anova followed by Tukey’s test) between: epcam and SMA-epcam in both cases (higher distances to EpCAM on average) SMA-Epcam to SMA (CD8s are closer to SMA+) Unclass to Epcam-SMA (CD8s closer to unclass) In the infiltrating case: Unclass to Epcam (CD8s closer to unclass, borderline significant) In the restricted cases, we see: Unclass to SMA (higher distance to unclass in the restricted case) SMA to epcam (CD8s are closer to the SMA) This last result is consistent with what we expect for a CD8+ cell which is stroma-restricted. 4.1.2 Associations with outcome We can also see if there is an association between these distances with growth and treatment Treatment: CD8 cells in PDL1 sample are further away to SMA+ cells and EpCAM+ (compared to vehicle or double agent) CD8 cells in LY treated samples are further away from unclassified cells (compared to any of the other treatments) ## quartz_off_screen ## 2 4.1.3 Growth All 95% confidence lines cross 0, but it appears that stable cases have a closer unclass-CD8 interaction distance compared to growing. ## quartz_off_screen ## 2 ## Df Sum Sq Mean Sq F value Pr(&gt;F) ## Growth 1 9517 9517 13.973 0.00026 *** ## knn 2 3782 1891 2.776 0.06536 . ## Residuals 155 105578 681 ## --- ## Signif. codes: 0 &#39;***&#39; 0.001 &#39;**&#39; 0.01 &#39;*&#39; 0.05 &#39;.&#39; 0.1 &#39; &#39; 1 ## 15 observations deleted due to missingness ## Df Sum Sq Mean Sq F value Pr(&gt;F) ## Growth 1 870600 870600 1.045 0.308 ## knn 2 106908 53454 0.064 0.938 ## Residuals 149 124163609 833313 ## 15 observations deleted due to missingness ## Df Sum Sq Mean Sq F value Pr(&gt;F) ## Growth 1 3018230 3018230 1.482 0.227 ## knn 2 25311 12655 0.006 0.994 ## Residuals 86 175173971 2036907 ## 9 observations deleted due to missingness ## Df Sum Sq Mean Sq F value Pr(&gt;F) ## Growth 1 9981 9981 3.155 0.0777 . ## knn 2 5180 2590 0.819 0.4429 ## Residuals 155 490409 3164 ## --- ## Signif. codes: 0 &#39;***&#39; 0.001 &#39;**&#39; 0.01 &#39;*&#39; 0.05 &#39;.&#39; 0.1 &#39; &#39; 1 ## 15 observations deleted due to missingness Combine the Epithelial samples, and SMA/unclassified samples together: Is there a difference here? Based on the above distributions, knn1, knn3, and knn5 analyses give similar results. In the following section, we will make comparisons using knn3 results. 4.1.4 Association between distance and content The spatial differences could be influenced by CD8 content. Here, we test if the distances from CD8Tcells to celltype B could be influenced by this. We see that there is a correlation between CD8 fraction and the SMA proportion (both SMA and double positive). But we don’t see an association with epcam+ cells or unclassified stromal cells CD8-Epcam distances are looked at in greater detail below. Here, we look at whether there is an association with CD8 fraction in a growing and stable tumors. In growing or spatially restricted tumors, there is an association between the CD8-epcam distances with the CD8 fraction, but not in infiltrating or stable tumours. Do any of the below metrics correlate with manual scoring: We can assess the distances from CD8 cells which come automatically: Ep-distance SMA distance Ep:SMA distance SMA distance. EpMIN: distance to any Epcam expressing cell (includes EP+SMA+) Ratios between Epcam and SMA: There are different values depending on whether the double positive fraction is used or not (Ratio 1): Ep/any SMA (Ratio 2): EP/SMA (Ratio 3): Any Ep / Any SMA (Ratio 4): Any Ep/ SMA Whilst the manual scorings associate strongly with CD8-EPcam distances, there is no association with any other cell type. 4.2 The interacting fraction The interacting fraction uses the knn-distances and determines the proportion of CD8 cells which are within a proximity of r um from celltype B. 4.2.1 Comparison to manual &amp; select optimal r Below are plots of the proportion of CD8 cells within an “interacting distance” as we increase r. This looks at both the interacting fraction of CD8 cells with Epcam+ and SMA+ cells. Lines are color coded according to the manual spatial-infiltration annotation. We notice from the line plots for each single sample that the restricted samples generally have low interacting fractins with EpCAM and SMA compared to the infiltrating samples. In addition, there is a statistical difference in EpCAM measurements compared to SMA. Using the boxplots as a guide, we can determine optimal “interacting distances” at which to perform downstream analysis. The best separation between restricted and infiltrating for EpCAM appears at: 1-nn: 10-15 um 3-nn: 15 um 5-nn: 20 um The interacting fraction does not distinguish SMA fractions (all restricted boxplots overlap with the infiltrating boxplots) The following plots use 3NN analysis with an interacting distance of 15um. We can firstly check if there is an association between different “interacting fraction” types and manual scoring, similar to what was performed for knn-analysis. Only CD8-EpCAM interacting distances is associated with manual scoring. All other metrics are not significant. Again, association between CD8 content and interacting fraction was observed ONLY in the growing samples or restricted cases. 4.2.2 Growth Here, we check if there is an association between the spatial pattern and tumor growth. ## quartz_off_screen ## 2 None of the above metrics associate with growth. (P value by wilcox test shown) 4.2.3 Treatment Similarly, compare the distances with treatment: ## quartz_off_screen ## 2 There appears to be a difference in CD8-unclass interactions in LY treated samples (LY, PDL1+LY), but not in the other cases 4.3 M-H distances The M-H distance (or Morisita Horn index) can be considered as a correlation coefficient in spatial distribution between cell type A and cell type B. To calculate this metric, the whole slide image is divided into grids of size 50 to 500um. Within each grid, the total number of cells A and B are determined. The M-H index is thus determined as: \\[ \\frac{2\\sum_{i=1}^n a_ib_i}{(D_a+D_b)AB} \\] where \\(a_i\\) and \\(b_i\\) are the number of cells in grid \\(i\\), \\(A\\) and \\(B\\) the total number of cells, and \\(D_x\\) is the Simpson’s index. 4.3.1 Comparison to Manual Scoring Similar to the interacting fraction, we plot the MH index for increasing values of gridsize to determine an optimal metric to compare spatial patterns. Ideally, we would pick a metric has the following properties: good separation of the different values a reasonable number of cells within each grid (avoid too small grids which give counts of 0) avoid plateauing of MH values because the grid size is too large With increasing grid size, optimal differences between infiltrating and restricted appear at the following sizes: epCAML 100um+ epcam:SMA most significant at 350+ SMA: 150+ Unclass:200+ We probably want to use a metric/gridsize of 250 um as the expected/mean number of cells in each grid is 10 here. Other notes: double positive cells (EpCAM+SMA+) appear in predominantly the restricted cases? higher SMA- stromal cells in restricted Below, we check whether these metrics can differentiate between infiltrating and restricted tumors: The above analysis shows that the MH-index shows differences in mixing between CD8 cells and mixing with most cell types. However MH-CD8-to-Epcam to MH-CD8-to-stroma ratios do not support this difference. 4.3.2 Growth Below are the MH indices with increasing grid-size for individual samples. In general, there is a subset of stable samples which have very high intermixing ## quartz_off_screen ## 2 Although the MH values for growing vs stable are not different, we can compare the mixing in epcam vs stroma in matched samples: ## ## Welch Two Sample t-test ## ## data: A4 by A2t$Growth[seq(1, nrow(A2t), by = 2)] ## t = -0.15604, df = 48.631, p-value = 0.8767 ## alternative hypothesis: true difference in means is not equal to 0 ## 95 percent confidence interval: ## -0.7547811 0.6460342 ## sample estimates: ## mean in group growing mean in group stable ## 0.0782986 0.1326721 ## quartz_off_screen ## 2 4.3.3 Treatment ## quartz_off_screen ## 2 There is no difference between the different spatial metrics compared to the vehicle, however, we can compare for a given treatment if there is a difference between the epcam and the stromal interaction scores. It appears that there is a difference only in the control, where SMA mixing is higher than EPcam mixing: ## quartz_off_screen ## 2 4.4 Comparison between metrics After assessing optimal parameters for each metric, in this section we assess which metric could be the best for spatial analysis. Below is a table of the different metrics and their values for each sample knn.EpCAM IF.EpCAM MH.EpCAM Treatment Growth Infil CD8frac TumSize 10LB 39.96193 0.2236555 0.4189067 PDL1 growing Infiltrating 0.0228977 35 10LC 32.12258 0.3168630 0.4097456 PDL1 growing Infiltrating 0.0100341 25 10LD 34.33110 0.2944373 0.6622844 PDL1 stable Infiltrating 0.0681088 10 10NA 23.80977 0.4808547 0.4314681 PDL1 NA restricted 0.0465627 12 10ND 26.20801 0.4408878 0.3700572 PDL1 stable restricted 0.0227195 15 10RBL 44.92703 0.2213380 0.5503682 PDL1 growing restricted 0.0202715 40 10RBU 87.12901 0.0816202 0.3462214 PDL1 NA restricted 0.0670641 12 10RC 25.68401 0.4119583 0.6703927 PDL1 NA Infiltrating NA 4 11LB 69.10296 0.2080105 0.2744403 PDL1 growing NA 0.1521777 25 11ND 26.89773 0.4326199 0.7165377 PDL1 stable Infiltrating 0.3800672 3 11RC 153.33513 0.0386688 0.0322613 PDL1 growing restricted 0.0504186 19 11RD 73.82461 0.2323507 0.3205903 PDL1 growing restricted 0.0224452 25 12LC 23.96795 0.4342496 0.5107043 PDL1 NA Infiltrating NA 4 12LD 12.74758 0.8362360 0.7436023 PDL1 stable Infiltrating 0.0223693 6 13NA 70.80101 0.1279338 0.2665830 Vehicle growing restricted 0.0355811 35 14NB 49.22243 0.2540062 0.4080962 PDL1+LY growing restricted 0.1061520 23 14NC 45.49485 0.3935173 0.2942917 PDL1+LY stable restricted 0.0541298 6 14RD 22.18326 0.5000000 0.5397764 PDL1+LY stable Infiltrating 0.0103371 1 15LB 32.69579 0.2226772 0.3289970 PDL1+LY growing restricted 0.0129612 10 15NC-D 39.22818 0.1299775 0.4076448 PDL1+LY growing restricted 0.0107875 22 15ND 15.54429 0.6025030 0.5347432 PDL1+LY stable Infiltrating 0.0104721 3 15RD 91.07517 0.1578969 0.3596139 PDL1+LY growing restricted 0.0328312 17 16LA 31.26867 0.2750368 0.2893526 PDL1+LY NA Infiltrating 0.0171528 5 16LC 71.64542 0.2411490 0.0605610 PDL1+LY stable Infiltrating 0.0476926 7 16LD 38.85862 0.3001624 0.5251390 PDL1+LY stable Infiltrating 0.0316168 24 16ND 29.84045 0.2842939 0.4721488 PDL1 stable Infiltrating 0.0753308 25 16RD 56.31604 0.2354937 0.3546068 PDL1 stable Infiltrating 0.0306486 3 17NA 61.86642 0.0907525 0.3039443 Vehicle growing restricted 0.0472687 28 17ND 15.06388 0.6664160 0.8321514 Vehicle stable Infiltrating 0.1115267 4 17RB 16.70828 0.6275561 0.4328760 Vehicle growing Infiltrating 0.0411074 35 2N 47.77260 0.2826408 0.4025944 Vehicle growing restricted 0.0301041 47 2RA 44.80857 0.4371043 0.6102479 Vehicle growing restricted 0.0858192 20 2RD 38.61221 0.1979009 0.6231933 Vehicle growing restricted 0.0742195 20 3LA 46.09601 0.2865240 0.3758729 Vehicle growing restricted 0.0531246 12 3NB 32.31159 0.4377911 0.6822122 Vehicle stable Infiltrating 0.2768299 6 3RB 42.63162 0.2910751 0.4183820 Vehicle growing restricted 0.0266554 35 3RC 32.11938 0.2962108 0.4551995 Vehicle growing Infiltrating 0.0232139 32 4LB 30.99117 0.2903294 0.4966275 Vehicle growing Infiltrating 0.0244474 35 4NC 15.33106 0.6851436 0.0923787 Vehicle growing restricted 0.0081388 15 4ND 20.75556 0.4768080 0.5107429 Vehicle growing Infiltrating 0.0076245 20 4RB 53.31478 0.1765476 0.3034436 Vehicle growing restricted 0.0280096 40 5LA 41.12871 0.2471295 0.3461071 Vehicle stable Infiltrating 0.0453952 6 5LB 41.91177 0.2807178 0.4172856 Vehicle growing restricted 0.0257830 4 5LC 82.68448 0.1168545 0.1727796 Vehicle growing restricted 0.0515055 22 5LD 91.41539 0.0735101 0.1716812 Vehicle stable restricted 0.0348108 15 5RB 39.00602 0.1934315 0.4100757 Vehicle growing restricted 0.0596672 35 6LDU 111.44785 0.1092889 0.2378287 LY growing restricted 0.0556253 32 6ND 28.41556 0.2756628 0.3822474 LY growing NA 0.0815901 40 6RB 76.37955 0.1446840 0.5471652 LY growing Infiltrating 0.1554804 18 6RC 50.21453 0.1966022 0.5204855 LY growing restricted 0.0788010 40 7NB 80.17580 0.0728176 0.1585330 LY growing restricted 0.0206734 31 7NC 89.34399 0.0531233 0.1828468 LY growing restricted 0.0479457 40 7RA 33.35958 0.2251296 0.3989243 LY stable restricted 0.0319310 8 7RB 34.39737 0.1917334 0.6536704 LY growing NA 0.0169469 20 7RD 44.13770 0.2386457 0.3585417 LY stable Infiltrating 0.0321690 20 8LD 16.36623 0.6508906 0.7091721 LY stable Infiltrating 0.0562336 6 8RCL 15.12966 0.6186366 0.6783535 LY growing restricted 0.0176691 12 8RCU 50.00101 0.2347423 0.4272626 LY growing restricted 0.0287668 27 knn.EpCAM knn.EpCAM..SMA knn.SMA knn.Unclass knn.EpMIN knn.EpStrRatio1 knn.EpStrRatio2 knn.EpStrRatio3 knn.EpStrRatio4 IF.CD8 IF.EpCAM IF.EpCAM..SMA IF.SMA IF.Unclass IF.EpMIN IF.EpStrRatio1 IF.EpStrRatio2 IF.EpStrRatio3 IF.EpStrRatio4 MH.EpCAM MH.EpCAM..SMA MH.SMA MH.Unclass MH.EpMIN MH.EpStrRatio1 MH.EpStrRatio2 MH.EpStrRatio3 MH.EpStrRatio4 Treatment Growth Infil CD8frac GrowthRate TumSize knn.EpCAMcut MH.EpCAMcut IF.EpCAMcut CD8Fraccut CD8 EpCAM EpCAM: SMA SMA Unclass 10LB 39.96193 52.72253 16.94935 28.07623 39.96193 0.5735732 2.3577258 1.3302993 5.4683183 0.2053826 0.2236555 0.0803884 0.5905018 0.3010823 0.0803884 3.333713e-01 3.787550e-01 4.531947e-01 5.148906e-01 0.4189067 0.4131540 0.5718496 0.5168234 0.4131540 0.4252844 0.7325470 0.8447286 1.4550342 PDL1 growing Infiltrating 0.0228977 6.2285714 35 NA high low low 0.0228977 0.2663149 0.1200304 0.3936498 0.1971072 10LC 32.12258 34.57734 17.87345 24.28626 32.12258 0.6124326 1.7972227 1.2716665 3.7317865 0.0784257 0.3168630 0.2375754 0.4768745 0.3714450 0.2375754 4.435062e-01 6.644578e-01 7.760354e-01 1.162651e+00 0.4097456 0.4514649 0.4699867 0.5056881 0.4097456 0.4446740 0.8718238 0.9346237 1.8324147 PDL1 growing Infiltrating 0.0100341 5.3571429 25 high low high low 0.0100341 0.2960411 0.1672355 0.3081967 0.2184926 10LD 34.33110 30.18133 15.97086 35.99495 30.18133 0.7438671 2.1496080 1.3978193 4.0393825 0.2816222 0.2944373 0.2563779 0.5786730 0.1450209 0.2563779 3.525981e-01 5.088147e-01 6.596187e-01 9.518592e-01 0.6622844 0.5987199 0.6967903 0.5894954 0.5987199 0.5112151 0.9504787 0.9733650 1.8097328 PDL1 stable Infiltrating 0.0681088 1.9729730 10 high high high high 0.0681088 0.1948931 0.2063845 0.4066703 0.1239434 10NA 23.80977 NA 27.49276 48.19205 23.80977 0.8660376 0.8660376 0.8660376 0.8660376 0.3591542 0.4808547 NA 0.3207166 0.1112743 0.4808547 1.499313e+00 1.499313e+00 1.499313e+00 1.499313e+00 0.4314681 NA 0.4720285 0.3768075 0.4314681 0.9140722 0.9140722 0.9140722 0.9140722 PDL1 NA restricted 0.0465627 NA 12 high high high high 0.0465627 0.5554448 0.0000000 0.2855199 0.1124726 10ND 26.20801 NA 30.06210 40.01762 26.20801 0.8717958 0.8717958 0.8717958 0.8717958 0.3008666 0.4408878 NA 0.1738438 0.1426298 0.4408878 2.536114e+00 2.536114e+00 2.536114e+00 2.536114e+00 0.3700572 NA 0.3088513 0.2854604 0.3700572 1.1981728 1.1981728 1.1981728 1.1981728 PDL1 stable restricted 0.0227195 0.3930533 15 high low high low 0.0227195 0.4651478 0.0000000 0.2837204 0.2284123 10RBL 44.92703 67.36295 18.22774 26.07893 44.92703 0.5249056 2.4647619 1.3119416 6.1603904 0.1279104 0.2213380 0.2039493 0.5758915 0.4544651 0.2039493 2.838246e-01 3.843398e-01 5.453515e-01 7.384852e-01 0.5503682 0.4903183 0.6513715 0.5568501 0.4903183 0.4820645 0.8449375 0.9115317 1.5976850 PDL1 growing restricted 0.0202715 4.9761905 40 NA high low low 0.0202715 0.3478534 0.1505455 0.2547647 0.2265650 10RBU 87.12901 76.12121 20.78384 35.23226 76.12121 0.8991173 4.1921519 1.6846410 7.8546713 0.4317687 0.0816202 0.3119480 0.4723411 0.2877489 0.0816202 1.040690e-01 1.727993e-01 5.018152e-01 8.332287e-01 0.3462214 0.4031007 0.5682643 0.5408522 0.3462214 0.3564277 0.6092612 0.7714114 1.3186154 PDL1 NA restricted 0.0670641 NA 12 NA low low high 0.0670641 0.1639585 0.3359050 0.2865291 0.1465433 10RC 25.68401 94.64722 31.71923 16.94124 25.68401 0.2032503 0.8097300 0.9522403 3.7936364 0.1695008 0.4119583 0.0142622 0.1579813 0.5798135 0.0142622 2.391720e+00 2.607639e+00 2.474522e+00 2.697917e+00 0.6703927 0.4382489 0.6383050 0.7045403 0.4382489 0.6227209 1.0502701 1.0298059 1.7368525 PDL1 NA Infiltrating NA NA 4 high high high NA 0.0417306 0.3618176 0.0276754 0.1311434 0.4376331 11LB 69.10296 7919.73815 6967.17455 17.47761 69.10296 0.0046419 0.0099184 0.5366352 1.1466400 0.6929437 0.2080105 0.0000000 0.0000102 0.5774735 0.0000000 2.041550e+04 2.041550e+04 2.041550e+04 2.041550e+04 0.2744403 0.0004057 0.0005077 0.5992535 0.0004057 300.4479496 540.5386932 300.8921190 541.3378024 PDL1 growing NA 0.1521777 3.7857143 25 NA low low high 0.1521777 0.4554672 0.0000101 0.0000364 0.3923085 11ND 26.89773 115.53783 92.98237 27.03077 26.89773 0.1289934 0.2892778 0.6830780 1.5318557 0.8951232 0.4326199 0.0146566 0.0079816 0.2765993 0.0146566 1.911018e+01 5.420238e+01 1.975761e+01 5.603869e+01 0.7165377 0.4393961 0.5134158 0.7286280 0.4393961 0.7520242 1.3956283 1.2131815 2.2514573 PDL1 stable Infiltrating 0.3800672 0.1065574 3 high high high high 0.3800672 0.4231776 0.0185443 0.0140030 0.1642079 11RC 153.33513 178.57028 70.26468 25.53931 153.33513 0.6162122 2.1822504 1.3338375 4.7236450 0.7894172 0.0386688 0.0222283 0.0532631 0.4286498 0.0222283 5.122274e-01 7.259953e-01 8.066755e-01 1.143325e+00 0.0322613 0.0348857 0.0474261 0.2139332 0.0322613 0.3919399 0.6802430 0.8157636 1.4158227 PDL1 growing restricted 0.0504186 2.6785714 19 NA low low high 0.0504186 0.3112585 0.1730174 0.2084050 0.2569004 11RD 73.82461 68.89859 24.26948 26.26985 68.89859 0.7923810 3.0418697 1.5318895 5.8807677 0.2660563 0.2323507 0.1251300 0.3447698 0.4433712 0.1251300 4.944686e-01 6.739300e-01 7.607594e-01 1.036868e+00 0.3205903 0.3051097 0.3583134 0.4727397 0.3051097 0.4832365 0.8947204 0.9431387 1.7462367 PDL1 growing restricted 0.0224452 3.6428571 25 NA low low low 0.0224452 0.2650348 0.1493557 0.2823673 0.2807970 12LC 23.96795 185.03912 202.99400 19.41965 23.96795 0.0617678 0.1180722 0.5386320 1.0296219 0.5118871 0.4342496 0.0115156 0.0018574 0.5401189 0.0115156 3.247222e+01 2.338000e+02 3.333333e+01 2.400000e+02 0.5107043 0.3796746 0.2861825 0.6939558 0.3796746 0.7669877 1.7845403 1.3371920 3.1112273 PDL1 NA Infiltrating NA NA 4 high high high NA 0.1070591 0.5811891 0.0114933 0.0049712 0.2952873 12LD 12.74758 285.85343 355.94915 26.97636 12.74758 0.0198622 0.0358129 0.4652537 0.8388867 0.1078652 0.8362360 0.0230337 0.0002809 0.3896067 0.0230337 3.586747e+01 2.977000e+03 3.685542e+01 3.059000e+03 0.7436023 0.1670409 0.1574188 0.6989078 0.1670409 2.2918175 4.7237215 2.8066455 5.7848461 PDL1 stable Infiltrating 0.0223693 0.7702703 6 high high high low 0.0223693 0.7397626 0.0110841 0.0019856 0.2247985 13NA 70.80101 NA 22.21206 41.36664 70.80101 3.1875036 3.1875036 3.1875036 3.1875036 0.4678459 0.1279338 NA 0.4849838 0.2605385 0.1279338 2.637897e-01 2.637897e-01 2.637897e-01 2.637897e-01 0.2665830 NA 0.3741890 0.2782626 0.2665830 0.7124287 0.7124287 0.7124287 0.7124287 Vehicle growing restricted 0.0355811 6.2000000 35 NA low low high 0.0355811 0.3384585 0.0000000 0.3573896 0.2685709 14NB 49.22243 100.58773 30.48163 18.51350 49.22243 0.3755449 1.6148228 1.1429838 4.9147687 0.5053671 0.2540062 0.0380039 0.2488995 0.5430442 0.0380039 8.853369e-01 1.020517e+00 1.017799e+00 1.173205e+00 0.4080962 0.2805678 0.4662048 0.6460109 0.2805678 0.5464799 0.8753583 0.9221871 1.4771706 PDL1+LY growing restricted 0.1061520 3.3150685 23 NA low low high 0.1061520 0.3688850 0.0639930 0.1816036 0.2793663 14NC 45.49485 76.76388 44.46686 19.26432 45.49485 0.3752749 1.0231182 1.0084796 2.7494347 0.4206746 0.3935173 0.1186159 0.1239597 0.4955760 0.1186159 1.622246e+00 3.174558e+00 2.111232e+00 4.131449e+00 0.2942917 0.2346100 0.3505322 0.6115874 0.2346100 0.5029405 0.8395568 0.9038858 1.5088534 PDL1+LY stable restricted 0.0541298 0.5595238 6 NA low high high 0.0541298 0.5460494 0.1262934 0.0814721 0.1920553 14RD 22.18326 43.27617 31.50346 22.40920 22.18326 0.2966485 0.7041532 0.8753645 2.0778489 0.1216955 0.5000000 0.1927985 0.1681860 0.4799453 0.1927985 1.385101e+00 2.972900e+00 1.919192e+00 4.119241e+00 0.5397764 0.4753382 0.5451002 0.5577639 0.4753382 0.5289652 0.9902334 0.9947828 1.8622533 PDL1+LY stable Infiltrating 0.0103371 -0.1666667 1 high high high low 0.0103371 0.5077127 0.1325255 0.0890900 0.2603347 15LB 32.69579 70.46882 20.89178 15.83206 32.69579 0.3578762 1.5650073 1.1292024 4.9380478 0.1064567 0.2226772 0.0332283 0.4615748 0.6502362 0.0332283 4.500318e-01 4.824292e-01 5.171865e-01 5.544183e-01 0.3289970 0.2931188 0.3878113 0.3817708 0.2931188 0.4831583 0.8483429 0.9136265 1.6041712 PDL1+LY growing restricted 0.0129612 3.5000000 10 high low low low 0.0129612 0.2153910 0.0414453 0.2667501 0.4634524 15NC-D 39.22818 NA 23.06369 22.18943 39.22818 1.7008635 1.7008635 1.7008635 1.7008635 0.1344853 0.1299775 NA 0.3683947 0.3005259 0.1299775 3.528212e-01 3.528212e-01 3.528212e-01 3.528212e-01 0.4076448 NA 0.4918426 0.3958551 0.4076448 0.8288115 0.8288115 0.8288115 0.8288115 PDL1+LY growing restricted 0.0107875 2.6857143 22 high low low low 0.0107875 0.2245321 0.0000000 0.2679737 0.4967068 15ND 15.54429 53.43276 37.28968 17.33598 15.54429 0.1713390 0.4168524 0.7603086 1.8497622 0.0286055 0.6025030 0.0643623 0.1877235 0.4928486 0.0643623 2.390071e+00 3.209524e+00 2.645390e+00 3.552381e+00 0.5347432 0.6408288 0.5953938 0.4876943 0.5347432 0.4325622 0.8981336 0.9509388 1.9744444 PDL1+LY stable Infiltrating 0.0104721 -0.2285714 3 high high high low 0.0104721 0.4017761 0.0548254 0.1042150 0.4287114 15RD 91.07517 NA NA 11.52589 91.07517 NA NA NA NA 0.2216630 0.1578969 NA NA 0.8819101 0.1578969 NA NA NA NA 0.3596139 NA NA 0.4852310 0.3596139 NA NA NA NA PDL1+LY growing restricted 0.0328312 3.5000000 17 NA low low low 0.0328312 0.1499809 0.0000000 0.0000000 0.8171879 16LA 31.26867 NA 19.19006 27.79750 31.26867 1.6294199 1.6294199 1.6294199 1.6294199 0.3536187 0.2750368 NA 0.4480477 0.3018298 0.2750368 6.138560e-01 6.138560e-01 6.138560e-01 6.138560e-01 0.2893526 NA 0.3032338 0.4666952 0.2893526 0.9542226 0.9542226 0.9542226 0.9542226 PDL1+LY NA Infiltrating 0.0171528 NA 5 high low high low 0.0171528 0.4248684 0.0000000 0.3742464 0.1837324 16LC 71.64542 NA 65.51353 21.56242 71.64542 1.0935973 1.0935973 1.0935973 1.0935973 0.6542978 0.2411490 NA 0.1293491 0.3635133 0.2411490 1.864327e+00 1.864327e+00 1.864327e+00 1.864327e+00 0.0605610 NA 0.0549540 0.1696059 0.0605610 1.1020311 1.1020311 1.1020311 1.1020311 PDL1+LY stable Infiltrating 0.0476926 0.6475410 7 NA low low high 0.0476926 0.4774508 0.0000000 0.2398580 0.2349986 16LD 38.85862 NA 19.42446 22.61613 38.85862 2.0004993 2.0004993 2.0004993 2.0004993 0.2420006 0.3001624 NA 0.4920473 0.3806520 0.3001624 6.100274e-01 6.100274e-01 6.100274e-01 6.100274e-01 0.5251390 NA 0.5469426 0.6761430 0.5251390 0.9601356 0.9601356 0.9601356 0.9601356 PDL1+LY stable Infiltrating 0.0316168 1.9151786 24 high high high low 0.0316168 0.3541756 0.0000000 0.4114572 0.2027504 16ND 29.84045 40.34701 26.33421 47.06903 29.84045 0.4475090 1.1331438 1.0525821 2.6652576 0.4492659 0.2842939 0.0509409 0.3098188 0.0600419 0.0509409 7.880422e-01 9.176134e-01 9.292468e-01 1.082035e+00 0.4721488 0.4676963 0.5315248 0.4264074 0.4676963 0.4725168 0.8882912 0.9405777 1.7682055 PDL1 stable Infiltrating 0.0753308 1.0745763 25 high high high high 0.0753308 0.3759357 0.1326910 0.3128979 0.1031446 16RD 56.31604 NA 16.51236 34.65626 56.31604 3.4105390 3.4105390 3.4105390 3.4105390 0.2959863 0.2354937 NA 0.6114905 0.2825043 0.2354937 3.851142e-01 3.851142e-01 3.851142e-01 3.851142e-01 0.3546068 NA 0.4669043 0.4610184 0.3546068 0.7594851 0.7594851 0.7594851 0.7594851 PDL1 stable Infiltrating 0.0306486 -0.1027397 3 NA low low low 0.0306486 0.2428567 0.0000000 0.5034447 0.2230500 17NA 61.86642 NA 22.48160 21.57101 61.86642 2.7518686 2.7518686 2.7518686 2.7518686 0.3757123 0.0907525 NA 0.3861962 0.5524496 0.0907525 2.349907e-01 2.349907e-01 2.349907e-01 2.349907e-01 0.3039443 NA 0.3286626 0.6139185 0.3039443 0.9247911 0.9247911 0.9247911 0.9247911 Vehicle growing restricted 0.0472687 6.8000000 28 NA low low high 0.0472687 0.1826840 0.0000000 0.5151503 0.2548971 17ND 15.06388 232.02438 111.85371 18.01790 15.06388 0.0438059 0.1346748 0.7185345 2.2090306 0.3246353 0.6664160 0.0003008 0.0029328 0.4851857 0.0003008 2.060930e+02 2.272308e+02 2.061860e+02 2.273333e+02 0.8321514 0.2993479 0.5550129 0.8030045 0.2993479 0.9740047 1.4993371 1.3243811 2.0386901 Vehicle stable Infiltrating 0.1115267 -0.3846154 4 high high high high 0.1115267 0.5278356 0.0017025 0.0111711 0.3477641 17RB 16.70828 88.48121 95.13230 35.71473 16.70828 0.0909970 0.1756320 0.5728853 1.1057178 0.3890573 0.6275561 0.0788001 0.0414694 0.2133747 0.0788001 5.217914e+00 1.513298e+01 5.873110e+00 1.703317e+01 0.4328760 0.3073275 0.2630260 0.4958643 0.3073275 0.7589609 1.6457535 1.2977977 2.8141834 Vehicle growing Infiltrating 0.0411074 8.2142857 35 high high high high 0.0411074 0.6606120 0.1202333 0.0539738 0.1240735 2N 47.77260 87.60001 35.15413 19.20262 47.77260 0.3891730 1.3589470 1.1027947 3.8508309 0.3846518 0.2826408 0.0808522 0.2448721 0.5902966 0.0808522 8.677302e-01 1.154238e+00 1.115953e+00 1.484420e+00 0.4025944 0.2711542 0.3477316 0.4980090 0.2711542 0.6505148 1.1577733 1.0886476 1.9375532 Vehicle growing restricted 0.0301041 11.7000000 47 NA low high low 0.0301041 0.3136859 0.0921483 0.1961374 0.3679243 2RA 44.80857 534.05443 132.80795 15.31048 44.80857 0.0671931 0.3373938 0.8680397 4.3586471 0.3464678 0.4371043 0.0009580 0.0452766 0.6856881 0.0009580 9.454054e+00 9.654094e+00 9.474775e+00 9.675253e+00 0.6102479 0.0311932 0.2966308 0.7722338 0.0311932 1.8615104 2.0572637 1.9566627 2.1624221 Vehicle growing restricted 0.0858192 3.5428571 20 NA high high high 0.0858192 0.4304185 0.0016908 0.0391991 0.4428724 2RD 38.61221 73.15221 27.66634 21.62384 38.61221 0.3829872 1.3956389 1.1085701 4.0397263 0.3219793 0.1979009 0.1740124 0.2492193 0.5216188 0.1740124 4.675947e-01 7.940835e-01 8.787464e-01 1.492314e+00 0.6231933 0.4778614 0.5903445 0.6193173 0.4778614 0.5834018 1.0556433 1.0307513 1.8651052 Vehicle growing restricted 0.0742195 20.0000000 20 high high low high 0.0742195 0.2659629 0.1222001 0.1820660 0.3555515 3LA 46.09601 104.05573 65.98973 41.88896 46.09601 0.2710805 0.6985331 0.8830094 2.2753805 0.4243628 0.2865240 0.0929863 0.0477520 0.2387958 0.0929863 2.035863e+00 6.000250e+00 2.696566e+00 7.947526e+00 0.3758729 0.3427403 0.3388976 0.3530573 0.3427403 0.5514261 1.1091046 1.0542448 2.1204434 Vehicle growing restricted 0.0531246 3.0000000 12 NA low high high 0.0531246 0.3953915 0.1475608 0.0995967 0.3043263 3NB 32.31159 NA 62.64161 29.70786 32.31159 0.5158168 0.5158168 0.5158168 0.5158168 0.7233868 0.4377911 NA 0.0275246 0.2218779 0.4377911 1.590545e+01 1.590545e+01 1.590545e+01 1.590545e+01 0.6822122 NA 0.5543399 0.6640324 0.6822122 1.2306750 1.2306750 1.2306750 1.2306750 Vehicle stable Infiltrating 0.2768299 0.0245902 6 high high high high 0.2768299 0.4731210 0.0000000 0.0426761 0.2073729 3RB 42.63162 NA 29.99254 46.16097 42.63162 1.4214077 1.4214077 1.4214077 1.4214077 0.1779959 0.2910751 NA 0.3592331 0.2055695 0.2910751 8.102681e-01 8.102681e-01 8.102681e-01 8.102681e-01 0.4183820 NA 0.4778455 0.4582325 0.4183820 0.8755592 0.8755592 0.8755592 0.8755592 Vehicle growing restricted 0.0266554 7.6857143 35 NA high high low 0.0266554 0.4366082 0.0000000 0.3803764 0.1563600 3RC 32.11938 55.92834 37.32758 27.31100 32.11938 0.3444219 0.8604733 0.9441516 2.3587846 0.2039175 0.2962108 0.0879309 0.2004961 0.3165683 0.0879309 1.026987e+00 1.477389e+00 1.331851e+00 1.915956e+00 0.4551995 0.4518587 0.5103199 0.4469473 0.4518587 0.4730925 0.8919884 0.9427129 1.7774304 Vehicle growing Infiltrating 0.0232139 5.5428571 32 high high high low 0.0232139 0.3885529 0.1160041 0.1513443 0.3208848 4LB 30.99117 57.04930 28.06937 16.66993 30.99117 0.3640937 1.1040920 1.0343262 3.1365315 0.2172720 0.2903294 0.1223870 0.2381757 0.5714738 0.1223870 8.052119e-01 1.218972e+00 1.144645e+00 1.732824e+00 0.4966275 0.4568203 0.5712444 0.6012689 0.4568203 0.4830702 0.8693783 0.9274200 1.6690717 Vehicle growing Infiltrating 0.0244474 6.8783784 35 high high high low 0.0244474 0.3498723 0.1053868 0.1496622 0.3706314 4NC 15.33106 NA 30.68159 155.44956 15.33106 0.4996826 0.4996826 0.4996826 0.4996826 0.2675045 0.6851436 NA 0.2188061 0.0832585 0.6851436 3.131282e+00 3.131282e+00 3.131282e+00 3.131282e+00 0.0923787 NA 0.0873791 0.0627897 0.0923787 1.0572175 1.0572175 1.0572175 1.0572175 Vehicle growing restricted 0.0081388 3.0000000 15 high low high low 0.0081388 0.7235846 0.0000000 0.1765309 0.0917458 4ND 20.75556 NA 14.30657 39.67271 20.75556 1.4507707 1.4507707 1.4507707 1.4507707 0.0356608 0.4768080 NA 0.7169576 0.1271820 0.4768080 6.650435e-01 6.650435e-01 6.650435e-01 6.650435e-01 0.5107429 NA 0.5367429 0.4200067 0.5107429 0.9515596 0.9515596 0.9515596 0.9515596 Vehicle growing Infiltrating 0.0076245 4.3000000 20 high high high low 0.0076245 0.3776893 0.0000000 0.5044369 0.1102494 4RB 53.31478 62.79761 25.09420 28.66758 53.31478 0.6065954 2.1245853 1.3210831 4.6270602 0.3672294 0.1765476 0.1182837 0.3346431 0.3210703 0.1182837 3.897928e-01 5.275699e-01 6.509470e-01 8.810323e-01 0.3034436 0.2661024 0.4238812 0.4178718 0.2661024 0.4397839 0.7158696 0.8254487 1.3436454 Vehicle growing restricted 0.0280096 7.8108108 40 NA low low low 0.0280096 0.3031804 0.1644440 0.2243090 0.2800569 5LA 41.12871 NA 15.84267 35.17202 41.12871 2.5960728 2.5960728 2.5960728 2.5960728 0.3901975 0.2471295 NA 0.5824421 0.1998228 0.2471295 4.242987e-01 4.242987e-01 4.242987e-01 4.242987e-01 0.3461071 NA 0.4612223 0.5172468 0.3461071 0.7504127 0.7504127 0.7504127 0.7504127 Vehicle stable Infiltrating 0.0453952 0.5000000 6 NA low low high 0.0453952 0.3487738 0.0000000 0.4772540 0.1285770 5LB 41.91177 NA NA 15.05867 41.91177 NA NA NA NA 0.3379618 0.2807178 NA NA 0.6502489 0.2807178 NA NA NA NA 0.4172856 NA NA 0.5278871 0.4172856 NA NA NA NA Vehicle growing restricted 0.0257830 4.0000000 4 NA high high low 0.0257830 0.4705880 0.0000000 0.0000000 0.5036290 5LC 82.68448 NA 23.56636 61.02936 82.68448 3.5085804 3.5085804 3.5085804 3.5085804 0.5297032 0.1168545 NA 0.4516540 0.1066662 0.1168545 2.587257e-01 2.587257e-01 2.587257e-01 2.587257e-01 0.1727796 NA 0.3463809 0.2105786 0.1727796 0.4988138 0.4988138 0.4988138 0.4988138 Vehicle growing restricted 0.0515055 3.5000000 22 NA low low high 0.0515055 0.2846330 0.0000000 0.4592795 0.2045821 5LD 91.41539 174.12079 36.47074 28.68030 91.41539 0.4340886 2.5065407 1.2609063 7.2808006 0.4943721 0.0735101 0.0027369 0.1400046 0.2530645 0.0027369 5.149878e-01 5.250551e-01 5.341615e-01 5.446035e-01 0.1716812 0.2319618 0.4372015 0.2273376 0.1716812 0.2565611 0.3926822 0.6032056 0.9232426 Vehicle stable restricted 0.0348108 0.9299769 15 NA low low high 0.0348108 0.2374921 0.0095635 0.0727253 0.6454083 5RB 39.00602 NA 20.88804 28.66510 39.00602 1.8673849 1.8673849 1.8673849 1.8673849 0.4820815 0.1934315 NA 0.5213079 0.2945054 0.1934315 3.710503e-01 3.710503e-01 3.710503e-01 3.710503e-01 0.4100757 NA 0.5059737 0.6487728 0.4100757 0.8104684 0.8104684 0.8104684 0.8104684 Vehicle growing restricted 0.0596672 10.3571429 35 high high low high 0.0596672 0.3435375 0.0000000 0.4625612 0.1342341 6LDU 111.44785 NA 21.09500 421.71225 111.44785 5.2831411 5.2831411 5.2831411 5.2831411 0.4110641 0.1092889 NA 0.6222455 0.0145634 0.1092889 1.756363e-01 1.756363e-01 1.756363e-01 1.756363e-01 0.2378287 NA 0.4852504 0.1358399 0.2378287 0.4901153 0.4901153 0.4901153 0.4901153 LY growing restricted 0.0556253 2.1974522 32 NA low low high 0.0556253 0.2676477 0.0000000 0.6471339 0.0295931 6ND 28.41556 47.86891 30.70313 51.92693 28.41556 0.3616497 0.9254938 0.9708856 2.4845825 0.5991449 0.2756628 0.0305404 0.2129080 0.0798398 0.0305404 1.132325e+00 1.294750e+00 1.257774e+00 1.438195e+00 0.3822474 0.3853507 0.4248926 0.3268783 0.3822474 0.4717687 0.8996331 0.9473675 1.8065698 LY growing NA 0.0815901 30.0000000 40 high low high high 0.0815901 0.4698473 0.1070807 0.2534581 0.0880237 6RB 76.37955 NA 15.75336 43.30215 76.37955 4.8484602 4.8484602 4.8484602 4.8484602 0.5258014 0.1446840 NA 0.6712516 0.2653502 0.1446840 2.155435e-01 2.155435e-01 2.155435e-01 2.155435e-01 0.5471652 NA 0.7513399 0.5827747 0.5471652 0.7282526 0.7282526 0.7282526 0.7282526 LY growing Infiltrating 0.1554804 2.8000000 18 NA high low high 0.1554804 0.1771439 0.0000000 0.4830327 0.1843430 6RC 50.21453 66.49674 18.16188 34.81308 50.21453 0.5931413 2.7648305 1.3786105 6.4261656 0.3830618 0.1966022 0.0674351 0.5424852 0.2411991 0.0674351 3.223408e-01 3.624103e-01 4.329047e-01 4.867181e-01 0.5204855 0.5362458 0.6880840 0.5730793 0.5204855 0.4251187 0.7564273 0.8631100 1.5357592 LY growing restricted 0.0788010 8.2142857 40 NA high low high 0.0788010 0.2478878 0.1192287 0.3914362 0.1626462 7NB 80.17580 NA 23.02340 30.71527 80.17580 3.4823613 3.4823613 3.4823613 3.4823613 0.3887826 0.0728176 NA 0.3846771 0.3060872 0.0728176 1.892955e-01 1.892955e-01 1.892955e-01 1.892955e-01 0.1585330 NA 0.2914050 0.2682998 0.1585330 0.5440298 0.5440298 0.5440298 0.5440298 LY growing restricted 0.0206734 2.8878505 31 NA low low low 0.0206734 0.2664928 0.0000000 0.3467436 0.3660903 7NC 89.34399 NA 18.52427 73.48726 89.34399 4.8230787 4.8230787 4.8230787 4.8230787 0.5526142 0.0531233 NA 0.5233799 0.0517752 0.0531233 1.015004e-01 1.015004e-01 1.015004e-01 1.015004e-01 0.1828468 NA 0.2878357 0.2738925 0.1828468 0.6352469 0.6352469 0.6352469 0.6352469 LY growing restricted 0.0479457 3.4444444 40 NA low low high 0.0479457 0.1405509 0.0000000 0.7359455 0.0755580 7RA 33.35958 39.17649 17.01392 25.12197 33.35958 0.5936880 1.9607221 1.2908975 4.2633357 0.2951535 0.2251296 0.1866754 0.4992183 0.1908445 0.1866754 3.282281e-01 4.509642e-01 6.003919e-01 8.248997e-01 0.3989243 0.4158760 0.4598109 0.4293819 0.3989243 0.4555559 0.8675835 0.9304700 1.7720336 LY stable restricted 0.0319310 1.1153846 8 high low low low 0.0319310 0.2323095 0.1931934 0.3383713 0.2041948 7RB 34.39737 14.99604 27.35225 37.09141 14.99604 0.8122495 1.2575703 1.1663616 1.8058266 0.0670603 0.1917334 0.6787431 0.1155631 0.1097005 0.1917334 2.413848e-01 1.659124e+00 1.095895e+00 7.532482e+00 0.6536704 0.6958696 0.6701924 0.6387453 0.6536704 0.4785071 0.9753474 0.9879054 2.0136605 LY growing NA 0.0169469 3.9615385 20 high high low low 0.0169469 0.2035659 0.5256130 0.1194875 0.1343866 7RD 44.13770 NA 14.33429 38.10895 44.13770 3.0791694 3.0791694 3.0791694 3.0791694 0.3013841 0.2386457 NA 0.6842436 0.1745901 0.2386457 3.487731e-01 3.487731e-01 3.487731e-01 3.487731e-01 0.3585417 NA 0.4674119 0.4316864 0.3585417 0.7670787 0.7670787 0.7670787 0.7670787 LY stable Infiltrating 0.0321690 0.9966997 20 NA low low low 0.0321690 0.2553332 0.0000000 0.5606542 0.1518436 8LD 16.36623 350.73208 292.95079 22.72937 16.36623 0.0254259 0.0558668 0.5703093 1.2531057 0.3456743 0.6508906 0.0008906 0.0035623 0.3871501 0.0008906 1.461714e+02 1.827143e+02 1.463714e+02 1.829643e+02 0.7091721 0.1873649 0.1961749 0.6375282 0.1873649 1.8490182 3.6149985 2.3375330 4.5700894 LY stable Infiltrating 0.0562336 0.2418033 6 high high high high 0.0562336 0.5936154 0.0018530 0.0036344 0.3446635 8RCL 15.12966 NA 36.87314 33.12931 15.12966 0.4103167 0.4103167 0.4103167 0.4103167 0.1051350 0.6186366 NA 0.3669765 0.2673749 0.6186366 1.685766e+00 1.685766e+00 1.685766e+00 1.685766e+00 0.6783535 NA 0.6126969 0.4886030 0.6783535 1.1071599 1.1071599 1.1071599 1.1071599 LY growing restricted 0.0176691 12.0000000 12 high high high low 0.0176691 0.5536036 0.0000000 0.2486459 0.1800814 8RCU 50.00101 NA 24.56317 37.07321 50.00101 2.0356094 2.0356094 2.0356094 2.0356094 0.2746806 0.2347423 NA 0.4697355 0.2889853 0.2347423 4.997329e-01 4.997329e-01 4.997329e-01 4.997329e-01 0.4272626 NA 0.4219108 0.5098793 0.4272626 1.0126846 1.0126846 1.0126846 1.0126846 LY growing restricted 0.0287668 5.5142857 27 NA high low low 0.0287668 0.2578575 0.0000000 0.5074018 0.2059739 Firstly, we can compare the different metrics to determine how similar or different they are: Do any of these metrics associate with growth or treatments? ## ## Wilcoxon rank sum exact test ## ## data: df.Spatial$CD8frac by df.Spatial$Growth ## W = 258, p-value = 0.2917 ## alternative hypothesis: true location shift is not equal to 0 We can also compare this to raw tumor size or growth rate data as well: 4.5 Other cell types We noted that the proportion of Unclassified cells seemed to be different between the treatments. Assess here whether the MH index for this cell type is associated with growth or treatment here: "],["expression-data.html", "Chapter 5 Expression data 5.1 Running alignment 5.2 RNA Initial QC 5.3 Normalisation 5.4 Processing files for external software", " Chapter 5 Expression data This file looks at loading and pre-processing data for: differential gene expression analysis PAM50 subtyping uploading into CIBERSORT/TIMER 5.1 Running alignment Samples were mapped in star using the following parameters. Note that the first two batches of samples run had shorter read lengths (~75 bp) whereas batch 3 had lengths of ~150bp ## Not run here STAR \\ --readFilesCommand zcat \\ --genomeDir /n/scratch2/at268/rn6_v2 \\ --sjdbGTFfile /n/scratch2/at268/rn6_v2/rn6.refGene.gtf \\ --runThreadN 10 \\ --runMode alignReads \\ --genomeLoad NoSharedMemory\\ --outSAMattributes NH HI AS nM NM\\ --outSAMstrandField intronMotif\\ --outFilterMultimapNmax 20\\ --alignSJoverhangMin 8\\ --readFilesIn $1 $2 \\ --alignSJDBoverhangMin 1\\ --outFilterMismatchNmax 999\\ --outFilterMismatchNoverLmax 0.1\\ --alignIntronMin 20\\ --alignIntronMax 1000000\\ --alignMatesGapMax 1000000\\ --outFilterType BySJout\\ --outFilterScoreMinOverLread 0.33 \\ --outFilterMatchNminOverLread 0.33 \\ --limitSjdbInsertNsj 1200000 \\ --outFilterIntronMotifs None \\ --alignSoftClipAtReferenceEnds Yes\\ --outSAMattrRGline ID:$4 SM:$4 \\ --chimSegmentMin 15 \\ --chimJunctionOverhangMin 15\\ --limitBAMsortRAM 0\\ --outSAMtype BAM SortedByCoordinate\\ --outSAMunmapped Within \\ --quantMode GeneCounts transcriptomeSAM \\ --quantTranscriptomeBan IndelSoftclipSingleend \\ --outFileNamePrefix $3 \\ --twopassMode Basic In addition, RSEM was run to obtain TPM, rsem and FPKM counts. Note: rn6.refGene.gtf.gz was used to generate the RSEM library!(This is the may version) 5.2 RNA Initial QC Default output from R showing the number of unique reads compared to multimapped, unmapped etc. This is shown for each batch. Note that batch 3 has differences (high percentage of unmapped) compared to the other batches, possibly due to DNA contamination. Below we check for three measures: mapped million reads (ideally, 10M+ reads) Gene Sparsity: This is a measurement of the number of genes which have non-zero values. Ideally, would be greater than 10K, but values which are too high may also suggest contamination from DNA (unexpressed genes are also counted) Varability: standard deviation of the transcriptomic counts. If this value is too low, would suggest that high DNA contamination, non-representative transcriptome. Samples to remove from analysis: The thresholds indicated below are based on the above density plots, and removes cases which are &lt;1.5 SD of the mean low total number of mapped reads (under 1.5M) sparsity: less than 8K genes variability : threshold under 500 The omitted samples are: MappedReadsM GeneSparsityK Batch GeneVariabilityCounts Type names 6R_C_CD45 2.287110 5.585 2 1063.38925 CD45 6R_C_CD45 10L_B_DN 0.864838 3.308 2 559.30659 DN 10L_B_DN NMU1_LL_Ep 1.032440 16.708 3 69.82645 Ep NMU1_LL_Ep NMU5_LA_Ep 0.500429 15.707 3 35.56084 Ep NMU5_LA_Ep Control1__Ep 8.224593 5.800 1 3164.00515 Ep Control1__Ep NMU13_RAU_Ep 3.049733 7.242 1 1069.99912 Ep NMU13_RAU_Ep We are left with 110 samples. There are 47, 32, 31 samples in the CD45, Ep, DN fractions. There are 20, 49, 41 samples from batches 1, 2 and 3 respectively. 5.3 Normalisation Run through DESEq and normalise the library. Using all samples, we run the model: expression ~ Celltype + factor (Batch) and keep the genes which have a total count of at least half the number of samples. ie. $ sum(gene_i) &gt; N_{samples}/2 $ 5.3.1 preliminary visualisation (to remove outliers) Below are PCA plots based on: Batch CellType Batches in general separate out well, however, some samples appear to be outliers in comparison to the main group. We look in closer detail the CD45, DN and EpCAM populations. In the CD45 population, narrow down to only immune related genes to see if there is a difference. Based on the above plots, we remove the following outliers and re-run the normalisation: 2R_D_DN 4L_B_CD45 5.4 Processing files for external software We also process these files for external software: Software RNA-data PAM50 rsem data after quantile normalised, genes converted to human TIMER TPM values, retain rat ids xcell rsem data, genes converted ti human cibersort tpm?? convert to rat genes and use lm22 rat ## named integer(0) ## named integer(0) Save the mouse names for TIMER cistrome: check that this is actually required for TIMER "],["rna-data-preliminary-plots.html", "Chapter 6 RNA data: preliminary plots 6.1 PCA plots 6.2 Expression patterns by cell type", " Chapter 6 RNA data: preliminary plots Prior to doing any comparative analysis, we will look at the following plots to get an overview of the data. 6.1 PCA plots We can check the new PCA plots, and overlay parameters of interest including treatment, growth, tumor size, CD8 fraction, spatial distribution. In addition, we can look at the CD45 population and the distributions based on CD8 content and spatial infiltration 6.2 Expression patterns by cell type Below, we check whether the different fractions are expressing expected markers The cell types are: Red: Cd45 Epcam: green DN:blue Reference Genes: purple: immune blue: epithelial green: stroma orange: myoepithelial red: endothelial Below, we see that the CD45 cells separate from the Ep/DN populations have high expression of immune related genes including CD3, CD4, IFNG. However, the DN/Ep fractions are more intermixed. The DN fraction has expression of keratins, as well as fibroblast markers (Acta1), and myeoepithelial markers (Tp63) "],["deseq-analysis.html", "Chapter 7 DESeq analysis 7.1 DN vs Ep 7.2 No. samples in comparisons 7.3 Set-up cell-type specifoc the comparisons 7.4 PCA plots 7.5 Collating results and running GSEA", " Chapter 7 DESeq analysis This document sets up DESeq runs to compare: DN vs Ep samples growing vs stable samples (all 3 fractions) treatments (all 3 fractions) spatial patterns (all 3 fractions) The outputs of these analyses will be used for Gene Set Enrichment Analysis, using MSigDB databases (c2, c5, hallmark), alongside pathways from Metacore (Process Networks, Pathway Maps) 7.1 DN vs Ep In section 6.2, we have noticed that some DN samples had expression of epithelial markers. Here, we perform a differential gene expression analysis to find genes which are different between these two fractions. Below is a summary of the number of differential genes, using p value cut off of 0.05 and log2 fold change of 1.5 and base expression of 100+. ## ## out of 16929 with nonzero total read count ## adjusted p-value &lt; 0.1 ## LFC &gt; 0 (up) : 3331, 20% ## LFC &lt; 0 (down) : 1972, 12% ## outliers [1] : 0, 0% ## low counts [2] : 1970, 12% ## (mean count &lt; 1) ## [1] see &#39;cooksCutoff&#39; argument of ?results ## [2] see &#39;independentFiltering&#39; argument of ?results ## [1] &quot;significant differential genes&quot; baseMean log2FoldChange lfcSE stat pvalue padj CellMarker Col1a1 23618.9407 5.726318 0.5660158 10.116888 0.0000000 0.0000000 1 Fap 241.1687 5.426892 0.6603145 8.218648 0.0000000 0.0000000 1 Cdh5 133.9952 3.201588 0.7538778 4.246826 0.0000217 0.0002014 1 Vim 6100.9927 2.604579 0.3873958 6.723301 0.0000000 0.0000000 1 Cdh3 122.5280 2.514449 0.4108614 6.119945 0.0000000 0.0000000 1 Mme 389.1301 2.410540 0.4538102 5.311780 0.0000001 0.0000019 1 Acta2 810.5272 2.191638 0.3519858 6.226496 0.0000000 0.0000000 1 Acta1 220.4697 2.002938 0.5823944 3.439143 0.0005836 0.0034350 1 Krt5 2428.7167 1.742587 0.2955009 5.897062 0.0000000 0.0000001 1 Tp63 276.4365 1.707863 0.3816019 4.475511 0.0000076 0.0000812 1 Krt14 1688.9052 1.703389 0.4155395 4.099223 0.0000415 0.0003557 1 Cnn1 1094.0549 1.591336 0.3750816 4.242639 0.0000221 0.0002043 1 Rn5-8s 646.3708 6.967022 1.2514676 5.567082 0.0000000 0.0000005 0 Tfpi2 1013.8400 6.782261 0.9290393 7.300295 0.0000000 0.0000000 0 Tnfaip6 2147.3764 6.328991 0.7291151 8.680373 0.0000000 0.0000000 0 Col3a1 75069.4773 6.242689 0.6375117 9.792275 0.0000000 0.0000000 0 Has1 1423.6626 5.849079 1.0061278 5.813455 0.0000000 0.0000001 0 Eln 6658.7061 5.822897 0.6230979 9.345075 0.0000000 0.0000000 0 Thbs2 2143.5066 5.770938 0.6290293 9.174355 0.0000000 0.0000000 0 Tnxa-ps1 126.1034 5.746321 0.6823115 8.421844 0.0000000 0.0000000 0 Rn45s 364.7818 5.724485 0.7622190 7.510289 0.0000000 0.0000000 0 Gfpt2 2059.5531 5.561419 0.5768219 9.641483 0.0000000 0.0000000 0 Col15a1 1337.4401 5.560307 0.6245844 8.902411 0.0000000 0.0000000 0 Mmp2 11105.2944 5.558362 0.5777826 9.620161 0.0000000 0.0000000 0 Kcnj8 245.0934 5.526459 0.7514916 7.353986 0.0000000 0.0000000 0 Efemp1 1498.7202 5.486844 0.6857745 8.000946 0.0000000 0.0000000 0 Twist2 185.4591 5.457104 0.6350370 8.593365 0.0000000 0.0000000 0 Mrgprg 159.5342 5.436056 1.2819551 4.240442 0.0000223 0.0002058 0 Cpxm1 2177.4236 5.435461 0.6265264 8.675549 0.0000000 0.0000000 0 Scara5 368.0080 5.432864 0.7035192 7.722410 0.0000000 0.0000000 0 Fbn1 1624.3106 5.424459 0.5290464 10.253277 0.0000000 0.0000000 0 Postn 22172.0888 5.381870 0.6120928 8.792572 0.0000000 0.0000000 0 Col5a3 1744.1883 5.374928 0.5967252 9.007376 0.0000000 0.0000000 0 RGD1566401 224.9537 5.362108 0.7870628 6.812808 0.0000000 0.0000000 0 Mmp23 215.7114 5.343524 0.5725280 9.333211 0.0000000 0.0000000 0 Cpz 439.0632 5.333774 0.8431887 6.325718 0.0000000 0.0000000 0 Col6a2 8582.6377 5.320969 0.5861963 9.077111 0.0000000 0.0000000 0 Lum 4358.4960 5.314668 0.6197195 8.575925 0.0000000 0.0000000 0 Lrrc15 234.7818 5.289271 0.6493885 8.145003 0.0000000 0.0000000 0 Gldn 585.5607 5.282934 0.7762567 6.805654 0.0000000 0.0000000 0 Pdgfra 896.6102 5.253834 0.5824643 9.020009 0.0000000 0.0000000 0 Fndc1 1047.4883 5.232145 0.5665954 9.234359 0.0000000 0.0000000 0 Olfml1 145.7458 5.219681 0.7271926 7.177852 0.0000000 0.0000000 0 Islr 522.7970 5.191028 0.5933090 8.749283 0.0000000 0.0000000 0 Col13a1 285.3767 5.190392 0.6850584 7.576568 0.0000000 0.0000000 0 Dcn 16280.1541 5.180590 0.5667647 9.140637 0.0000000 0.0000000 0 Tnc 1589.6204 5.174259 0.5849373 8.845835 0.0000000 0.0000000 0 Aoc3 546.2487 5.149838 0.7125029 7.227813 0.0000000 0.0000000 0 Tspan11 236.9381 5.139212 0.6134784 8.377170 0.0000000 0.0000000 0 Dpt 920.0959 5.134567 0.6383375 8.043655 0.0000000 0.0000000 0 Itm2a 1847.8700 5.131726 0.5466554 9.387498 0.0000000 0.0000000 0 Srpx2 190.6172 5.121515 0.5911400 8.663793 0.0000000 0.0000000 0 Pdgfrb 1515.3709 5.111582 0.6276893 8.143491 0.0000000 0.0000000 0 Loxl1 3186.3173 5.109936 0.5703463 8.959356 0.0000000 0.0000000 0 Igfbp6 3823.5545 5.100391 0.5817097 8.767932 0.0000000 0.0000000 0 Osr2 134.2850 5.083115 0.7968460 6.379043 0.0000000 0.0000000 0 Mfap2 977.3437 5.078349 0.5847472 8.684692 0.0000000 0.0000000 0 Bgn 2180.8025 5.077573 0.4782880 10.616142 0.0000000 0.0000000 0 Aebp1 3570.1295 5.055794 0.4405986 11.474830 0.0000000 0.0000000 0 Col5a1 3249.9628 5.029484 0.5155584 9.755412 0.0000000 0.0000000 0 Apod 753.8268 5.017742 0.5400101 9.291940 0.0000000 0.0000000 0 Ptprn 566.0434 4.984419 0.6890841 7.233398 0.0000000 0.0000000 0 Mrgprf 166.8197 4.959040 0.7187057 6.899959 0.0000000 0.0000000 0 Lrrc17 152.7924 4.955037 0.7158374 6.922015 0.0000000 0.0000000 0 Sparcl1 2405.8672 4.949126 0.6393911 7.740373 0.0000000 0.0000000 0 Lox 521.9770 4.940725 0.6074187 8.133969 0.0000000 0.0000000 0 Ccn4 255.2067 4.921607 0.6031455 8.159900 0.0000000 0.0000000 0 Col5a2 3406.0131 4.918194 0.4220019 11.654436 0.0000000 0.0000000 0 Galnt16 337.5513 4.916124 0.6941247 7.082479 0.0000000 0.0000000 0 Thy1 2137.2166 4.864043 0.5090971 9.554253 0.0000000 0.0000000 0 Tmeff2 212.6393 4.855749 0.6793003 7.148163 0.0000000 0.0000000 0 Cdh11 520.7112 4.842726 0.6284696 7.705584 0.0000000 0.0000000 0 Fn1 6406.4356 4.828989 0.5559227 8.686440 0.0000000 0.0000000 0 Cilp 1100.9927 4.812298 0.8034801 5.989319 0.0000000 0.0000001 0 C1qtnf5 257.0158 4.808971 0.6329612 7.597576 0.0000000 0.0000000 0 Col26a1 279.7418 4.804680 0.7784168 6.172374 0.0000000 0.0000000 0 Ccdc80 2836.1193 4.798665 0.4767511 10.065347 0.0000000 0.0000000 0 Dpep1 162.5931 4.787958 0.6994409 6.845408 0.0000000 0.0000000 0 Loxl2 837.8112 4.783938 0.4896831 9.769458 0.0000000 0.0000000 0 Mfap5 899.1383 4.781925 0.5444327 8.783318 0.0000000 0.0000000 0 Cpe 2833.1014 4.773485 0.4766535 10.014581 0.0000000 0.0000000 0 Sparc 26655.3232 4.772961 0.4568224 10.448176 0.0000000 0.0000000 0 Ctsk 1503.8227 4.752393 0.5590685 8.500555 0.0000000 0.0000000 0 Fxyd1 258.1318 4.750907 0.5703196 8.330254 0.0000000 0.0000000 0 Adcyap1r1 235.0748 4.749064 0.6054146 7.844317 0.0000000 0.0000000 0 Procr 405.0923 4.729111 0.5295553 8.930345 0.0000000 0.0000000 0 Pla1a 468.2159 4.720765 0.6021896 7.839333 0.0000000 0.0000000 0 LOC691995 275.7236 4.705164 0.6241946 7.537976 0.0000000 0.0000000 0 Itgbl1 381.7100 4.701729 0.7123222 6.600565 0.0000000 0.0000000 0 Fbln1 1048.6915 4.700320 0.4606437 10.203808 0.0000000 0.0000000 0 Adam33 387.9650 4.682978 0.6033146 7.762083 0.0000000 0.0000000 0 Prss23 1083.7409 4.680821 0.4782715 9.786955 0.0000000 0.0000000 0 PCOLCE2 212.8162 4.662670 0.5954232 7.830850 0.0000000 0.0000000 0 Vtn 108.8240 4.660007 0.7951942 5.860213 0.0000000 0.0000001 0 Sfrp4 594.7387 4.646489 0.6215171 7.476044 0.0000000 0.0000000 0 Srpx 1395.6753 4.645402 0.4779051 9.720345 0.0000000 0.0000000 0 Fbln5 479.1781 4.644147 0.4583875 10.131486 0.0000000 0.0000000 0 Gpr153 226.0421 4.634029 0.5336494 8.683658 0.0000000 0.0000000 0 Pdgfrl 287.1724 4.614351 0.5271015 8.754197 0.0000000 0.0000000 0 Gpc3 420.6613 4.609944 0.5667416 8.134120 0.0000000 0.0000000 0 Frzb 519.3137 4.562938 0.6326193 7.212770 0.0000000 0.0000000 0 Cpxm2 303.5400 4.562091 0.7511497 6.073479 0.0000000 0.0000000 0 Itga11 230.6776 4.551065 0.7266357 6.263201 0.0000000 0.0000000 0 Tmem119 598.0487 4.543089 0.6103469 7.443453 0.0000000 0.0000000 0 Grem2 104.6191 4.525993 0.8520596 5.311826 0.0000001 0.0000019 0 Htra3 1581.8937 4.502807 0.5688138 7.916134 0.0000000 0.0000000 0 Plxdc1 190.9109 4.483562 0.6667286 6.724719 0.0000000 0.0000000 0 Ackr3 1193.3036 4.471868 0.5066290 8.826712 0.0000000 0.0000000 0 C1s 4902.7645 4.462707 0.5651718 7.896194 0.0000000 0.0000000 0 Rem1 273.0018 4.458095 0.5783784 7.707920 0.0000000 0.0000000 0 Igsf10 236.5255 4.454897 0.7127254 6.250509 0.0000000 0.0000000 0 Mab21l1 142.4069 4.442645 0.5369438 8.273948 0.0000000 0.0000000 0 Pcdh7 120.3456 4.441019 0.7285085 6.096043 0.0000000 0.0000000 0 Igfbp4 11775.2669 4.439193 0.4391960 10.107546 0.0000000 0.0000000 0 Nid2 450.4482 4.438885 0.5544867 8.005394 0.0000000 0.0000000 0 Rarres2 435.6827 4.436406 0.5448112 8.143015 0.0000000 0.0000000 0 Gdf10 518.4529 4.414306 0.6765679 6.524557 0.0000000 0.0000000 0 Olfml3 506.6436 4.403864 0.5111571 8.615480 0.0000000 0.0000000 0 Serpine1 2581.0544 4.394455 0.4963202 8.854073 0.0000000 0.0000000 0 Ptgis 169.3081 4.350808 0.5972145 7.285169 0.0000000 0.0000000 0 Dchs1 250.3222 4.345966 0.6474727 6.712199 0.0000000 0.0000000 0 Rcn3 1042.1428 4.332820 0.4431814 9.776627 0.0000000 0.0000000 0 Aldh1a2 1191.2031 4.331141 0.6161852 7.028960 0.0000000 0.0000000 0 Ebf1 194.0457 4.326332 0.5580121 7.753115 0.0000000 0.0000000 0 Olfml2b 361.7737 4.294461 0.6025528 7.127111 0.0000000 0.0000000 0 Ddr2 537.0761 4.282515 0.5183098 8.262461 0.0000000 0.0000000 0 Adamts2 758.5144 4.282225 0.5979913 7.161016 0.0000000 0.0000000 0 C1qtnf2 162.4259 4.273449 0.6446417 6.629186 0.0000000 0.0000000 0 Ror2 399.3368 4.259612 0.3900349 10.921105 0.0000000 0.0000000 0 Col4a1 8468.2985 4.253007 0.3525939 12.062055 0.0000000 0.0000000 0 Ednra 377.8694 4.232666 0.4892416 8.651484 0.0000000 0.0000000 0 Lrrn4cl 322.4136 4.228645 0.5252028 8.051451 0.0000000 0.0000000 0 Clec11a 359.3135 4.205880 0.4485772 9.376044 0.0000000 0.0000000 0 Pdpn 538.6567 4.190919 0.4551350 9.208080 0.0000000 0.0000000 0 Egflam 518.0367 4.175104 0.4027936 10.365369 0.0000000 0.0000000 0 Mxra8 1323.9902 4.153454 0.3876725 10.713821 0.0000000 0.0000000 0 Sod3 1006.5374 4.147900 0.3989581 10.396831 0.0000000 0.0000000 0 Ednrb 250.5256 4.142434 0.5535065 7.483984 0.0000000 0.0000000 0 Fam131b 100.6868 4.135955 0.5716968 7.234525 0.0000000 0.0000000 0 Ccl21 1026.0626 4.134443 0.6284105 6.579207 0.0000000 0.0000000 0 Enpp2 406.6358 4.127585 0.6479852 6.369875 0.0000000 0.0000000 0 Gpx7 419.7657 4.121917 0.4152010 9.927522 0.0000000 0.0000000 0 Il6 304.2368 4.121767 0.8091419 5.093997 0.0000004 0.0000054 0 Pi16 306.6778 4.115233 0.4624705 8.898368 0.0000000 0.0000000 0 Wfdc1 198.1632 4.115215 0.6304874 6.527038 0.0000000 0.0000000 0 Angpt2 262.1297 4.103774 0.5887059 6.970839 0.0000000 0.0000000 0 Aqp1 502.9767 4.103299 0.6822548 6.014320 0.0000000 0.0000000 0 Gjc1 196.5105 4.088684 0.6203247 6.591201 0.0000000 0.0000000 0 Pcsk5 277.4921 4.071447 0.5466630 7.447819 0.0000000 0.0000000 0 Lgals1 2959.2935 4.070660 0.4959040 8.208566 0.0000000 0.0000000 0 Crlf1 184.7652 4.066944 0.4950034 8.215993 0.0000000 0.0000000 0 Ccn5 147.4171 4.064622 0.5521299 7.361713 0.0000000 0.0000000 0 Serpinf1 6036.8587 4.062639 0.4096250 9.917945 0.0000000 0.0000000 0 Col18a1 2857.3395 4.062554 0.3259107 12.465234 0.0000000 0.0000000 0 Cthrc1 1127.5960 4.037359 0.4432927 9.107659 0.0000000 0.0000000 0 Thbd 338.4656 4.027841 0.5380069 7.486598 0.0000000 0.0000000 0 Spon1 2233.7039 4.024138 0.6224126 6.465387 0.0000000 0.0000000 0 Gpr176 187.1321 4.021231 0.6336028 6.346612 0.0000000 0.0000000 0 Chrd 139.3470 4.014938 0.6554075 6.125865 0.0000000 0.0000000 0 Plvap 464.0182 4.001680 0.6045636 6.619122 0.0000000 0.0000000 0 Tspan18 159.2317 3.997680 0.5798279 6.894598 0.0000000 0.0000000 0 Ccl11 724.6513 3.995725 0.7623933 5.241029 0.0000002 0.0000027 0 Slc41a2 162.7295 3.993486 0.5999865 6.655960 0.0000000 0.0000000 0 Plac9 190.0792 3.979106 0.4799403 8.290836 0.0000000 0.0000000 0 Serpine2 2749.3714 3.970331 0.4121560 9.633079 0.0000000 0.0000000 0 Cygb 290.7714 3.969134 0.4423110 8.973625 0.0000000 0.0000000 0 Colec12 437.6058 3.960543 0.4453094 8.893913 0.0000000 0.0000000 0 Clec14a 323.8001 3.953003 0.5412131 7.303967 0.0000000 0.0000000 0 Esam 162.5833 3.947385 0.7003721 5.636125 0.0000000 0.0000004 0 Dnm1 413.4595 3.938316 0.4516459 8.719920 0.0000000 0.0000000 0 Cnrip1 101.9362 3.937197 0.5953583 6.613156 0.0000000 0.0000000 0 Pth1r 283.4413 3.893975 0.5430032 7.171183 0.0000000 0.0000000 0 S1pr3 362.8422 3.881331 0.4989759 7.778594 0.0000000 0.0000000 0 Fhl1 151.6888 3.872951 0.6031371 6.421344 0.0000000 0.0000000 0 Cacna1g 155.3204 3.870826 0.5936353 6.520546 0.0000000 0.0000000 0 Adgrf5 123.7058 3.870361 0.7667482 5.047760 0.0000004 0.0000067 0 Igfbp7 2230.5176 3.865947 0.4561988 8.474260 0.0000000 0.0000000 0 Hba-a1 147.2625 3.863368 0.7362403 5.247428 0.0000002 0.0000026 0 Cxcl14 802.7980 3.825617 0.3491337 10.957457 0.0000000 0.0000000 0 Clmp 543.7066 3.824299 0.4439586 8.614090 0.0000000 0.0000000 0 Bcat1 296.5920 3.803747 0.5794115 6.564846 0.0000000 0.0000000 0 Frem1 107.4991 3.801972 0.6804102 5.587764 0.0000000 0.0000005 0 Pcdh19 171.9757 3.794780 0.5418573 7.003283 0.0000000 0.0000000 0 Vcan 652.5514 3.794409 0.3833749 9.897386 0.0000000 0.0000000 0 Mmp16 126.8241 3.794027 0.5299545 7.159156 0.0000000 0.0000000 0 Col8a1 602.3175 3.785426 0.5318233 7.117826 0.0000000 0.0000000 0 Prdm8 115.5995 3.768575 0.5722558 6.585474 0.0000000 0.0000000 0 Ptn 2177.6717 3.758703 0.3421298 10.986190 0.0000000 0.0000000 0 Exoc3l4 185.1169 3.734490 0.4990044 7.483882 0.0000000 0.0000000 0 Atp10a 112.7659 3.728525 0.5681012 6.563135 0.0000000 0.0000000 0 Mnda 265.7300 3.726016 0.5731747 6.500664 0.0000000 0.0000000 0 Akr1c14 126.9164 3.723836 0.6843694 5.441267 0.0000001 0.0000010 0 Il1rl1 1135.9063 3.710796 0.6740093 5.505556 0.0000000 0.0000007 0 Crabp1 989.5432 3.708932 0.5094882 7.279720 0.0000000 0.0000000 0 Acvrl1 259.5261 3.695486 0.5622610 6.572546 0.0000000 0.0000000 0 Vcam1 135.1955 3.685483 0.5053019 7.293625 0.0000000 0.0000000 0 Fibin 105.9405 3.678812 0.6914751 5.320239 0.0000001 0.0000018 0 Ssc5d 127.2281 3.676362 0.5786552 6.353286 0.0000000 0.0000000 0 Prrx2 293.6987 3.670858 0.5563559 6.598038 0.0000000 0.0000000 0 Igfbp3 1778.9231 3.663105 0.5899450 6.209232 0.0000000 0.0000000 0 F5 583.5018 3.662537 0.5056695 7.242946 0.0000000 0.0000000 0 Qprt 253.7643 3.654273 0.5495715 6.649313 0.0000000 0.0000000 0 Zeb1 399.5203 3.641911 0.5271493 6.908689 0.0000000 0.0000000 0 Pcdh18 312.7013 3.632378 0.5625348 6.457161 0.0000000 0.0000000 0 Numbl 315.5350 3.619374 0.4327042 8.364546 0.0000000 0.0000000 0 Cdc42ep2 103.0887 3.616160 0.5508253 6.564984 0.0000000 0.0000000 0 Nkd2 827.3550 3.610184 0.4128302 8.744960 0.0000000 0.0000000 0 Dio2 168.8127 3.608382 0.4587063 7.866432 0.0000000 0.0000000 0 Gria3 109.0346 3.603472 0.4921030 7.322597 0.0000000 0.0000000 0 Palm2 100.6265 3.601057 0.4656446 7.733487 0.0000000 0.0000000 0 LOC100134871 887.1477 3.599900 0.7976839 4.512941 0.0000064 0.0000695 0 Enpep 225.2875 3.582405 0.5902412 6.069392 0.0000000 0.0000000 0 Col7a1 647.6241 3.581726 0.4537597 7.893442 0.0000000 0.0000000 0 Nxph3 127.4595 3.569685 0.3355171 10.639355 0.0000000 0.0000000 0 Shc4 146.1813 3.557632 0.4498423 7.908621 0.0000000 0.0000000 0 Snai1 595.1247 3.556576 0.3882430 9.160694 0.0000000 0.0000000 0 Tie1 198.3739 3.553724 0.6066267 5.858174 0.0000000 0.0000001 0 Loxl3 264.5793 3.539433 0.4502746 7.860610 0.0000000 0.0000000 0 Mgp 8600.5194 3.537569 0.4494176 7.871452 0.0000000 0.0000000 0 Sema3a 125.4272 3.530616 0.4455784 7.923669 0.0000000 0.0000000 0 Serping1 4231.0217 3.522311 0.4403314 7.999228 0.0000000 0.0000000 0 F2r 769.7308 3.520952 0.4222687 8.338179 0.0000000 0.0000000 0 Jam2 142.8647 3.495788 0.5933310 5.891801 0.0000000 0.0000001 0 Lama1 110.1153 3.491409 0.5696945 6.128563 0.0000000 0.0000000 0 Abcc9 199.7610 3.481201 0.7648141 4.551695 0.0000053 0.0000593 0 Hmcn1 294.0097 3.480459 0.5176129 6.724058 0.0000000 0.0000000 0 Lrrc32 622.8923 3.477315 0.4261087 8.160628 0.0000000 0.0000000 0 Atp1b2 127.7142 3.469360 0.4891704 7.092335 0.0000000 0.0000000 0 Cxcl12 2252.8912 3.459090 0.3579334 9.664063 0.0000000 0.0000000 0 Dkk2 125.6002 3.434520 0.5586255 6.148161 0.0000000 0.0000000 0 Zfp521 139.4505 3.423172 0.5397961 6.341601 0.0000000 0.0000000 0 Dpysl3 116.7495 3.419226 0.4920467 6.948986 0.0000000 0.0000000 0 Dact3 188.1667 3.418701 0.4389931 7.787596 0.0000000 0.0000000 0 Mmp19 915.6852 3.411489 0.3550156 9.609408 0.0000000 0.0000000 0 Flnc 247.9848 3.401140 0.6598522 5.154396 0.0000003 0.0000041 0 LOC100909539 280.2333 3.400798 0.4555330 7.465536 0.0000000 0.0000000 0 Zcchc24 339.5992 3.397785 0.4349789 7.811379 0.0000000 0.0000000 0 Dkk3 1003.1543 3.391410 0.3373925 10.051822 0.0000000 0.0000000 0 Sema5a 588.6621 3.366793 0.3809879 8.837008 0.0000000 0.0000000 0 Fgl2 2459.2189 3.357473 0.7196082 4.665695 0.0000031 0.0000367 0 Fscn1 665.5523 3.353338 0.4892518 6.854013 0.0000000 0.0000000 0 Abcb1b 124.2460 3.352589 0.4778803 7.015541 0.0000000 0.0000000 0 Itga1 178.7644 3.336151 0.4682034 7.125431 0.0000000 0.0000000 0 Art3 187.0617 3.324565 0.3806480 8.733961 0.0000000 0.0000000 0 Kazald1 143.2970 3.321400 0.4079228 8.142228 0.0000000 0.0000000 0 C1qtnf1 751.1032 3.317064 0.3965821 8.364129 0.0000000 0.0000000 0 RGD1564664 1474.4935 3.311346 0.4300746 7.699468 0.0000000 0.0000000 0 Tbx2 220.5571 3.306141 0.3693258 8.951827 0.0000000 0.0000000 0 Selenom 873.5283 3.299343 0.3824049 8.627877 0.0000000 0.0000000 0 Ltbp4 1206.9010 3.291806 0.3534000 9.314676 0.0000000 0.0000000 0 Lhfpl6 376.8189 3.283998 0.3365525 9.757758 0.0000000 0.0000000 0 Axl 1393.9990 3.279151 0.4040998 8.114707 0.0000000 0.0000000 0 Tril 661.3142 3.276348 0.3566654 9.186053 0.0000000 0.0000000 0 Mdk 508.5394 3.240024 0.3891097 8.326763 0.0000000 0.0000000 0 Upk3a 788.3217 -3.221880 0.8058789 -3.997970 0.0000639 0.0005212 0 Sfrp2 368.8970 3.202463 0.3954815 8.097631 0.0000000 0.0000000 0 Penk 2483.8937 3.182268 0.3248519 9.796058 0.0000000 0.0000000 0 Nell1 102.1992 3.178670 0.5154812 6.166414 0.0000000 0.0000000 0 Lpar1 571.4751 3.165497 0.4302207 7.357844 0.0000000 0.0000000 0 Tspan5 305.6419 3.153353 0.4329608 7.283229 0.0000000 0.0000000 0 Gpihbp1 158.2721 3.147467 0.8284452 3.799245 0.0001451 0.0010506 0 Smoc2 2632.5687 3.145362 0.4779106 6.581486 0.0000000 0.0000000 0 Ptprv 141.2250 3.142574 0.4792399 6.557413 0.0000000 0.0000000 0 Ntrk2 252.4903 3.138736 0.6977837 4.498150 0.0000069 0.0000740 0 C1r 4990.1992 3.137515 0.3952350 7.938351 0.0000000 0.0000000 0 Gpx3 4247.1870 3.132247 0.4447684 7.042422 0.0000000 0.0000000 0 Pcsk6 162.7802 3.128262 0.5732342 5.457215 0.0000000 0.0000009 0 Tnfrsf11b 460.8675 3.121292 0.5566237 5.607545 0.0000000 0.0000004 0 Cxcl13 226.6853 3.120053 0.5916540 5.273442 0.0000001 0.0000023 0 Dlc1 346.7489 3.108438 0.4119221 7.546179 0.0000000 0.0000000 0 Runx1t1 119.3703 3.107210 0.6408801 4.848348 0.0000012 0.0000166 0 Col17a1 545.6073 3.100296 0.4188870 7.401271 0.0000000 0.0000000 0 Apold1 287.3202 3.099614 0.7239703 4.281410 0.0000186 0.0001759 0 Fam102b 403.4009 3.095401 0.4256908 7.271477 0.0000000 0.0000000 0 Slc12a4 510.3016 3.094257 0.3997211 7.741039 0.0000000 0.0000000 0 Il16 133.0967 3.092863 0.5361487 5.768666 0.0000000 0.0000002 0 Emp3 707.4352 3.091062 0.4461074 6.928964 0.0000000 0.0000000 0 Rab3il1 109.1259 3.085552 0.4992863 6.179926 0.0000000 0.0000000 0 Fkbp9 1481.6386 3.083289 0.3858850 7.990175 0.0000000 0.0000000 0 Sema3b 1039.1561 3.075476 0.3283606 9.366153 0.0000000 0.0000000 0 Adora2b 130.6251 3.060963 0.4582401 6.679823 0.0000000 0.0000000 0 Upk1b 281.4449 3.049506 0.3252781 9.375073 0.0000000 0.0000000 0 Cav1 2220.8901 3.038389 0.3138451 9.681174 0.0000000 0.0000000 0 Rftn1 449.5032 3.034218 0.5134653 5.909295 0.0000000 0.0000001 0 Htra1 2766.5740 3.033742 0.4417951 6.866855 0.0000000 0.0000000 0 Fzd1 590.8730 3.028443 0.3100909 9.766306 0.0000000 0.0000000 0 Nol3 133.3412 3.021753 0.4159256 7.265127 0.0000000 0.0000000 0 Oaf 1448.7798 3.019487 0.4376973 6.898574 0.0000000 0.0000000 0 Cyp1b1 105.0529 3.012439 0.6428213 4.686277 0.0000028 0.0000335 0 Jam3 644.3821 3.003404 0.2996066 10.024491 0.0000000 0.0000000 0 Col27a1 136.4656 2.998731 0.4604948 6.511976 0.0000000 0.0000000 0 Lix1l 167.9946 2.973664 0.4713837 6.308373 0.0000000 0.0000000 0 Zeb2 205.1850 2.972308 0.5581211 5.325560 0.0000001 0.0000018 0 B4galt2 127.7717 2.965324 0.4032528 7.353512 0.0000000 0.0000000 0 Scarf1 100.5658 2.956363 0.4812180 6.143500 0.0000000 0.0000000 0 Gpx8 534.1358 2.928093 0.3201203 9.146852 0.0000000 0.0000000 0 Cdh13 354.4445 2.925847 0.3673725 7.964250 0.0000000 0.0000000 0 Ncam1 100.7264 2.925136 0.5778769 5.061867 0.0000004 0.0000063 0 Col14a1 2833.3622 2.920337 0.3056482 9.554572 0.0000000 0.0000000 0 Pecam1 183.6669 2.911640 0.4273503 6.813240 0.0000000 0.0000000 0 Igf1 286.5929 2.911071 0.5007628 5.813273 0.0000000 0.0000001 0 Slc7a5 1107.5923 2.909632 0.3746406 7.766463 0.0000000 0.0000000 0 Dscam 132.5769 -2.905794 0.6667670 -4.358035 0.0000131 0.0001307 0 Dse 196.7943 2.905608 0.4676832 6.212770 0.0000000 0.0000000 0 Cacna2d1 147.7032 2.902892 0.4388243 6.615158 0.0000000 0.0000000 0 Cybrd1 233.6760 2.900978 0.4771556 6.079731 0.0000000 0.0000000 0 Twist1 365.9784 2.900536 0.3588450 8.082979 0.0000000 0.0000000 0 Rgl1 202.5890 2.898987 0.4347422 6.668288 0.0000000 0.0000000 0 Chst12 242.5970 2.890400 0.3323157 8.697753 0.0000000 0.0000000 0 Anpep 470.9687 2.878753 0.5309196 5.422202 0.0000001 0.0000011 0 Rgs5 300.2458 2.866901 0.6175683 4.642241 0.0000034 0.0000405 0 Gng2 588.6754 2.860471 0.4386450 6.521154 0.0000000 0.0000000 0 Smpd3 303.5242 2.844436 0.4712034 6.036535 0.0000000 0.0000000 0 Gask1b 463.9801 2.843836 0.3334652 8.528134 0.0000000 0.0000000 0 Gpm6b 742.7629 2.838811 0.2824285 10.051434 0.0000000 0.0000000 0 Reck 549.1038 2.835363 0.3197277 8.868057 0.0000000 0.0000000 0 Egr2 1058.2192 2.826388 0.3429404 8.241630 0.0000000 0.0000000 0 Nt5e 421.5463 2.819527 0.3726106 7.566952 0.0000000 0.0000000 0 Col2a1 791.4075 2.817939 0.4684319 6.015686 0.0000000 0.0000000 0 Septin5 199.1482 2.809953 0.4483708 6.267030 0.0000000 0.0000000 0 Bicc1 174.4927 2.806071 0.4222716 6.645181 0.0000000 0.0000000 0 Lrp1 3018.1950 2.797152 0.3736193 7.486637 0.0000000 0.0000000 0 Plod2 160.3864 2.789210 0.4228754 6.595818 0.0000000 0.0000000 0 Cspg4 127.0395 2.783979 0.6307618 4.413677 0.0000102 0.0001043 0 Susd2 190.3349 2.780393 0.5034666 5.522498 0.0000000 0.0000007 0 LOC310926 3340.9152 2.777177 0.4386296 6.331487 0.0000000 0.0000000 0 Tpst1 378.8238 2.773113 0.4294760 6.456969 0.0000000 0.0000000 0 Osr1 416.2648 2.764075 0.3118686 8.862947 0.0000000 0.0000000 0 Il34 331.7695 2.755964 0.3559588 7.742366 0.0000000 0.0000000 0 Cercam 466.2355 2.755729 0.3720951 7.405981 0.0000000 0.0000000 0 Adamts12 386.1301 2.725159 0.5557480 4.903588 0.0000009 0.0000129 0 Cyp2s1 197.1440 2.712164 0.5633218 4.814591 0.0000015 0.0000193 0 Hbb 1321.4563 2.711326 0.7464383 3.632351 0.0002809 0.0018383 0 Crispld2 1362.0626 2.708600 0.2910507 9.306285 0.0000000 0.0000000 0 Eng 630.6189 2.706890 0.3391724 7.980867 0.0000000 0.0000000 0 Selp 101.4683 2.678829 0.6460429 4.146520 0.0000338 0.0002969 0 Ecrg4 118.9276 2.666184 0.4241879 6.285385 0.0000000 0.0000000 0 Septin4 429.6586 2.645722 0.4029789 6.565412 0.0000000 0.0000000 0 Tgfbr3 342.3764 2.643506 0.2692689 9.817345 0.0000000 0.0000000 0 Adamts4 772.9674 2.642827 0.4473599 5.907607 0.0000000 0.0000001 0 Emilin1 1370.0069 2.642351 0.2926761 9.028241 0.0000000 0.0000000 0 Gsn 29582.7616 2.636810 0.4276990 6.165106 0.0000000 0.0000000 0 Dnm3 117.9613 2.634847 0.4061163 6.487914 0.0000000 0.0000000 0 Ccl7 653.5993 2.633831 0.5949168 4.427226 0.0000095 0.0000988 0 Adamts1 3206.9248 2.632098 0.3043937 8.647017 0.0000000 0.0000000 0 Ccl2 2852.3299 2.624594 0.6800264 3.859548 0.0001136 0.0008567 0 Lhfpl2 644.4885 2.619306 0.4439851 5.899536 0.0000000 0.0000001 0 Gem 883.6119 2.609832 0.4642971 5.621039 0.0000000 0.0000004 0 Plpp3 1606.7103 2.608515 0.3229819 8.076348 0.0000000 0.0000000 0 Spock2 114.3529 2.602698 0.4691650 5.547510 0.0000000 0.0000006 0 Fst 394.7378 2.596740 0.4970610 5.224188 0.0000002 0.0000029 0 Gpnmb 1496.1482 2.595528 0.4508387 5.757111 0.0000000 0.0000002 0 Reln 394.4076 2.589380 0.3750306 6.904450 0.0000000 0.0000000 0 Nfatc4 175.6242 2.583825 0.4157614 6.214683 0.0000000 0.0000000 0 Enc1 395.5011 2.578549 0.4080289 6.319526 0.0000000 0.0000000 0 Ndrg4 223.2030 2.578225 0.3877806 6.648670 0.0000000 0.0000000 0 Adcy7 473.3677 2.577621 0.3466058 7.436753 0.0000000 0.0000000 0 Gas7 680.5193 2.570699 0.3350583 7.672393 0.0000000 0.0000000 0 Ramp3 482.7606 2.562886 0.5858101 4.374943 0.0000121 0.0001217 0 Fmod 229.0674 2.560216 0.4568493 5.604072 0.0000000 0.0000004 0 Tmem204 105.9487 2.552303 0.4310563 5.921042 0.0000000 0.0000001 0 Prkar1b 100.0586 2.548675 0.5112011 4.985660 0.0000006 0.0000089 0 Ptx3 252.4271 2.537825 0.5135296 4.941926 0.0000008 0.0000108 0 Csn2 1484.3714 2.524105 0.8640745 2.921166 0.0034872 0.0153650 0 Angptl2 959.4925 2.520335 0.4035653 6.245173 0.0000000 0.0000000 0 Itga4 309.9774 2.517153 0.6346755 3.966048 0.0000731 0.0005863 0 Grb10 159.2062 2.508878 0.4491213 5.586193 0.0000000 0.0000005 0 Antxr1 232.4040 2.505607 0.4302649 5.823407 0.0000000 0.0000001 0 Abca8a 398.9002 2.504300 0.3367116 7.437524 0.0000000 0.0000000 0 Dll1 113.0938 2.499336 0.3817295 6.547402 0.0000000 0.0000000 0 Bche 178.6865 -2.498925 0.4806422 -5.199137 0.0000002 0.0000033 0 Shc2 249.3406 2.490768 0.4209437 5.917105 0.0000000 0.0000001 0 Prdm1 218.1960 2.487205 0.5357894 4.642132 0.0000034 0.0000405 0 Rnase4 1323.5759 2.485140 0.3887929 6.391936 0.0000000 0.0000000 0 Emp1 3747.5812 2.479963 0.4324960 5.734073 0.0000000 0.0000002 0 Adamts18 281.1375 2.459051 0.3760726 6.538768 0.0000000 0.0000000 0 Macroh2a2 144.8875 2.454735 0.2903260 8.455096 0.0000000 0.0000000 0 Serpinh1 5853.7264 2.454648 0.2744355 8.944354 0.0000000 0.0000000 0 Cdr2 186.3575 2.454230 0.3683962 6.661931 0.0000000 0.0000000 0 Spats2l 188.8600 2.452352 0.3353191 7.313490 0.0000000 0.0000000 0 Akap2 872.3341 2.450348 0.3276382 7.478825 0.0000000 0.0000000 0 Arhgap31 111.5465 2.447727 0.4163406 5.879146 0.0000000 0.0000001 0 Begain 133.7512 2.445000 0.3621152 6.751996 0.0000000 0.0000000 0 Igfbp2 3187.3795 2.433660 0.3501083 6.951162 0.0000000 0.0000000 0 Daglb 450.2521 2.429355 0.4142948 5.863832 0.0000000 0.0000001 0 Csf1 468.5954 2.425532 0.3554508 6.823820 0.0000000 0.0000000 0 Lefty1 491.7467 -2.424016 0.4958479 -4.888628 0.0000010 0.0000138 0 Unc5b 360.4142 2.407906 0.3178839 7.574799 0.0000000 0.0000000 0 Mitf 302.3200 2.400747 0.3450386 6.957909 0.0000000 0.0000000 0 Mark1 306.9292 2.400044 0.4245985 5.652501 0.0000000 0.0000003 0 Adamts7 176.9368 2.398231 0.4066732 5.897195 0.0000000 0.0000001 0 Wnt6 122.9730 2.390567 0.3266658 7.318081 0.0000000 0.0000000 0 Pcdhgc3 397.1692 2.390108 0.2897674 8.248370 0.0000000 0.0000000 0 Fbn2 199.1335 2.389875 0.3850718 6.206310 0.0000000 0.0000000 0 Fxyd6 444.3905 2.387818 0.3811330 6.265050 0.0000000 0.0000000 0 Smim38 8119.2866 -2.383005 0.4398426 -5.417858 0.0000001 0.0000011 0 Tgfbi 585.7200 2.379578 0.3889346 6.118195 0.0000000 0.0000000 0 Efemp2 1207.8933 2.379182 0.2570542 9.255565 0.0000000 0.0000000 0 Rprml 120.3243 2.365343 0.4091114 5.781661 0.0000000 0.0000002 0 Cmtm3 279.1797 2.360282 0.2934795 8.042408 0.0000000 0.0000000 0 Fkbp7 302.8251 2.358437 0.3148879 7.489765 0.0000000 0.0000000 0 Flna 2444.1644 2.357180 0.2340796 10.069994 0.0000000 0.0000000 0 Myh11 859.1861 2.356544 0.4366147 5.397308 0.0000001 0.0000013 0 Cpq 871.8399 2.350743 0.3239162 7.257256 0.0000000 0.0000000 0 Nes 106.1876 2.349658 0.3792161 6.196093 0.0000000 0.0000000 0 Mrvi1 104.8388 2.327789 0.4231978 5.500475 0.0000000 0.0000007 0 Hspa12b 122.1713 2.317444 0.4402558 5.263858 0.0000001 0.0000024 0 Aadat 177.9661 -2.316014 0.4329710 -5.349121 0.0000001 0.0000016 0 Papss2 209.0147 2.310007 0.5092647 4.535965 0.0000057 0.0000631 0 Gprc5b 120.1190 2.305973 0.2790378 8.264014 0.0000000 0.0000000 0 Ptprb 111.8884 2.296513 0.5957520 3.854813 0.0001158 0.0008708 0 Il1r1 167.8646 2.295915 0.3734539 6.147787 0.0000000 0.0000000 0 Mmd 905.7223 2.290735 0.3745968 6.115201 0.0000000 0.0000000 0 Palm 429.6788 2.284678 0.3289211 6.945974 0.0000000 0.0000000 0 Lzts3 119.3629 2.280359 0.3883959 5.871223 0.0000000 0.0000001 0 Flrt2 197.3082 2.252728 0.4520570 4.983282 0.0000006 0.0000090 0 Ramp2 259.9998 2.252714 0.3573526 6.303896 0.0000000 0.0000000 0 Inhba 163.7853 2.250190 0.5144556 4.373925 0.0000122 0.0001222 0 Ccl22 101.4999 -2.240661 0.7008198 -3.197200 0.0013877 0.0071477 0 Runx2 238.5121 2.238187 0.3415328 6.553360 0.0000000 0.0000000 0 Hdgfl3 123.9819 2.237990 0.3497898 6.398100 0.0000000 0.0000000 0 Prnp 3434.0603 2.234893 0.2830195 7.896605 0.0000000 0.0000000 0 Slc43a3 121.3600 2.233617 0.5299961 4.214404 0.0000250 0.0002286 0 Ptp4a3 162.9598 2.232448 0.3579957 6.235963 0.0000000 0.0000000 0 Megf6 214.5995 2.228890 0.4625785 4.818403 0.0000014 0.0000189 0 Rarres1 692.3008 2.225378 0.4248093 5.238534 0.0000002 0.0000027 0 Pcolce 2323.0430 2.222591 0.4323547 5.140667 0.0000003 0.0000043 0 Tcf4 1150.8625 2.221749 0.3226485 6.885974 0.0000000 0.0000000 0 Nrcam 133.2881 2.216599 0.4147882 5.343929 0.0000001 0.0000016 0 Rgma 726.5645 2.213217 0.2697522 8.204633 0.0000000 0.0000000 0 Ptgs2 192.2413 2.210491 0.8961631 2.466616 0.0136396 0.0465459 0 Csrp2 173.8134 2.202842 0.4216127 5.224799 0.0000002 0.0000029 0 Lrg1 292.0465 2.194472 0.4557481 4.815099 0.0000015 0.0000192 0 Rspo3 217.0326 -2.193289 0.4262989 -5.144957 0.0000003 0.0000043 0 Phlda3 669.0042 2.193277 0.2347928 9.341329 0.0000000 0.0000000 0 Jag2 397.4450 2.191055 0.3298827 6.641923 0.0000000 0.0000000 0 Itga5 710.4103 2.190287 0.3800142 5.763697 0.0000000 0.0000002 0 Lef1 147.9467 2.184183 0.3720886 5.870061 0.0000000 0.0000001 0 Ppic 1841.8759 2.175869 0.3921562 5.548474 0.0000000 0.0000006 0 P2ry14 130.0805 -2.173069 0.5343359 -4.066859 0.0000477 0.0004008 0 Timp2 7088.9776 2.172977 0.3653826 5.947128 0.0000000 0.0000001 0 Bdkrb2 192.9493 2.160832 0.4139064 5.220580 0.0000002 0.0000030 0 Alas2 110.7376 2.155679 0.7621005 2.828601 0.0046752 0.0194589 0 Plpp1 320.0070 2.152741 0.2882076 7.469411 0.0000000 0.0000000 0 Scpep1 3644.4909 2.150081 0.2445198 8.793076 0.0000000 0.0000000 0 Vwf 167.3556 2.146961 0.3809412 5.635937 0.0000000 0.0000004 0 Rbp7 657.3019 -2.144750 0.3587147 -5.978985 0.0000000 0.0000001 0 Ccn3 254.3234 2.142841 0.5171161 4.143830 0.0000342 0.0002997 0 Nrgn 300.4902 2.129246 0.7284252 2.923081 0.0034659 0.0152843 0 Tns1 322.6064 2.121534 0.3374609 6.286755 0.0000000 0.0000000 0 Nnat 320.0474 2.118320 0.3430343 6.175244 0.0000000 0.0000000 0 Chsy1 348.9624 2.111802 0.3264637 6.468719 0.0000000 0.0000000 0 Kdr 132.8522 2.111645 0.6760797 3.123367 0.0017879 0.0088352 0 Krt17 3165.8624 2.107356 0.3810992 5.529678 0.0000000 0.0000006 0 Spef2 353.1161 -2.106277 0.3283794 -6.414156 0.0000000 0.0000000 0 P3h3 815.4425 2.105157 0.2645743 7.956770 0.0000000 0.0000000 0 Tgfbr2 774.9813 2.100430 0.2984957 7.036715 0.0000000 0.0000000 0 Zfhx4 175.5838 2.094610 0.4028859 5.199014 0.0000002 0.0000033 0 Pthlh 114.9678 2.094431 0.3263659 6.417434 0.0000000 0.0000000 0 Cd48 974.4632 2.082031 0.3800856 5.477795 0.0000000 0.0000008 0 Rps4y2 120.7338 2.079510 0.4401057 4.725024 0.0000023 0.0000283 0 Vsir 277.8053 2.078914 0.2885379 7.204993 0.0000000 0.0000000 0 Apoe 44435.0745 2.069904 0.2743201 7.545579 0.0000000 0.0000000 0 Fstl1 4836.5303 2.066790 0.2897093 7.134014 0.0000000 0.0000000 0 Nrp2 152.7282 2.063204 0.3837499 5.376429 0.0000001 0.0000014 0 Cdkn1c 376.0666 2.062469 0.3886471 5.306792 0.0000001 0.0000020 0 Ccl3 127.1550 -2.059621 0.6299330 -3.269587 0.0010770 0.0057971 0 Arc 168.7765 2.055382 0.4749757 4.327342 0.0000151 0.0001479 0 Phldb1 590.8156 2.053968 0.3091370 6.644198 0.0000000 0.0000000 0 Cdo1 4213.2359 -2.048688 0.3383167 -6.055534 0.0000000 0.0000000 0 Abcc5 186.1390 2.039198 0.3093206 6.592507 0.0000000 0.0000000 0 Mllt11 164.6249 2.039191 0.2457632 8.297381 0.0000000 0.0000000 0 Tgfb1i1 478.1620 2.037312 0.2652556 7.680561 0.0000000 0.0000000 0 Nrg2 191.5248 2.036211 0.3424484 5.946036 0.0000000 0.0000001 0 Adm 358.1838 2.034742 0.3851795 5.282582 0.0000001 0.0000022 0 Bco2 2469.9775 -2.032112 0.3269436 -6.215480 0.0000000 0.0000000 0 Tent5a 394.6876 2.016925 0.2884229 6.992942 0.0000000 0.0000000 0 Capn6 139.6396 2.013373 0.4497923 4.476228 0.0000076 0.0000811 0 P3h1 777.6716 1.998406 0.2605474 7.670026 0.0000000 0.0000000 0 Foxa1 967.2220 -1.976790 0.3267742 -6.049407 0.0000000 0.0000000 0 Cfap77 104.0725 -1.975423 0.3307899 -5.971837 0.0000000 0.0000001 0 Afap1l2 222.7816 1.971291 0.3228717 6.105495 0.0000000 0.0000000 0 Irak3 229.6248 1.967927 0.3774932 5.213145 0.0000002 0.0000031 0 Rhoj 957.3351 1.966950 0.2213780 8.885027 0.0000000 0.0000000 0 Spry4 258.1436 1.962823 0.3045133 6.445772 0.0000000 0.0000000 0 Id3 1160.9061 1.961442 0.3613197 5.428551 0.0000001 0.0000011 0 Fkbp14 186.9944 1.959809 0.3037552 6.451936 0.0000000 0.0000000 0 Dpp4 143.5438 1.954322 0.6079097 3.214822 0.0013053 0.0068027 0 Vegfc 135.6573 1.950214 0.4496622 4.337064 0.0000144 0.0001421 0 Praf2 239.1089 1.948095 0.2850065 6.835265 0.0000000 0.0000000 0 Stard13 234.0770 1.947479 0.2975881 6.544210 0.0000000 0.0000000 0 Kirrel1 121.7888 1.947392 0.2520810 7.725264 0.0000000 0.0000000 0 Cited4 2335.8131 -1.938469 0.3378359 -5.737901 0.0000000 0.0000002 0 Spp1 1145.9973 1.929532 0.5613678 3.437198 0.0005878 0.0034569 0 Mcam 165.4784 1.922274 0.3637071 5.285227 0.0000001 0.0000022 0 Snai2 126.3892 1.919757 0.3530212 5.438077 0.0000001 0.0000010 0 Gja1 4243.0828 1.919267 0.3433512 5.589807 0.0000000 0.0000005 0 Gpsm1 272.0116 1.919067 0.3574974 5.368060 0.0000001 0.0000015 0 Kctd8 150.8724 -1.917079 0.3439654 -5.573465 0.0000000 0.0000005 0 Myl9 2009.7089 1.915863 0.3033816 6.315027 0.0000000 0.0000000 0 Timp1 3024.0672 1.913752 0.3496099 5.473964 0.0000000 0.0000009 0 Fbp2 157.1759 -1.908509 0.2951823 -6.465526 0.0000000 0.0000000 0 Olfm1 103.2304 1.902150 0.4698879 4.048094 0.0000516 0.0004309 0 Scara3 627.4913 1.896222 0.3664970 5.173908 0.0000002 0.0000037 0 Pgr 1053.8770 -1.889558 0.3392201 -5.570299 0.0000000 0.0000005 0 Pamr1 162.6180 1.883333 0.5352891 3.518347 0.0004342 0.0026827 0 Pxdn 1708.7109 1.879982 0.2285945 8.224091 0.0000000 0.0000000 0 Pde2a 268.5033 1.876865 0.3241064 5.790890 0.0000000 0.0000002 0 Il18 1746.5610 -1.876248 0.2996070 -6.262366 0.0000000 0.0000000 0 Slit3 696.1098 1.871654 0.4462017 4.194636 0.0000273 0.0002467 0 Plat 4342.5292 1.870963 0.3258474 5.741839 0.0000000 0.0000002 0 B4galt5 311.8365 1.867767 0.4322674 4.320860 0.0000155 0.0001518 0 Rasa3 168.3716 1.867648 0.3599097 5.189214 0.0000002 0.0000034 0 Plagl1 117.1561 1.866061 0.4577889 4.076248 0.0000458 0.0003874 0 Col9a2 636.2130 1.862511 0.2608074 7.141328 0.0000000 0.0000000 0 Arhgef25 654.1540 1.860317 0.2082681 8.932321 0.0000000 0.0000000 0 Hs3st1 150.0095 1.851171 0.3096475 5.978316 0.0000000 0.0000001 0 Sulf1 262.5807 1.846637 0.3654231 5.053421 0.0000004 0.0000065 0 Hpgd 939.3799 -1.842757 0.4501817 -4.093363 0.0000425 0.0003639 0 Chst8 294.4151 -1.842657 0.4138792 -4.452161 0.0000085 0.0000892 0 Clic2 202.6435 1.829544 0.5107717 3.581922 0.0003411 0.0021717 0 Btc 160.5154 -1.829117 0.3540044 -5.166934 0.0000002 0.0000038 0 Tmprss6 287.5316 -1.821977 0.4246939 -4.290093 0.0000179 0.0001704 0 Tpm2 3093.1884 1.820140 0.3186052 5.712839 0.0000000 0.0000003 0 Nbl1 2539.0808 1.819643 0.3847042 4.729978 0.0000022 0.0000277 0 Sgcb 504.3680 1.812927 0.2500935 7.248995 0.0000000 0.0000000 0 Ptgfrn 1115.8317 1.808888 0.2773658 6.521668 0.0000000 0.0000000 0 Dclk1 577.7272 1.808853 0.2966535 6.097528 0.0000000 0.0000000 0 Aqp5 4790.9935 -1.797177 0.3333185 -5.391770 0.0000001 0.0000013 0 Gulp1 149.3323 1.793143 0.3405501 5.265429 0.0000001 0.0000024 0 Adamts9 113.0675 1.791069 0.4111173 4.356588 0.0000132 0.0001313 0 Col16a1 3247.3847 1.790478 0.2630643 6.806237 0.0000000 0.0000000 0 Prlr 1830.2520 -1.788853 0.2908595 -6.150229 0.0000000 0.0000000 0 Areg 5738.6354 -1.785208 0.3414109 -5.228913 0.0000002 0.0000028 0 Car2 920.1181 1.784736 0.4125369 4.326246 0.0000152 0.0001484 0 Padi3 121.3018 1.781312 0.4625349 3.851196 0.0001175 0.0008820 0 Slc7a8 139.5822 1.778907 0.4961996 3.585063 0.0003370 0.0021494 0 Schip1 175.6069 1.777938 0.3505882 5.071301 0.0000004 0.0000060 0 Esr1 224.0700 -1.774220 0.3259256 -5.443637 0.0000001 0.0000010 0 Ptprm 246.8389 1.763532 0.3127544 5.638712 0.0000000 0.0000004 0 Mmp14 11659.4689 1.762158 0.2879969 6.118669 0.0000000 0.0000000 0 Metrnl 525.9811 1.754758 0.2804253 6.257489 0.0000000 0.0000000 0 Vldlr 250.5702 1.754625 0.3031471 5.788030 0.0000000 0.0000002 0 Tmem150c 921.8799 -1.749252 0.3629124 -4.820039 0.0000014 0.0000189 0 Bcar3 222.0998 1.746383 0.3913208 4.462792 0.0000081 0.0000855 0 Fabp4 131.6055 1.745334 0.5320583 3.280344 0.0010368 0.0056107 0 Shisa8 488.2182 -1.744847 0.4055915 -4.301981 0.0000169 0.0001631 0 Klf4 1311.7147 1.740997 0.3321124 5.242191 0.0000002 0.0000027 0 Akap12 337.3340 1.739330 0.4047791 4.296986 0.0000173 0.0001662 0 Acsm3 619.8282 -1.732318 0.3753817 -4.614819 0.0000039 0.0000455 0 Slc6a8 175.8189 1.726498 0.3000728 5.753598 0.0000000 0.0000002 0 Il17b 299.0491 1.724299 0.4045464 4.262301 0.0000202 0.0001895 0 Zfp36l2 411.7016 1.721964 0.2651594 6.494070 0.0000000 0.0000000 0 Cd302 373.2032 1.721762 0.2368938 7.268072 0.0000000 0.0000000 0 Abcc8 318.7616 -1.718633 0.4899581 -3.507715 0.0004520 0.0027660 0 Tph1 1150.4348 -1.714776 0.3373177 -5.083565 0.0000004 0.0000057 0 Vasn 812.5685 1.714069 0.3354931 5.109102 0.0000003 0.0000051 0 Insyn1 140.7366 1.709526 0.2985606 5.725891 0.0000000 0.0000002 0 Sgce 345.8542 1.707644 0.3633766 4.699377 0.0000026 0.0000317 0 Evc 172.5371 1.705499 0.4089077 4.170865 0.0000303 0.0002709 0 Cfd 103.2919 1.705180 0.5255550 3.244533 0.0011764 0.0062201 0 Ctse 1016.3349 -1.702829 0.3245447 -5.246823 0.0000002 0.0000026 0 Slc43a2 358.7947 1.693392 0.2720174 6.225309 0.0000000 0.0000000 0 Lrp12 141.0970 1.692678 0.3303652 5.123659 0.0000003 0.0000047 0 Map6 376.7269 1.685383 0.3080463 5.471200 0.0000000 0.0000009 0 Gpc1 2328.4743 1.682722 0.2214336 7.599214 0.0000000 0.0000000 0 Tmem263 150.3927 1.678469 0.2541402 6.604500 0.0000000 0.0000000 0 Glb1l 275.9631 1.676486 0.2901912 5.777176 0.0000000 0.0000002 0 Crip1 1977.6282 1.675823 0.4073677 4.113785 0.0000389 0.0003365 0 Cd200 6760.6787 -1.675388 0.2805830 -5.971094 0.0000000 0.0000001 0 Msx2 407.4077 -1.675011 0.3393384 -4.936109 0.0000008 0.0000111 0 Rps6ka2 118.6621 1.673294 0.4564952 3.665524 0.0002468 0.0016473 0 Hdhd3 312.7452 -1.672435 0.2128887 -7.855913 0.0000000 0.0000000 0 Srxn1 693.5379 1.668068 0.4429237 3.766040 0.0001659 0.0011756 0 Bcl2a1 241.9477 -1.657547 0.4997168 -3.316973 0.0009100 0.0050188 0 Fzd2 186.9258 1.655353 0.2730855 6.061667 0.0000000 0.0000000 0 Slc39a2 356.0166 -1.654753 0.3965334 -4.173048 0.0000301 0.0002688 0 Fer1l4 124.1589 -1.654401 0.4922240 -3.361073 0.0007764 0.0044005 0 Plod1 2051.9489 1.652251 0.1940068 8.516457 0.0000000 0.0000000 0 Fgfrl1 236.9568 1.651685 0.2486313 6.643112 0.0000000 0.0000000 0 Actg2 539.8916 1.649824 0.5019804 3.286630 0.0010139 0.0055010 0 Rab31 748.2437 1.646877 0.3279322 5.022006 0.0000005 0.0000075 0 Tnfsf10 1097.3777 -1.645927 0.2669959 -6.164615 0.0000000 0.0000000 0 Krt15 1705.1517 1.644313 0.3953128 4.159524 0.0000319 0.0002819 0 Mfsd2a 222.5901 1.644011 0.3969442 4.141667 0.0000345 0.0003019 0 Dlx3 132.1440 1.643874 0.3973418 4.137180 0.0000352 0.0003069 0 Pls1 119.6970 -1.641552 0.3203104 -5.124880 0.0000003 0.0000047 0 Des 401.3741 1.639154 0.5026964 3.260724 0.0011113 0.0059365 0 Sh3kbp1 395.6466 1.636813 0.3375887 4.848542 0.0000012 0.0000166 0 Dgkb 110.9180 -1.636492 0.5178996 -3.159863 0.0015784 0.0079818 0 Nrp1 497.3358 1.635359 0.3693311 4.427894 0.0000095 0.0000986 0 Cspg5 124.8139 1.630541 0.3816266 4.272608 0.0000193 0.0001820 0 Rasl11b 246.0697 1.628369 0.2911849 5.592215 0.0000000 0.0000005 0 Tmem100 461.4873 1.626095 0.2528052 6.432205 0.0000000 0.0000000 0 Serpinb9 2992.0232 -1.624124 0.2870347 -5.658285 0.0000000 0.0000003 0 Iffo1 406.2362 1.617511 0.2752392 5.876748 0.0000000 0.0000001 0 Cited1 7906.8887 -1.615559 0.3795161 -4.256892 0.0000207 0.0001932 0 Epha4 138.1749 1.610480 0.2429482 6.628905 0.0000000 0.0000000 0 Fcrlb 369.3775 -1.609652 0.4842464 -3.324035 0.0008872 0.0049115 0 Mustn1 116.2718 1.603387 0.3318055 4.832309 0.0000013 0.0000178 0 Slpi 397.7191 -1.600147 0.5095737 -3.140168 0.0016885 0.0084302 0 Ccnd2 705.9704 1.599913 0.2871723 5.571264 0.0000000 0.0000005 0 Ghr 360.5454 1.594410 0.2777837 5.739754 0.0000000 0.0000002 0 Podxl2 285.3952 1.578838 0.2209865 7.144499 0.0000000 0.0000000 0 Pear1 1186.9914 1.578822 0.2104603 7.501756 0.0000000 0.0000000 0 Spdef 436.7141 -1.578703 0.3010778 -5.243505 0.0000002 0.0000027 0 Frmpd1 179.6637 -1.578377 0.5002591 -3.155120 0.0016043 0.0080936 0 Klf2 1438.5342 1.571775 0.3242437 4.847511 0.0000013 0.0000167 0 Pelo 681.5882 1.570255 0.2332854 6.731046 0.0000000 0.0000000 0 Arhgdib 786.4187 1.570099 0.4605865 3.408912 0.0006522 0.0037871 0 Nectin1 445.3311 1.559745 0.1709112 9.126056 0.0000000 0.0000000 0 C4b 6332.3885 1.559685 0.3801207 4.103130 0.0000408 0.0003503 0 Vstm4 268.8867 1.559367 0.3314511 4.704667 0.0000025 0.0000310 0 Pdlim1 571.6938 1.558993 0.3123685 4.990878 0.0000006 0.0000087 0 Tubb6 2199.7301 1.556347 0.2739198 5.681761 0.0000000 0.0000003 0 Cbs 991.0743 -1.554683 0.3533517 -4.399816 0.0000108 0.0001104 0 Slit2 311.9405 1.553595 0.4555367 3.410471 0.0006485 0.0037699 0 Pcp4 177.4179 -1.553452 0.4763417 -3.261213 0.0011094 0.0059326 0 Egfr 509.8697 1.552845 0.2609059 5.951742 0.0000000 0.0000001 0 Nrg1 360.5283 1.551680 0.3079499 5.038740 0.0000005 0.0000069 0 Rps19 209.2642 1.551030 0.5409993 2.866973 0.0041442 0.0176313 0 Aplp1 553.1096 1.550737 0.2886425 5.372517 0.0000001 0.0000014 0 Il1rn 545.8045 -1.549482 0.3716479 -4.169221 0.0000306 0.0002721 0 Cst6 503.1537 1.548567 0.3865136 4.006501 0.0000616 0.0005053 0 Cerk 266.2464 1.548556 0.2926497 5.291501 0.0000001 0.0000021 0 Prr7 112.0424 1.545974 0.3094572 4.995760 0.0000006 0.0000085 0 Fam181b 113.1225 1.545330 0.4185720 3.691911 0.0002226 0.0015049 0 Tagln 2624.4932 1.544899 0.2958339 5.222185 0.0000002 0.0000029 0 Lrrc8c 239.2720 1.543264 0.3984249 3.873413 0.0001073 0.0008160 0 Scn1b 214.9447 1.543260 0.2974027 5.189123 0.0000002 0.0000034 0 Pik3cd 194.6883 1.541470 0.4128931 3.733340 0.0001890 0.0013138 0 Ckb 3038.5151 1.540677 0.2448073 6.293425 0.0000000 0.0000000 0 Fads3 135.8083 1.539584 0.3182040 4.838357 0.0000013 0.0000174 0 Prkcb 135.0218 1.538840 0.4532593 3.395056 0.0006861 0.0039579 0 Erbb4 125.6701 -1.537713 0.3590362 -4.282890 0.0000184 0.0001749 0 Fut2 336.6208 -1.536448 0.3755802 -4.090864 0.0000430 0.0003668 0 Tnfaip2 419.8491 1.535503 0.2989798 5.135807 0.0000003 0.0000045 0 Paqr5 354.3519 -1.531292 0.3074586 -4.980482 0.0000006 0.0000091 0 Npr2 206.1419 1.530276 0.3701870 4.133792 0.0000357 0.0003107 0 Pmp22 1647.3979 1.527858 0.2791268 5.473708 0.0000000 0.0000009 0 Wnt4 1279.7850 -1.527614 0.2745663 -5.563737 0.0000000 0.0000005 0 Rasip1 138.5032 1.523296 0.3551644 4.288988 0.0000179 0.0001711 0 Uap1 1175.6289 1.521917 0.3408833 4.464628 0.0000080 0.0000849 0 Smtn 715.9009 1.521074 0.2601365 5.847216 0.0000000 0.0000001 0 Thbs3 335.9262 1.517784 0.2961045 5.125838 0.0000003 0.0000047 0 Sidt1 656.7297 -1.514287 0.2648492 -5.717544 0.0000000 0.0000002 0 Timp3 3167.9109 1.513588 0.2674382 5.659580 0.0000000 0.0000003 0 Kremen1 268.4609 1.513346 0.3096050 4.887990 0.0000010 0.0000139 0 Rpl8 254.1429 1.510537 0.4786577 3.155777 0.0016007 0.0080803 0 Maged2 1039.7005 1.510531 0.2242516 6.735878 0.0000000 0.0000000 0 Ankh 365.6035 1.507616 0.3102127 4.859944 0.0000012 0.0000158 0 Kdelr3 1070.8402 1.504935 0.2185224 6.886869 0.0000000 0.0000000 0 Sh2d3c 149.8640 1.504773 0.3034615 4.958696 0.0000007 0.0000101 0 Note that there seems to be two main groups of Ep cells: The first one is enriched for canonical tumour progression pathways: eg. expression of wnt, fox1a etc. The second one doesn’t seem to have as high expression of these genes, but have high immune related signalling pathways. We can append this information into the overall data file and determine whether there is an association with growth or treatment ## 10L_D_Ep 10R_BL_Ep 10R_BU_Ep 11L_B_Ep 11N_D_Ep 11R_D_Ep ## 1 2 2 2 3 2 ## ## growing stable ## 1 3 4 ## 2 8 3 ## 3 0 2 ## ## LY PDL1 PDL1+LY Vehicle ## 1 2 2 2 1 ## 2 1 5 3 3 ## 3 1 1 0 0 ## ## Infiltrating restricted ## 1 4 1 ## 2 3 6 ## 3 2 0 7.2 No. samples in comparisons Separate out the tables into CD45, DN and Ep fractions. Compare Differences based on treatment (and treatment vs control) Specific treatments vs control Growing vs stable (overall) Growing vs stable (in each subgroup) Below, we check the number of samples in each subgroup: ## , , = inf ## ## ## LY PDL1 PDL1+LY Vehicle ## CD45 3 3 1 6 ## DN 3 2 1 5 ## Ep 3 4 0 3 ## ## , , = res ## ## ## LY PDL1 PDL1+LY Vehicle ## CD45 2 5 4 3 ## DN 0 6 3 4 ## Ep 0 4 2 1 Note that based on the above tables, there some comparisons which are slightly imbalanced: There are few “stable” samples for comparisons LY samples are overwhelmingly “infiltrating” 7.3 Set-up cell-type specifoc the comparisons Setup the following comparisons for each cell type: expression ~ growing + treatment + batch (exclude 1) (start with vehicle vs some treatment) 4 categories only: immunotherapy vs non-immuno Separate out the tables into CD45, DN and Ep fractions. Compare: Treatment (EpddsTreat) Comp4: Growth + any immunotherapy treatment (Epdds) Comp8: Growth + immunotherapy (EpddsTreatG) Growth alone: (EpddsGrowth) MH index: (EpddsStrMH) Interacting Fraction (EpddsStrIF) knn values (EpddsStrknn) CD8 content (EpddsCD8) Manual scoring spatial (EpddsSpatMan) MH index + CD8 frac (Epddscd8MH) We remove genes which have 0 counts in more than half the samples, and genes which have a row sum less than \\(10^{(log10(mean(rowsums))-log10(sd(rowsums)))}\\). These comparisons are saved in the temporary outputfile outputs/subfraction_analysis_2020-12-30.RData. In each comparison, there are 13134 genes compared. 7.4 PCA plots Below, we look at PCA plots with information on treatment, growth, spatial patterns overlaid. These are separated based on cell type 7.4.1 EpCAM ## quartz_off_screen ## 2 7.4.2 CD45 ## quartz_off_screen ## 2 7.4.3 DN ## quartz_off_screen ## 2 7.5 Collating results and running GSEA In this section, we combine all the comparisons together for downstream analysis, including number of differential genes per comparisons number of samples per comparison write the output to file (outputs/DESeq/Ep_growth_treat.xlsx) For GSEA we convert rat to human symbols run overlap analysis if there are more than 3 hits (outputs/DESeq/HyperGeo_Ep_growth_treat.xlsx) run gene set enrichment analysis on all samples (outputs/DESeq/GSEA_Ep_growth_treat.xlsx) all outputs saved to outputs/all_differential_comparisons.RData) ## ## growingcontrol growingimm stablecontrol stableimm ## 2 9 2 7 "],["deseq-analysis-1.html", "Chapter 8 DESeq analysis 8.1 Summary of comparisons 8.2 Summary of comaprisons 8.3 Growing vs stable emphasis", " Chapter 8 DESeq analysis 8.1 Summary of comparisons Quick plot of the differences in number of differential genes: Notes: Comparison Type Main cell type impacted Treatment CD45+, PDL1+LY in the DN, LY may affect Ep growth Ep and CD45 growth in control CD and DN Spatial Patterns CD45, Ep Spatial, high cd8 all cases 8.2 Summary of comaprisons Pearson correlation: Pearson correlation of all the samples Unlist all genes, and pick out genes which are impacted in at least 1 comparison, and base expression &gt;100 columns are colored by: Spatial Distribution (MH), Growth, Treatment, CD8 content Differential genes: top 100 variable genes DEG in at least 2 samples differential genes in each comparison shown Gene sets: c2, c5, Process networks, metacore, hallmark 8.2.1 EPCAM samples Note that there are a subset of samples different from the other based on CD8, growth and MH index (6RB, 3NB, 10LD, 8LD, 11ND) but these parameters don’t group the other samples well There is a small subset of samples which have high expression of CCls and based on the top variable genes, there seems to be three types of epithelial cases. We can also view this in the form of what is highly expressed in each comparison. Below is a heatmap of the fold changes: Below, we visualise the enrichment scores using different gene sets and ## quartz_off_screen ## 2 8.2.2 CD45 comparisons 8.2.3 DN samples 8.3 Growing vs stable emphasis Below, we focus specifically on the growing vs stable comparison in greater depth. Here, we look at the 3 different fractions in greater depth and look at volcano plots of DEG and heatmaps of differential genes. Samples are colored according to whether they are growing or stable 8.3.1 DN fraction 8.3.2 CD fraction ## quartz_off_screen ## 2 8.3.3 Ep Fraction ### Summary of GSEA runs ## quartz_off_screen ## 2 Plot of the network maps for each cell type 8.3.4 Pathways of Interest 2 Focus on: JAK-STAT signalling interferon-gamma signalling IL-6 signalling BCR pathway TCR pathway antigen presentation KRAS signalling? T helper differentiation In DN samples: androgen receptor signalling? esr1 signalling? myc targets EMT Perform GSVA on these pathways ## Estimating ssGSEA scores for 37 gene sets. ## | | | 0% | |==== | 5% | |======= | 10% | |========== | 15% | |============== | 20% | |================== | 25% | |===================== | 30% | |======================== | 35% | |============================ | 40% | |================================ | 45% | |=================================== | 50% | |====================================== | 55% | |========================================== | 60% | |============================================== | 65% | |================================================= | 70% | |==================================================== | 75% | |======================================================== | 80% | |============================================================ | 85% | |=============================================================== | 90% | |================================================================== | 95% | |======================================================================| 100% ## Estimating ssGSEA scores for 36 gene sets. ## | | | 0% | |== | 3% | |===== | 7% | |======= | 10% | |========= | 13% | |============ | 17% | |============== | 20% | |================ | 23% | |=================== | 27% | |===================== | 30% | |======================= | 33% | |========================== | 37% | |============================ | 40% | |============================== | 43% | |================================= | 47% | |=================================== | 50% | |===================================== | 53% | |======================================== | 57% | |========================================== | 60% | |============================================ | 63% | |=============================================== | 67% | |================================================= | 70% | |=================================================== | 73% | |====================================================== | 77% | |======================================================== | 80% | |========================================================== | 83% | |============================================================= | 87% | |=============================================================== | 90% | |================================================================= | 93% | |==================================================================== | 97% | |======================================================================| 100% ## Estimating ssGSEA scores for 30 gene sets. ## | | | 0% | |== | 3% | |==== | 6% | |====== | 9% | |======== | 12% | |========== | 15% | |============ | 18% | |============== | 21% | |================ | 24% | |=================== | 26% | |===================== | 29% | |======================= | 32% | |========================= | 35% | |=========================== | 38% | |============================= | 41% | |=============================== | 44% | |================================= | 47% | |=================================== | 50% | |===================================== | 53% | |======================================= | 56% | |========================================= | 59% | |=========================================== | 62% | |============================================= | 65% | |=============================================== | 68% | |================================================= | 71% | |=================================================== | 74% | |====================================================== | 76% | |======================================================== | 79% | |========================================================== | 82% | |============================================================ | 85% | |============================================================== | 88% | |================================================================ | 91% | |================================================================== | 94% | |==================================================================== | 97% | |======================================================================| 100% ## quartz_off_screen ## 2 Also on the hallmark genes: ## Estimating ssGSEA scores for 13 gene sets. ## | | | 0% | |==== | 5% | |======= | 10% | |========== | 15% | |============== | 20% | |================== | 25% | |===================== | 30% | |======================== | 35% | |============================ | 40% | |================================ | 45% | |=================================== | 50% | |====================================== | 55% | |========================================== | 60% | |============================================== | 65% | |================================================= | 70% | |==================================================== | 75% | |======================================================== | 80% | |============================================================ | 85% | |=============================================================== | 90% | |================================================================== | 95% | |======================================================================| 100% ## Estimating ssGSEA scores for 23 gene sets. ## | | | 0% | |== | 3% | |===== | 7% | |======= | 10% | |========= | 13% | |============ | 17% | |============== | 20% | |================ | 23% | |=================== | 27% | |===================== | 30% | |======================= | 33% | |========================== | 37% | |============================ | 40% | |============================== | 43% | |================================= | 47% | |=================================== | 50% | |===================================== | 53% | |======================================== | 57% | |========================================== | 60% | |============================================ | 63% | |=============================================== | 67% | |================================================= | 70% | |=================================================== | 73% | |====================================================== | 77% | |======================================================== | 80% | |========================================================== | 83% | |============================================================= | 87% | |=============================================================== | 90% | |================================================================= | 93% | |==================================================================== | 97% | |======================================================================| 100% ## Estimating ssGSEA scores for 12 gene sets. ## | | | 0% | |== | 3% | |==== | 6% | |====== | 9% | |======== | 12% | |========== | 15% | |============ | 18% | |============== | 21% | |================ | 24% | |=================== | 26% | |===================== | 29% | |======================= | 32% | |========================= | 35% | |=========================== | 38% | |============================= | 41% | |=============================== | 44% | |================================= | 47% | |=================================== | 50% | |===================================== | 53% | |======================================= | 56% | |========================================= | 59% | |=========================================== | 62% | |============================================= | 65% | |=============================================== | 68% | |================================================= | 71% | |=================================================== | 74% | |====================================================== | 76% | |======================================================== | 79% | |========================================================== | 82% | |============================================================ | 85% | |============================================================== | 88% | |================================================================ | 91% | |================================================================== | 94% | |==================================================================== | 97% | |======================================================================| 100% ## quartz_off_screen ## 2 8.3.5 Inflammatory vs non-inflammatory samples Remove inflammatory samples Also remove samples which are basal-like ## quartz_off_screen ## 2 Quickly run gsea for these samples: ## -Preprocessing for input gene list and hit list ... ## --Removing genes without values in geneList ... ## --Removing duplicated genes ... ## --Converting annotations ... ## -- 527 genes (out of 12341) could not be mapped to any identifier, and were removed from the data. ## -- 9 genes (out of 88) could not be mapped to any identifier, and were removed from the data. ## --Ordering Gene List decreasingly ... ## -Preprocessing complete! ## --146 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c2List! ## --848 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5BP! ## --269 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5MF! ## --110 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5CC! ## --377 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named MetPathway! ## -Performing hypergeometric analysis ... ## -Hypergeometric analysis complete ## ## -Performing gene set enrichment analysis using HTSanalyzeR2... ## --Calculating the permutations ... ## -Gene set enrichment analysis using HTSanalyzeR2 complete ## ============================================== ## ## -No of genes in Gene set collections: ## input above min size ## c2List 2199 2053 ## c5BP 7530 6682 ## c5MF 1663 1394 ## c5CC 999 889 ## ProcessNetworks 158 158 ## MetPathway 1480 1103 ## Hallmark 50 50 ## ## ## -No of genes in Gene List: ## input valid duplicate removed converted to entrez ## Gene List 12449 12449 12341 11814 ## ## ## -No of hits: ## input preprocessed ## Hits 88 79 ## ## ## -Parameters for analysis: ## minGeneSetSize pValueCutoff pAdjustMethod ## HyperGeo Test 5 0.05 BH ## ## minGeneSetSize pValueCutoff pAdjustMethod nPermutations exponent ## GSEA 5 0.05 BH 100 1 ## ## ## -Significant gene sets (adjusted p-value&lt; 0.05 ): ## c2List c5BP c5MF c5CC ProcessNetworks MetPathway Hallmark ## HyperGeo 4 2 0 2 0 0 1 ## GSEA 185 598 99 109 17 6 20 ## Both 1 2 0 2 0 0 1 Associate the signature with outcome in TCGA. Note that the stable and growing signatures appear correlated Load the old file ## Estimating ssGSEA scores for 2 gene sets. ## | | | 0% | | | 1% | |= | 1% | |= | 2% | |== | 2% | |== | 3% | |== | 4% | |=== | 4% | |=== | 5% | |==== | 5% | |==== | 6% | |===== | 6% | |===== | 7% | |===== | 8% | |====== | 8% | |====== | 9% | |======= | 9% | |======= | 10% | |======= | 11% | |======== | 11% | |======== | 12% | |========= | 12% | |========= | 13% | |========= | 14% | |========== | 14% | |========== | 15% | |=========== | 15% | |=========== | 16% | |============ | 16% | |============ | 17% | |============ | 18% | |============= | 18% | |============= | 19% | |============== | 19% | |============== | 20% | |============== | 21% | |=============== | 21% | |=============== | 22% | |================ | 22% | |================ | 23% | |================ | 24% | |================= | 24% | |================= | 25% | |================== | 25% | |================== | 26% | |=================== | 26% | |=================== | 27% | |=================== | 28% | |==================== | 28% | |==================== | 29% | |===================== | 29% | |===================== | 30% | |===================== | 31% | |====================== | 31% | |====================== | 32% | |======================= | 32% | |======================= | 33% | |======================= | 34% | |======================== | 34% | |======================== | 35% | |========================= | 35% | |========================= | 36% | |========================== | 36% | |========================== | 37% | |========================== | 38% | |=========================== | 38% | |=========================== | 39% | |============================ | 39% | |============================ | 40% | |============================ | 41% | |============================= | 41% | |============================= | 42% | |============================== | 42% | |============================== | 43% | |============================== | 44% | |=============================== | 44% | |=============================== | 45% | |================================ | 45% | |================================ | 46% | |================================= | 46% | |================================= | 47% | |================================= | 48% | |================================== | 48% | |================================== | 49% | |=================================== | 49% | |=================================== | 50% | |=================================== | 51% | |==================================== | 51% | |==================================== | 52% | |===================================== | 52% | |===================================== | 53% | |===================================== | 54% | |====================================== | 54% | |====================================== | 55% | |======================================= | 55% | |======================================= | 56% | |======================================== | 56% | |======================================== | 57% | |======================================== | 58% | |========================================= | 58% | |========================================= | 59% | |========================================== | 59% | |========================================== | 60% | |========================================== | 61% | |=========================================== | 61% | |=========================================== | 62% | |============================================ | 62% | |============================================ | 63% | |============================================ | 64% | |============================================= | 64% | |============================================= | 65% | |============================================== | 65% | |============================================== | 66% | |=============================================== | 66% | |=============================================== | 67% | |=============================================== | 68% | |================================================ | 68% | |================================================ | 69% | |================================================= | 69% | |================================================= | 70% | |================================================= | 71% | |================================================== | 71% | |================================================== | 72% | |=================================================== | 72% | |=================================================== | 73% | |=================================================== | 74% | |==================================================== | 74% | |==================================================== | 75% | |===================================================== | 75% | |===================================================== | 76% | |====================================================== | 76% | |====================================================== | 77% | |====================================================== | 78% | |======================================================= | 78% | |======================================================= | 79% | |======================================================== | 79% | |======================================================== | 80% | |======================================================== | 81% | |========================================================= | 81% | |========================================================= | 82% | |========================================================== | 82% | |========================================================== | 83% | |========================================================== | 84% | |=========================================================== | 84% | |=========================================================== | 85% | |============================================================ | 85% | |============================================================ | 86% | |============================================================= | 86% | |============================================================= | 87% | |============================================================= | 88% | |============================================================== | 88% | |============================================================== | 89% | |=============================================================== | 89% | |=============================================================== | 90% | |=============================================================== | 91% | |================================================================ | 91% | |================================================================ | 92% | |================================================================= | 92% | |================================================================= | 93% | |================================================================= | 94% | |================================================================== | 94% | |================================================================== | 95% | |=================================================================== | 95% | |=================================================================== | 96% | |==================================================================== | 96% | |==================================================================== | 97% | |==================================================================== | 98% | |===================================================================== | 98% | |===================================================================== | 99% | |======================================================================| 99% | |======================================================================| 100% New list ## Estimating ssGSEA scores for 2 gene sets. ## | | | 0% | | | 1% | |= | 1% | |= | 2% | |== | 2% | |== | 3% | |== | 4% | |=== | 4% | |=== | 5% | |==== | 5% | |==== | 6% | |===== | 6% | |===== | 7% | |===== | 8% | |====== | 8% | |====== | 9% | |======= | 9% | |======= | 10% | |======= | 11% | |======== | 11% | |======== | 12% | |========= | 12% | |========= | 13% | |========= | 14% | |========== | 14% | |========== | 15% | |=========== | 15% | |=========== | 16% | |============ | 16% | |============ | 17% | |============ | 18% | |============= | 18% | |============= | 19% | |============== | 19% | |============== | 20% | |============== | 21% | |=============== | 21% | |=============== | 22% | |================ | 22% | |================ | 23% | |================ | 24% | |================= | 24% | |================= | 25% | |================== | 25% | |================== | 26% | |=================== | 26% | |=================== | 27% | |=================== | 28% | |==================== | 28% | |==================== | 29% | |===================== | 29% | |===================== | 30% | |===================== | 31% | |====================== | 31% | |====================== | 32% | |======================= | 32% | |======================= | 33% | |======================= | 34% | |======================== | 34% | |======================== | 35% | |========================= | 35% | |========================= | 36% | |========================== | 36% | |========================== | 37% | |========================== | 38% | |=========================== | 38% | |=========================== | 39% | |============================ | 39% | |============================ | 40% | |============================ | 41% | |============================= | 41% | |============================= | 42% | |============================== | 42% | |============================== | 43% | |============================== | 44% | |=============================== | 44% | |=============================== | 45% | |================================ | 45% | |================================ | 46% | |================================= | 46% | |================================= | 47% | |================================= | 48% | |================================== | 48% | |================================== | 49% | |=================================== | 49% | |=================================== | 50% | |=================================== | 51% | |==================================== | 51% | |==================================== | 52% | |===================================== | 52% | |===================================== | 53% | |===================================== | 54% | |====================================== | 54% | |====================================== | 55% | |======================================= | 55% | |======================================= | 56% | |======================================== | 56% | |======================================== | 57% | |======================================== | 58% | |========================================= | 58% | |========================================= | 59% | |========================================== | 59% | |========================================== | 60% | |========================================== | 61% | |=========================================== | 61% | |=========================================== | 62% | |============================================ | 62% | |============================================ | 63% | |============================================ | 64% | |============================================= | 64% | |============================================= | 65% | |============================================== | 65% | |============================================== | 66% | |=============================================== | 66% | |=============================================== | 67% | |=============================================== | 68% | |================================================ | 68% | |================================================ | 69% | |================================================= | 69% | |================================================= | 70% | |================================================= | 71% | |================================================== | 71% | |================================================== | 72% | |=================================================== | 72% | |=================================================== | 73% | |=================================================== | 74% | |==================================================== | 74% | |==================================================== | 75% | |===================================================== | 75% | |===================================================== | 76% | |====================================================== | 76% | |====================================================== | 77% | |====================================================== | 78% | |======================================================= | 78% | |======================================================= | 79% | |======================================================== | 79% | |======================================================== | 80% | |======================================================== | 81% | |========================================================= | 81% | |========================================================= | 82% | |========================================================== | 82% | |========================================================== | 83% | |========================================================== | 84% | |=========================================================== | 84% | |=========================================================== | 85% | |============================================================ | 85% | |============================================================ | 86% | |============================================================= | 86% | |============================================================= | 87% | |============================================================= | 88% | |============================================================== | 88% | |============================================================== | 89% | |=============================================================== | 89% | |=============================================================== | 90% | |=============================================================== | 91% | |================================================================ | 91% | |================================================================ | 92% | |================================================================= | 92% | |================================================================= | 93% | |================================================================= | 94% | |================================================================== | 94% | |================================================================== | 95% | |=================================================================== | 95% | |=================================================================== | 96% | |==================================================================== | 96% | |==================================================================== | 97% | |==================================================================== | 98% | |===================================================================== | 98% | |===================================================================== | 99% | |======================================================================| 99% | |======================================================================| 100% Construct survival curves, segment based on score#1 based on subtype 8.3.6 Samples with matching cases Do growing vs stable comparisons in the samples which do not have inflammatory ep fractions: done below for both the DN and CD fractions ## quartz_off_screen ## 2 8.3.7 Specific pathways The above plots suggest that there could be a different in growing and stable based on : inflammation Kras signalling MHC presentation checkpoint proteins We can pull out the genes in these sets and visualise the relative expression in a heatmap in the DN, CD45 and Ep samples: Note that red is growing and green is stable 8.3.7.1 DN samples: Note the distribution of growing/stable in DN is: 21, 9 8.3.7.2 CD45 samples: Note the distribution of growing/stable in CD is: 26, 8 8.3.7.3 Epithelial samples: "],["deseq-analysis-characterisation-cohort-big-vs-small.html", "Chapter 9 DESeq analysis: Characterisation cohort (big vs small) 9.1 CD45 samples 9.2 Epithelial samples", " Chapter 9 DESeq analysis: Characterisation cohort (big vs small) This document sets up DESeq runs to compare: CD45 samples Ep samples according to size of the cohort samples 9.1 CD45 samples In section 6.2, we have noticed that some DN samples had expression of epithelial markers. Here, we perform a differential gene expression analysis to find genes which are different between these two fractions. Below is a summary of the number of differential genes, using p value cut off of 0.05 and log2 fold change of 1.5 and base expression of 100+. 9.1.1 PCA plot First, have a look at the samples in a PCA plot: do they separate based on size: 9.1.2 Differential Gene Expression ## [1] &quot;significant differential genes&quot; ### GSEA Run GSEA. Here, we will look specifically at the Process Network pathways which are enriched ## -Preprocessing for input gene list and hit list ... ## --Removing genes without values in geneList ... ## --Removing duplicated genes ... ## --Converting annotations ... ## -- 476 genes (out of 11277) could not be mapped to any identifier, and were removed from the data. ## -- 12 genes (out of 330) could not be mapped to any identifier, and were removed from the data. ## --Ordering Gene List decreasingly ... ## -Preprocessing complete! ## --184 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c2List! ## --1100 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5BP! ## --328 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5MF! ## --140 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5CC! ## --395 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named MetPathway! ## -Performing hypergeometric analysis ... ## -Hypergeometric analysis complete ## ## -Performing gene set enrichment analysis using HTSanalyzeR2... ## --Calculating the permutations ... ## -Gene set enrichment analysis using HTSanalyzeR2 complete ## ============================================== ## ## -No of genes in Gene set collections: ## input above min size ## c2List 2199 2015 ## c5BP 7530 6430 ## c5MF 1663 1335 ## c5CC 999 859 ## ProcessNetworks 158 158 ## MetPathway 1480 1085 ## Hallmark 50 50 ## ## ## -No of genes in Gene List: ## input valid duplicate removed converted to entrez ## Gene List 11386 11386 11277 10801 ## ## ## -No of hits: ## input preprocessed ## Hits 330 318 ## ## ## -Parameters for analysis: ## minGeneSetSize pValueCutoff pAdjustMethod ## HyperGeo Test 5 0.05 BH ## ## minGeneSetSize pValueCutoff pAdjustMethod nPermutations exponent ## GSEA 5 0.05 BH 100 1 ## ## ## -Significant gene sets (adjusted p-value&lt; 0.05 ): ## c2List c5BP c5MF c5CC ProcessNetworks MetPathway Hallmark ## HyperGeo 11 24 10 16 0 0 3 ## GSEA 298 730 218 126 35 166 13 ## Both 10 17 10 16 0 0 2 ## quartz_off_screen ## 2 9.2 Epithelial samples 9.2.1 PCA plot First, have a look at the samples in a PCA plot: do they separate based on size: ## [1] &quot;significant differential genes&quot; 9.2.2 GSEA Run GSEA. Here, we will look specifically at the Process Network pathways which are enriched ## -Preprocessing for input gene list and hit list ... ## --Removing genes without values in geneList ... ## --Removing duplicated genes ... ## --Converting annotations ... ## -- 449 genes (out of 11863) could not be mapped to any identifier, and were removed from the data. ## -- 2 genes (out of 12) could not be mapped to any identifier, and were removed from the data. ## --Ordering Gene List decreasingly ... ## -Preprocessing complete! ## --157 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c2List! ## --926 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5BP! ## --302 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5MF! ## --125 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5CC! ## --384 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named MetPathway! ## -Performing hypergeometric analysis ... ## -Hypergeometric analysis complete ## ## -Performing gene set enrichment analysis using HTSanalyzeR2... ## --Calculating the permutations ... ## -Gene set enrichment analysis using HTSanalyzeR2 complete ## ============================================== ## ## -No of genes in Gene set collections: ## input above min size ## c2List 2199 2042 ## c5BP 7530 6604 ## c5MF 1663 1361 ## c5CC 999 874 ## ProcessNetworks 158 158 ## MetPathway 1480 1096 ## Hallmark 50 50 ## ## ## -No of genes in Gene List: ## input valid duplicate removed converted to entrez ## Gene List 11956 11956 11863 11414 ## ## ## -No of hits: ## input preprocessed ## Hits 12 10 ## ## ## -Parameters for analysis: ## minGeneSetSize pValueCutoff pAdjustMethod ## HyperGeo Test 5 0.05 BH ## ## minGeneSetSize pValueCutoff pAdjustMethod nPermutations exponent ## GSEA 5 0.05 BH 100 1 ## ## ## -Significant gene sets (adjusted p-value&lt; 0.05 ): ## c2List c5BP c5MF c5CC ProcessNetworks MetPathway Hallmark ## HyperGeo 0 0 0 0 0 0 0 ## GSEA 230 687 167 94 35 65 9 ## Both 0 0 0 0 0 0 0 ## quartz_off_screen ## 2 Double check the above result by running a ssGSEA and checking the directionality ## Estimating ssGSEA scores for 159 gene sets. ## | | | 0% | |======= | 10% | |============== | 20% | |===================== | 30% | |============================ | 40% | |=================================== | 50% | |========================================== | 60% | |================================================= | 70% | |======================================================== | 80% | |=============================================================== | 90% | |======================================================================| 100% "],["erpgr-subtyping.html", "Chapter 10 ER/Pgr Subtyping 10.1 In-house classifier 10.2 PAM50 (Parker) scoring 10.3 Clustering based on random genes 10.4 Consolidating the different results", " Chapter 10 ER/Pgr Subtyping In this section, we will look at whether there are differences in rat subtype using the following approaches: Creating our own subtyping approach using specific markers of interest (e.g. using PAM clustering) Using known gene list Using random genes (top 50, 100, 200 etc variable genes) PAM50 subtyping using the methods published by Parker et al. This method uses rsem scores to classify samples. As the DN samples do have keratin expression, we will also try to determine the subtypes in these samples too. In the below analyses, we will conduct this subtyping as follows: progression specific epithelial cohort characterisation specific epithelial cohort dn specific cohort (progression) 10.1 In-house classifier The selected gene list includes three lists: A. is a mroe comprehensive list containing epithelial, mesenchymal markers and proliferation markers, B. has a more narrow list of subtype specific markers ‘Ar’, ‘Cd24’, ‘Cdh1’, ‘Foxa1’, ‘Gata3’, ‘Krt8’, ‘Krt18’, ‘Krt5’, ‘Vim’, ‘Erbb2’, ‘Esr1’, ‘Pgr’, ‘Mki67’, ‘Pcna’ ‘Ar’, ‘Foxa1’, ‘Gata3’, ‘Erbb2’, ‘Esr1’, ‘Pgr’ We will be using variance stabilised counts in this section. Firstly, we will look at the progression cohort. Note that the overlap between the two gene-sets are similar, and the heatmap is row-scaled. ## ColB ## ColA Basal Lum ## Basal 0 10 ## Lum 9 1 ## quartz_off_screen ## 2 We can perform a similar analysis to the characterisation cohort: (and save to file) 10.1.1 DN samples? DN samples: note there is variability in DN expression of PR, Foxa1, Esr1, Ar, Erbb2 and Gata3 shows fairly stable expression values ## quartz_off_screen ## 2 Do a heatmap with the Epithelial samples ## quartz_off_screen ## 2 We can collate these different scores and assess whether there are similarities with PgR and ER staining: Finally, look at whether any of the above samples have similar DN and Ep calls: it appears that this call is random, and the subtype does not dictate growth rate ## [1] &quot;extended list&quot; ## , , = growing ## ## ## Basal Lum ## Basal 3 1 ## Lum 3 3 ## ## , , = stable ## ## ## Basal Lum ## Basal 3 0 ## Lum 1 2 ## [1] &quot;narrow list&quot; ## , , = growing ## ## ## Basal Lum ## Basal 3 3 ## Lum 3 1 ## ## , , = stable ## ## ## Basal Lum ## Basal 0 2 ## Lum 4 0 10.2 PAM50 (Parker) scoring Here, we have used rsem counts in PAM50 subtyping. Plot all samples together and compare the confidence and scores in different subtypes: There is overlap between the LumB and Her2 scores, similarly Normal and LumA scores are similar We can pull out the main markers of interest: ER, PGR, Erbb2 and Ki67 (or PCNA). We also compare these expression distribution of these markers to CD45, DN and Ep overall: Notes: Pgr highest in luminal samples Esr1 dynamic range is lower Ar is higher in basal samples Pcna is higher in Basal heatmap based on the previous markers: Based on the above calls, we can condense the calls: Her2, LumB are sumilar and can be combined with LumA Normal and Basal are most likely most similar 10.3 Clustering based on random genes In this section we randomly select the most variable 200, 500, 1000, 2000 genes: we use both the standard deviation and coefficient of variation (sd normalised by the mean) to select these most variable genes. Below is a correlation plot which visualises the concordance between the different methods. 10.4 Consolidating the different results Below is a concordance map of the similarity between the different metrics calculated as \\[ \\frac{N_{b,b}+N_{l,l}}{N_{total}} \\] where \\(N_{b,b}\\) is the number of cases which are basal in two comparisons and \\(N_{l,l}\\) the number of cases which are luminal in both comparisons. Note that the values extend from 0.5 to 1, which indicates that any two methods overlap more than just by chance. There is good overlap between the in-house specific list characterisation, and some overlap between pam50 calling and in-house short list. Below is a summary of the average expression values of the classes defined by the different methods: The targeted lists show differences in esr1, pgr, erbb2, pcna Ar has differing directions for the pam classifications Random genes selected show differences in pgr, erbb2, Ar and perhaps Mki67 We can summarise the outputs for each sample below PAM50 pamshort top200sd top500sd top1000sd top2000sd 10L_D_Ep Basal Basal 1 1 1 1 10R_BL_Ep Lum Lum 2 2 2 2 10R_BU_Ep Lum NA 2 2 2 2 11L_B_Ep Lum Lum 2 2 2 2 11N_D_Ep Lum Lum 1 1 2 2 11R_D_Ep Lum Lum 2 2 2 2 11R_C_Ep Basal Lum 2 2 2 2 12L_D_Ep Basal Basal 1 2 2 2 14N_C_Ep Lum Lum 2 2 2 2 14N_D_Ep Basal Basal 2 2 2 2 14R_B_Ep Lum Lum 2 2 2 2 15N_C_Ep Basal Basal 2 2 2 2 16L_C_Ep Lum Lum 2 2 2 2 17N_D_Ep Lum Lum 2 2 2 2 2N__Ep Lum Basal 2 2 2 2 3N_B_Ep Basal Basal 1 1 1 1 3R_C_Ep Lum Lum 2 2 2 2 6R_B_Ep Lum Basal 1 1 1 2 7N_A_Ep Lum Basal 2 2 2 2 8L_D_Ep Basal Basal 1 1 1 2 8R_CU_Ep Basal Basal 2 2 2 2 "],["signature-analysis.html", "Chapter 11 Signature analysis 11.1 MHC signature analysis 11.2 Cancer pathways", " Chapter 11 Signature analysis In this section, we use a combination of gene-set enrichment analysis, heatmap visualisation and XX to investigate differences in PAM50 expression Major signalling pathways MHC expression signatures 11.1 MHC signature analysis Look if there is an association between MHC class I and class II and checkpoint proteins with growth in the different fractions. The summary appears: class I: association with stable in ep samples class II: low expression in DN stable sampels MHC presentation: higher in stable samples Ep (and also the characterisation cohort in general), may also be the case in DN samples 11.1.1 MHC-I 11.1.2 MHC-II 11.1.3 MHC presentation proteins 11.2 Cancer pathways In this section, we will assess whether certain fractions (eg. ep or dn) or certain tumors depend on specific cancer signalling axes. We will utilise the following information: Common cancer pathways listed by Bailey et al: This includes PIk3CA, cell cycle, Myc, tp53, notch, TGFB manually curated list of breast-specific genes (esr1, gata3, erbb2, pgr, tp53) 11.2.1 ssGSEA Figure out the signalling pathway expression (e.g using ssGSEA). From top to bottom, the color codes are: cd8 content infiltration cd8 Growht Fraction treatment From the above plots: higher Hippom Notch RTK Wnt and TGFB signalling in DN samples LY epithelial samples are enriched in cell cycle genes 11.2.2 regression model for covariates Linear model: Create a linear model to explain the above, focusing on the Progression cohort. I.e. Signature Score ~ Fraction + Treatment + CD8Fraction + Spatial Score + GrowthRate + Tumour size + PAM50 Note that the reference levels are: Fraction: DN Treatment: Vehicle PAM50: basal We see: TP53 and Wnt pathways associated with CD8 content (particularly in CD8 low samples) TP53 more associated basal DN, and with treatment in DN samples, infiltrating tumors TGFB signalling higher in ep treated ith PDL1+LY Focus specifically on the DN and Ep samples separately: Associations: notch signalling with LY treatment TGFB with PDL1+LY treatment Ras and Wnt signalling lower CD8Fraction TP53 with CD8 fraction 11.2.3 Taking into account directionality Do the same scoring, taking into account oncogenic vs tumor suppressor activity (i.e.) Usually, there is no difference. The pathway is increased either way Do a regression analysis for TSG vs ONCO signatures in this pathway Looking at up vs down genes: are any of these differentially expressed? ## [1] big big big small small big big small small small ## Levels: big small "],["immune-estimation.html", "Chapter 12 Immune estimation 12.1 ssGSEA 12.2 Deconvolution methods", " Chapter 12 Immune estimation In this section, we will look at a number of methods for immune estimation: ssGSEA using known signatures: This includes the Thorsson signatures, as well as signatures for activation and dysfunction as described by Tirosh and in the supplementary tables from Gil del Alcazar. Deconvolution methods (CIBERSORT, TIMER etc) 12.1 ssGSEA Below, we use the GSVA package and TPM counts to assess variability in the different signatures. We will compare this to: growth CD8 counts spatial patterns (infiltrating vs restricted, MH index) ## ## inf res ## 34 34 ## [1] 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ## [26] 29 30 31 32 33 34 35 36 37 38 Based on wilcoxon tests for differences between growth, cd8 content, spatial arrangement, we can also pull out the significantly different signatures and plot these below: For the MH scores and the CD8 scores, we can do a correlation analysis using the raw values 12.2 Deconvolution methods Deconvolution was performed using the TIMER website, which lists results from TIMER, XCELL, CIBERSORT, EPIC, MMPCOUNTER For TIDE, we need to: compute log(RPKM+1) values Determine the values of the reference/or compute a sample average Subtract the two We can convert from Rat gene names to Human and exclude all the non mapping gnes. TPM counts were used for this analysis (using Rat gene names) 12.2.1 Overview of the cell types Below, we will look at the enrichment scores of specific cell types compared to others using these different methods. It appears that most methods have scores which skews towards high representation of T cells: TIMER for example shows an enrichment of dendritic and CD8 T cells. EPIC in contrast shows enrichment for CD4+ and to a lesser extend CD8 T cells MMPCOUNTER puts an unusually large weighting to T cells and this does not fit our FACS analysis XCELL enriches for T cells 12.2.2 Association between characterisation cohort and size Associations with size? Perform a correlation test between all of the information above and tumor size ## quartz_off_screen ## 2 Make the plots with individual samples: ## quartz_off_screen ## 2 12.2.3 Comparison with FACS data In this section, we compare how well the estimates from RNAseq deconvolution methods associate with FACS data. We can plot associations between the different cell types below, here selecting: Bcells CD8 T cells M2 macophage M1 macrophage 12.2.4 Progression cohort Plot the cibersort and/or EPIC output: ## quartz_off_screen ## 2 ## quartz_off_screen ## 2 Make the plots with individual samples: ## quartz_off_screen ## 2 12.2.5 Associate with Treatment Look at association with treatment, growth and spatial infiltration for each method. Associations with treatment: higher CD4, CD8 in most treatments growth: stable associated with higher CD8 infiltration: more neutrophils and CD8? maybe CD4 cells Using wilcox tests for significance, we can make the above comparisons and see if there is an association with outcome: There are differences in B-cell content between LY vs V comaprisons using xcell and cibersort Macrophages are different in PDL1+LY 12.2.6 Association with Growth 12.2.7 Association with infiltration ### Summary of the outcome LYvs.Vehicle PDL1vs.Vehicle PDL1+LYvs.Vehicle Grow.Stable Inf.res CIBERSORT 0.4126984 0.5476190 1.0000000 0.5880289 0.1892774 CIBERSORT-ABS 0.4126984 1.0000000 0.6623377 0.6426471 0.5358197 EPIC 0.5031709 0.6764350 0.3052553 0.2388414 0.8841264 facs 0.0265187 0.1979593 0.0265187 0.1028077 0.5031709 MMCPCOUNTER 0.0004218 0.0110240 0.0372030 0.0027499 0.8841264 QUANTISEQ 0.8735909 0.1566299 0.3301798 0.4282170 0.0562203 TIMER 0.7506528 0.9082682 0.1930218 0.3922756 0.4516905 XCELL 0.0912068 0.0288056 0.0802331 0.2334498 0.6325687 facs 0.9047619 0.6904762 0.5367965 1.0000000 0.8665113 CIBERSORT 0.3710934 0.4237108 NaN 0.0572674 0.4226781 CIBERSORT-ABS 0.3710934 0.4237108 NaN 0.0572674 0.4226781 QUANTISEQ 0.2857143 0.3095238 0.1610557 0.0707781 0.6843748 XCELL 0.1111111 0.0952381 0.0519481 0.0033561 0.7282210 facs 0.2857143 0.2222222 0.5367965 0.2749226 0.1205905 CIBERSORT 0.2857143 0.0317460 0.2467532 0.1574303 0.4634033 CIBERSORT-ABS 0.1904762 0.0317460 0.0519481 0.0968008 0.2809635 QUANTISEQ 0.2622393 0.4633439 0.1908413 0.0288101 0.9048611 XCELL 0.5555556 0.4633439 0.5830249 0.0088199 0.6843748 CIBERSORT 0.1904762 0.6904762 0.5367965 0.0144737 0.3968920 CIBERSORT-ABS 0.1904762 1.0000000 0.2467532 0.0144737 0.5358197 facs 0.1904762 1.0000000 0.3290043 0.4377967 0.1519814 MMCPCOUNTER 0.1312104 0.0720057 0.4652088 0.3530684 1.0000000 QUANTISEQ 0.5023350 0.4237108 0.3613104 0.5293681 NaN XCELL 0.1399825 0.1612376 0.0995755 0.0080464 0.6827511 CIBERSORT NaN NaN 0.4652088 0.2084128 0.3495748 CIBERSORT-ABS NaN NaN 0.4652088 0.2084128 0.3495748 facs 0.7301587 0.5476190 0.6623377 0.8167957 1.0000000 QUANTISEQ 0.2404208 0.1797125 0.1363802 0.3228308 0.4226781 TIMER 0.5555556 1.0000000 0.9307359 0.1574303 0.2318570 XCELL 0.9008654 1.0000000 0.6321424 1.0000000 0.5500973 facs 0.6666667 0.5333333 0.3333333 0.4206349 0.1904762 EPIC 0.9047619 0.2222222 0.6623377 0.4854231 0.6943279 MMCPCOUNTER 0.2857143 0.4206349 0.3290043 0.0004902 1.0000000 QUANTISEQ 0.9047619 0.4206349 0.9307359 0.0264435 0.9550894 XCELL 0.4126984 0.5476190 0.9307359 0.0296956 0.0400932 facs 0.3333333 0.2666667 1.0000000 0.0317460 0.0634921 CIBERSORT 0.2857143 0.3095238 0.1255411 0.3928793 0.5358197 CIBERSORT-ABS 0.1904762 0.6904762 0.1255411 0.5880289 1.0000000 EPIC 0.9047619 0.8412698 0.0519481 0.3506966 0.2809635 QUANTISEQ 0.5385943 0.0317460 0.0519481 0.7807063 0.5207033 TIMER 0.4126984 0.8412698 0.6623377 0.0455624 0.0721057 XCELL 1.0000000 0.8412698 1.0000000 0.0011610 0.2809635 facs 1.0000000 0.2666667 0.3333333 0.3095238 0.1111111 CIBERSORT 0.9047619 1.0000000 0.7922078 0.0455624 0.7788656 CIBERSORT-ABS 0.9047619 0.4206349 0.5367965 0.0186017 0.8665113 QUANTISEQ 0.5555556 0.4206349 0.5367965 0.9384675 0.5358197 XCELL 0.7301587 0.1507937 0.1255411 0.1826883 0.6943279 CIBERSORT 0.2857143 0.0555556 0.2467532 0.1574303 0.4634033 CIBERSORT-ABS 0.1904762 0.0317460 0.0519481 0.1146285 0.2809635 EPIC 0.1111111 0.0952381 0.1774892 0.0034056 0.8665113 facs 0.1904762 0.2222222 0.7922078 0.4854231 0.2809635 QUANTISEQ 0.4126984 0.5476190 0.1669941 0.0054748 0.7721395 TIMER 0.2622393 0.4633439 0.2621926 0.6271128 1.0000000 XCELL 0.1111111 0.2222222 0.1774892 0.0034056 0.7788656 CIBERSORT 0.2857143 0.2222222 0.2722293 0.1653588 0.9538159 CIBERSORT-ABS 0.4126984 0.2222222 0.2722293 0.2845377 0.8620647 EPIC 0.4126984 0.1507937 0.0173160 0.2749226 0.4634033 facs 0.3333333 0.5333333 0.3333333 0.0555556 0.1904762 QUANTISEQ 0.5023350 1.0000000 0.3413145 1.0000000 0.1582563 TIMER 0.2008251 0.1059975 0.0616637 0.4698277 0.5207033 XCELL 0.2857143 0.0952381 0.1774892 0.7573013 0.5358197 "],["bcr-clonotype-analysis.html", "Chapter 13 BCR clonotype analysis 13.1 Processing summary 13.2 Summary Stats 13.3 Diversity metrics 13.4 Compare the characterisation cohort 13.5 Associate with clinicopathological data 13.6 Associate with signature scores 13.7 Check whether the clonotype percentages match with gsva signatures or CD20 populations", " Chapter 13 BCR clonotype analysis 13.1 Processing summary Fastq files have previously been run through TRUST4 using the Rn6 BCR annotations using the following code (not run here). Note that the bcr/tcr .fa files were assembled using the ensembl annotation (these annotations are not present in the UCSC genomic files). Annotation files for the rn6 BCR regions are available at IMGT, but TCR regions are not available # obtain the gene names for rat: library(biomaRt) human = useEnsembl(&quot;ensembl&quot;, mirror=&quot;useast&quot;, dataset = &quot;hsapiens_gene_ensembl&quot;) rat = useEnsembl(&quot;ensembl&quot;, mirror=&quot;useast&quot;, data=&quot;rnorvegicus_gene_ensembl&quot;) TS = human_igg_trv_list Hum2RatProt = getLDS(attributes = c(&quot;hgnc_symbol&quot;, &quot;ensembl_transcript_id&quot;), filters = &quot;hgnc_symbol&quot;, values = TS , mart = human, attributesL = c(&quot;rgd_symbol&quot;, &quot;ensembl_transcript_id”, “ensemble_gene_id&quot;), martL = rat, uniqueRows=T) write.table(unique(Hum2RatProt$ensemble_gene_id), &quot;ensbl_rat_bcr.txt&quot;, quote=F, row.names=F,colnames=F) # obtain the tcr/bcr.fa file #(Note that BuildDatabaseFa.pl needs to be edited on lines 95, 102, 114 and 121 to use transcript_id or gene_id instead) perl BuildDatabaseFa.pl Rattus_norvegicus.Rnor_6.0.dna_sm.toplevel.fa Rattus_norvegicus.Rnor_6.0.99.gtf ensbl_rat_bcr.txt &gt; bcrtcr_rat_ens.fa # Obtain the reference annotation file perl BuildImgtAnnot.pl Rattus_norvegicus &gt; Rnor_IMGT+C.fa # Run TRUST (below is single end) ./run-trust4 -u 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001.fastq.gz -f bcrtcr_rat_ens.fa --ref Rnor_IMGT+C.fa 13.2 Summary Stats Firstly, look at the number of BCR regions which have been identified by TRUST4. In green are the CD45 populations, which as expected appear to have a higher number of clonotypes compared to the epithelial and the double-negative populations (in read and orange). We will refine the above plot to contain only the CD45 population and assess: number of clonotypes number of clonotypes with at least 2 reads number of clonotypes which have a complete CDR3a region Note: although this does not look like a big drop, the data is plotted on a log-scale. For example, in the control 4 (first column) a quarter of the clonotypes have at least 2 counts and about half have a complete CDR3 sequence. For the following analyses, the clonotypes are filtered to only clonotypes with at least 2 supporting reads and a complete VDJ read . When applying this restriction, we have the following distribution of BCR regions. Almost all the epithelial cases do not have supporting reads, and few of the DN cases have supporting reads too. 13.3 Diversity metrics We will assess BCR diversity using the following metrics: ** Shannon index ** The shannon index is computed by: filtering through reads of interest recalculate the fraction such that the new list sums to 1 compute entropy as the sum of log(freq_x)*freq_x amongst all populations x compute the maximum entropy expected for that case -log(1/N), where N is the number of populations present to determine confidence intervals, bootstrap the population (500 times) and compute the expected entropy ** Gini index ** The Gini index can be considered as an inverse of the Shannon index ** Top Clonotypes ** We will see the proportion of the BCR repertoire which is computed using the top 10 frequent clones. This will give an idea of whether there is a clonal expansion The following plot demonstrates the relationship between the above metrics Notice that some samples have very few clones. An example is 5RB which is represented by a single clonotype, accounting for the absence of a Gini or shannon index 13.4 Compare the characterisation cohort In the characterisation cohort, we have 3 cases which have CD45 samples in both the tumor and a matched NMU treated mammary gland. Is there a difference in the clonotypes between these samples? 13.5 Associate with clinicopathological data We will associate the following metrics: total unique clones diversity with the following immune data: CD45 fraction (from FACS) CD8 fraction (from WSI) MH-mixing indices Tumor Size Growth Treatment ## &lt; table of extent 0 &gt; ## quartz_off_screen ## 2 13.6 Associate with signature scores Compare to B cell counts and activation status based on RNA-seq B cell signature enrichments scores (from RNA data) B cell frequencies based on FACS: 13.7 Check whether the clonotype percentages match with gsva signatures or CD20 populations associate with immune signature scores (ssgsea) fdr adjust the correlation p values "],["whole-genome-sequencing-mutations.html", "Chapter 14 Whole Genome Sequencing Mutations 14.1 Data 14.2 Plots 14.3 Coding variants 14.4 Overview of the mutations 14.5 Metacore analysis of commonly mutated pathways", " Chapter 14 Whole Genome Sequencing Mutations Whole genome sequencing was performed on XX samples by the new york genome centre. The pipeline involves: Insert information on the NYGC pipeline here 14.1 Data In this section, we load the maf output files and create lists which filter out coding mutations Determine mutational signatures by: Creating bed files with genomic locations of the SNP +- 1 base location Extracting the nucleotide sequence using bedtools Convert all mutations to C &gt; N and T &gt; N to obtain 96 mutational signatures run with single sample SigProfiler to obtain the signature scores Annotate data with common human variants ## [1] &quot;no of mutations&quot; ## C1R-tumor C2N-tumor C2R1-tumor C2R2-tumor C2R3-tumor C4P-tumor ## 240153 262425 235677 222717 238324 258677 14.1.1 Extract mutation signatures Annotate the files so that the nucleotide codon can be extracted based on the genome file. See the bash file extract-trinucleotide-forSigProfiler.sh to see the output of this. The output table $fout3 should have 6 columns with the genomic location, the reference and alt allele and codon context. TBed=lapply(AllMutWGS, function(x) cbind(as.character(x$Chromosome), x$Start_Position-2, x$End_Position+1, as.character(x$Reference_Allele), as.character(x$Tumor_Seq_Allele2))) TBed=lapply(TBed, function(x) x[which(nchar(x[ ,4])==1), ]) sapply(1:length(TBed), function(x) write.table(TBed[[x]], file=paste(names(TBed)[x], &quot;tricodon.bed&quot;, sep=&quot;_&quot;),col.names=F, row.names = F, sep=&quot;\\t&quot;, quote = F)) ## bedtools command bedtools getfasta -fi ../Genomic_Files/rn6.fa -bed $f -tab -fo $fout f3() { awk &#39;{print $1, $2, $3, $4 ,$5}&#39; &quot;$1&quot;; }; paste &lt;(f3 $f) &lt;(f3 $fout) &gt; $fout2 awk &#39;{if (length($7)==3) print $1, $2, $3, $4, $5, toupper($7)}&#39; $fout2 &gt; $fout3 ## see the bash file extract-trinucleotide-forSigProfiler.sh to see the output of this. Following running the above bash script, we can run the following extract the tri-nucleotide sequence FFiles=dir(&quot;../data/tricodon_mut_sigs/&quot;, &quot;*.txt&quot;,full.names=T) OutputList=sapply(FFiles, function(x) FindTriNucleotideContext(x)) TableOut=sapply(1:ncol(OutputList), function(x) unlist(OutputList[3, x])) a1=basename(FFiles) a2=sapply(strsplit(a1, &quot;_&quot;), function(x) x[1]) TableOut=cbind(as.character(unlist(OutputList[1, 1])), as.character(unlist(OutputList[2, 1])), TableOut) colnames(TableOut)=c(&quot;MutationType&quot;,&quot;Nutrinucleotide&quot;, paste(&quot;BRCA&quot;, a2, sep=&quot;::&quot;)) write.csv(TableOut, file=&quot;../data/tricodon_mut_sigs/output4SigProfiler.csv&quot;, sep = &quot;,&quot;, row.names = F) This is then run in python (sigprofiler) with the following code: module load gcc module load python/3.7.4 from SigProfilerExtractor import spss_pcwag (spss uses only vcf files) spss_pcwag.single_sample_pcwag(&quot;output4SigProfiler.csv&quot;, output=&quot;example_output&quot;) The results from this analysis are shown below 14.1.2 Annotate the data with human common variants From this analysis, below are the genes with mutations in known human hotpot mutations in common genes L1 AAno Gene AAno.1 AA1 Variant HumGene RatSequence RatProt HumSequence HumProt HumAAno 166 NMU12-tumor-LA 12 Hras 12 G E HRAS VVVGAGGVGKS ENSRNOP00000022363 VVVGAGGVGKS ENSP00000380722 12 168 NMU12-tumor-LA 264 Tp53 264 G R TP53 SGNLLGRDSFE ENSRNOP00000047840 SGNLLGRNSFE ENSP00000352610 266 131 NMU1-tumor 118 Pik3ca 118 G D PIK3CA LNREIGFVIGM ENSRNOP00000072496 LNREIGFAIGM ENSP00000263967 118 181 NMU12-tumor-LA 542 Pik3ca 542 E K PIK3CA RDPLSEITEQE ENSRNOP00000072496 RDPLSEITEQE ENSP00000263967 542 155 NMU1-tumor 3016 Atm 3016 R H ATM NKVAERVLMRL ENSRNOP00000045529 NKVAERVLMRL ENSP00000388058 3008 And here, we plot the frequency of these different mutations 14.2 Plots 14.2.1 Quick overview WGS all mutations summary: Look at the overall mutation burden, and the tumor mutational burden, defined as # coding mutations per MB. The following plot lists tumors in increasing size Make plots of: overall types of mutations per sample (ranked by size) correlation between mutation type and size type of mutation? 14.2.2 Coding variants &amp; TMB There are a few ways of figuring out the TMB. We can report the number of mutations (missense, insertion/deletion, frameshifts, nonsense) normalise the above value to the known length of coding regions in the rat genome (UCSC exon length 43,423,804) plot of TMB vs objective response rate: there is no true relationship between final tumor size and mutational burden. Could also be confounded by subclonality 14.3 Coding variants 14.3.1 Sites which are commonly mutated? Could this be a variant (SD strain “rsSNP”) or is it actually a mutation? Variants were annotated with snpeff. Raw data from this was obtained from https://www.biorxiv.org/content/10.1101/412924v1.full Note that the nihRats package may not be required here. We probably just want the harlan snps Look at the distribution of mutations: Whole genome 1188 genes in more than 2 animals (1435 in at least 2) 59 variants were identified as population variant in Harlan 47 in charles river (6 are novel in this cohort only) Cosmic genes: 42 sites which have mutations in more than 2 animals 50 sites in more than 1 animal 5 sites which have been identified in GWAS studies of harlan rats. On average, the variant is found at a frequency of ~15%. The CR set, these variants appear in 50% of the population 4 of the 5 rats from above were identified in 0 sites in the nih dbSNP database for rats Here, compare the frequencies of the most common mutations in our population with those reported in the harlan and charles river data-bases: filter out mutatations occuring in 2+ samples ## [1] 1093 freq.Freq gene VariantClass Cosmic variable value 140 11 Prf1 Missense_Mutation 1 HarlanFreq 0.4528715 699 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1402893 700 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1402893 701 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1411662 805 3 Tcf3 Missense_Mutation 1 HarlanFreq 0.0679527 953 2 Ptpn13 Missense_Mutation 1 HarlanFreq 0.0271811 1792 3 Rnf213 Missense_Mutation 1 CRFreq 0.5264045 1793 3 Rnf213 Missense_Mutation 1 CRFreq 0.5264045 1794 3 Rnf213 Missense_Mutation 1 CRFreq 0.5365169 1898 3 Tcf3 Missense_Mutation 1 CRFreq 0.1488764 14.4 Overview of the mutations 14.4.1 All mutations SNPs are removed from this analysis: based on frequencies in the harlan cohort Color codes: black: pink: green: blue: Note that in this table, the distribution of samples with mutations is as follows: 2042, 342, 196, 222, 65, 43, 30, 25, 23, 23, 15, 14, 10, 11, 7, 7, 1, 1, 1, 1, 1 The number of genes which have shared mutations in 10 or more samples is: 92, which is why we have use these values here. The number of genes which are cosmic associated are: 162 and the number which appear in more than 1 sample is 44. These genes are tabulated below: 14.5 Metacore analysis of commonly mutated pathways Save these lists for metacore Load the metacore results: ## Inflammation_IL-2 signaling Signal transduction_ESR1-nuclear pathway ## C1R-tumor 2 8 ## C2N-tumor 0 0 ## C2R1-tumor 2 1 ## C2R2-tumor 2 2 ## C2R3-tumor 2 2 ## C4P-tumor 0 4 ## Signal Transduction_Cholecystokinin signaling ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 0 ## Signal transduction_NOTCH signaling ## C1R-tumor 9 ## C2N-tumor 4 ## C2R1-tumor 4 ## C2R2-tumor 4 ## C2R3-tumor 2 ## C4P-tumor 4 ## Signal transduction_ESR1-membrane pathway ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 3 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 1 ## Cell adhesion_Integrin priming Inflammation_IL-6 signaling ## C1R-tumor 8 1 ## C2N-tumor 0 4 ## C2R1-tumor 6 2 ## C2R2-tumor 1 4 ## C2R3-tumor 3 1 ## C4P-tumor 3 2 ## Cell adhesion_Cadherins DNA damage_MMR repair ## C1R-tumor 4 4 ## C2N-tumor 3 0 ## C2R1-tumor 7 2 ## C2R2-tumor 4 1 ## C2R3-tumor 6 2 ## C4P-tumor 6 3 ## Cell adhesion_Integrin-mediated cell-matrix adhesion ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 5 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 2 ## Development_EMT_Regulation of epithelial-to-mesenchymal transition ## C1R-tumor 7 ## C2N-tumor 4 ## C2R1-tumor 6 ## C2R2-tumor 4 ## C2R3-tumor 5 ## C4P-tumor 4 ## Reproduction_Feeding and Neurohormone signaling ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Cell cycle_G1-S Growth factor regulation ## C1R-tumor 4 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Blood vessel morphogenesis ## C1R-tumor 5 ## C2N-tumor 5 ## C2R1-tumor 8 ## C2R2-tumor 6 ## C2R3-tumor 5 ## C4P-tumor 7 ## Cell adhesion_Platelet aggregation ## C1R-tumor 4 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Cell adhesion_Attractive and repulsive receptors ## C1R-tumor 1 ## C2N-tumor 1 ## C2R1-tumor 5 ## C2R2-tumor 1 ## C2R3-tumor 3 ## C4P-tumor 2 ## Signal transduction_ERBB-family signaling ## C1R-tumor 5 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 2 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Neurogenesis_Axonal guidance ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 6 ## C2R2-tumor 1 ## C2R3-tumor 4 ## C4P-tumor 1 ## Cell adhesion_Cell-matrix interactions ## C1R-tumor 12 ## C2N-tumor 6 ## C2R1-tumor 3 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 4 ## Development_Regulation of angiogenesis ## C1R-tumor 12 ## C2N-tumor 3 ## C2R1-tumor 8 ## C2R2-tumor 6 ## C2R3-tumor 4 ## C4P-tumor 3 ## Reproduction_Progesterone signaling Muscle contraction ## C1R-tumor 3 6 ## C2N-tumor 1 3 ## C2R1-tumor 3 1 ## C2R2-tumor 2 0 ## C2R3-tumor 2 0 ## C4P-tumor 3 2 ## Cytoskeleton_Cytoplasmic microtubules ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 5 ## Development_Neurogenesis in general ## C1R-tumor 9 ## C2N-tumor 1 ## C2R1-tumor 6 ## C2R2-tumor 3 ## C2R3-tumor 3 ## C4P-tumor 8 ## Reproduction_Male sex differentiation Cell cycle_Meiosis ## C1R-tumor 6 6 ## C2N-tumor 0 1 ## C2R1-tumor 4 2 ## C2R2-tumor 3 1 ## C2R3-tumor 3 2 ## C4P-tumor 0 1 ## Development_ERK5 in cell proliferation and neuronal survival ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 1 ## Development_Hedgehog signaling ## C1R-tumor 7 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 4 ## Cardiac development_Wnt_beta-catenin, Notch, VEGF, IP3 and integrin signaling ## C1R-tumor 10 ## C2N-tumor 1 ## C2R1-tumor 3 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 1 ## Development_Neuromuscular junction ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 3 ## Inflammation_Kallikrein-kinin system ## C1R-tumor 6 ## C2N-tumor 8 ## C2R1-tumor 4 ## C2R2-tumor 4 ## C2R3-tumor 2 ## C4P-tumor 4 ## Proteolysis_Connective tissue degradation Cell cycle_S phase ## C1R-tumor 9 5 ## C2N-tumor 15 2 ## C2R1-tumor 3 5 ## C2R2-tumor 2 3 ## C2R3-tumor 3 5 ## C4P-tumor 14 4 ## Cell adhesion_Platelet-endothelium-leucocyte interactions ## C1R-tumor 5 ## C2N-tumor 5 ## C2R1-tumor 5 ## C2R2-tumor 5 ## C2R3-tumor 4 ## C4P-tumor 6 ## Immune response_IL-3 signaling via ERK and PI3K ## C1R-tumor 2 ## C2N-tumor 3 ## C2R1-tumor 4 ## C2R2-tumor 2 ## C2R3-tumor 3 ## C4P-tumor 2 ## NF-AT signaling in cardiac hypertrophy ## C1R-tumor 4 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 4 ## Development_Prolactin receptor signaling ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Immune response_M-CSF-receptor signaling pathway ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Negative regulation of WNT/Beta-catenin signaling in the cytoplasm ## C1R-tumor 0 ## C2N-tumor 3 ## C2R1-tumor 3 ## C2R2-tumor 2 ## C2R3-tumor 4 ## C4P-tumor 2 ## CHDI_DEGs from Replication data_Causal network ## C1R-tumor 3 ## C2N-tumor 2 ## C2R1-tumor 0 ## C2R2-tumor 3 ## C2R3-tumor 0 ## C4P-tumor 0 ## IGF family, invasion and metastasis in colorectal cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Development_Positive regulation of WNT/Beta-catenin signaling in the cytoplasm ## C1R-tumor 1 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 3 ## C2R3-tumor 5 ## C4P-tumor 3 ## PI3K signaling in gastric cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Immune response_IL-4 signaling pathway ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 2 ## CHDI_Correlations from Discovery data_Causal network ## C1R-tumor 1 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Immune response_Function of MEF2 in T lymphocytes ## C1R-tumor 2 ## C2N-tumor 2 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Signal transduction_Angiotensin II/ AGTR1 signaling via p38, ERK and PI3K ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 2 ## CHDI_Correlations from Replication data_Causal network (positive correlations) ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Signal transduction_Angiotensin II/ AGTR1 signaling via JAK/STAT ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 3 ## Development_Fetal brown fat cell differentiation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 2 ## Signal transduction_Angiotensin II/AGTR1 signaling via Notch, Beta-catenin and NF-kB pathways ## C1R-tumor 4 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 3 ## Cytoskeleton remodeling_FAK signaling ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## WNT signaling in proliferative-type melanoma cells ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Cytoskeleton remodeling_Hyaluronic acid/ CD44 signaling pathways ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## EGF- and HGF-dependent stimulation of metastasis in gastric cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## CHDI_Correlations from Replication data_Cytoskeleton and adhesion module ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Role of adhesion of SCLC cells in tumor progression ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Mechanisms of CAM-DR in multiple myeloma ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## CHDI_Correlations from Replication data_Causal network (negative correlations) ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 0 ## Aberrant B-Raf signaling in melanoma progression ## C1R-tumor 1 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 1 ## Development_Thromboxane A2 signaling pathway ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## IGF-1 signaling in multiple myeloma ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Chemotaxis_Lysophosphatidic acid signaling via GPCRs ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 3 ## C4P-tumor 1 ## Cell cycle_Role of Nek in cell cycle regulation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## High shear stress-induced platelet activation ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Development_Negative regulation of WNT/Beta-catenin signaling in the nucleus ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## wtCFTR and deltaF508-CFTR traffic / Clathrin coated vesicles formation (normal and CF) ## C1R-tumor 0 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Development_The role of GDNF ligand family/ RET receptor in cell survival, growth and proliferation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Chemotaxis_SDF-1/ CXCR4-induced chemotaxis of immune cells ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Proliferative action of Gastrin in gastric cancer ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Positive regulation of WNT/Beta-catenin signaling at the receptor level ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Development_Regulation of cytoskeleton proteins in oligodendrocyte differentiation and myelination ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 2 ## Neurogenesis_NGF/ TrkA MAPK-mediated signaling ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 2 ## C2R3-tumor 1 ## C4P-tumor 1 ## Muscle contraction_S1P2 receptor-mediated smooth muscle contraction ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## EGFR signaling pathway in colorectal cancer ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 0 ## Langerhans cell migration to lymph nodes in allergic contact dermatitis ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Stem cells_Pancreatic cancer stem cells in tumor metastasis ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Role of cell adhesion molecules in progression of pancreatic cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 "],["mutations-in-rna.html", "Chapter 15 Mutations in RNA 15.1 Haplotype caller 15.2 Load files 15.3 Identifying polymorphisms: compare frequencies in CD45 and Ep data 15.4 Find coding mutations which are specific to ep cells 15.5 Filtering WGS data based on CD45 data", " Chapter 15 Mutations in RNA In this section, we will check RNA data for the common mutations identified in the previous section. Some of these mutations could be uncharacterised polymoprphisms, and if this is the case, we will see in both CD45 and Epithelial fractions 15.1 Haplotype caller Mutational calling from RNA data was performed using haplotype caller. The key steps are: run haplotype caller run snpeff to annotate from snpsift to convert to a text file that can be read Note that a dbSNP file is needed to filter for polymorphisms. We have used the harlan variants to perform filtering due to similarity in population frequencies in the previous section An example of the code is shown here: From processing the mutational information: Header information - Genotypes: GT: genotype AD: Allelic depths for the ref and alt alleles in the order listed DP: Approximate read depth (reads with MQ=255 or with bad mates are filtered) GQ: Genotype Quality PL: Normalized, Phred-scaled likelihoods for genotypes Header info: Info AC: Allele count in genotypes, for each ALT allele, in the same order as listed AF: Allele Frequency, for each ALT allele, in the same order as listed AN: Total number of alleles in called genotypes DB: dbSNP Membership DP: Approximate read depth; some reads may have been filtered ExcessHet: Phred-scaled p-value for exact test of excess heterozygosity FS: Phred-scaled p-value using Fisher’s exact test to detect strand bias MLEAC: Maximum likelihood expectation (MLE) for the allele counts (not necessarily the same as the AC) MLEAF: Maximum likelihood expectation (MLE) for the allele frequency (not necessarily the same as the AF) MQ: RMS Mapping Quality QD:Variant Confidence/Quality by Depth SOR: Symmetric Odds Ratio of 2x2 contingency table to detect strand bias SnpEff Annotations: Allele : C Annotation: missense_variant Annotation_Impact MODERATE Gene_Name Raet1l Gene_ID ENSRNOG00000040300 Feature_Type transcript Feature_ID ENSRNOT00000062027.4 Transcript_BioType protein_coding HGVS.c c.1017C&gt;G HGVS.p p.Cys339Trp cDNA.pos / cDNA.length 1017/1185 CDS.pos / CDS.length 1017/1185 AA.pos / AA.length 339/394 missense_variant|MODERATE|Raet1l|ENSRNOG00000040300|transcript|ENSRNOT00000062027.4|protein_coding|6/7|c.1017C&gt;G|p.Cys339Trp|1017/1185|1017/1185|339/394|| AC=2;AF=1.00;AN=2;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.99;SOR=0.874;ANN=GC|frameshift_variant&amp;splice_region_variant|HIGH|Reps1|ENSRNOG00000059224|transcript|ENSRNOT00000089607.1|protein_coding|8/29|c.119dupC|p.Gln41fs|142/2608|120/1842|40/613||INFO_REALIGN_3_PRIME;LOF=(Reps1|ENSRNOG00000059224|2|0.50) AC=2;AF=1.00;AN=2;BaseQRankSum=1.593;ClippingRankSum=0.000;DP=9;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=33.20;ReadPosRankSum=0.765;SOR=1.609;ANN=AT|frameshift_variant&amp;stop_gained|HIGH|Pacs1|ENSRNOG00000020350|transcript|ENSRNOT00000027632.5|protein_coding|3/24|c.464dupA|p.Tyr155fs|464/2886|464/2886|155/961||;LOF=(Pacs1|ENSRNOG00000020350|1|1.00);NMD=(Pacs1|ENSRNOG00000020350|1|1.00) 15.2 Load files 15.3 Identifying polymorphisms: compare frequencies in CD45 and Ep data Search for whether mutations in the cosmic set is present in the RNA data. We will firstly look at the 90 most common genes, and then repeat the same for the top cosmic genes. 15.4 Find coding mutations which are specific to ep cells Here, look for mutations from RNA which are present in the epithelial cells specific ## quartz_off_screen ## 2 Location specific mutations: There are 6 mutations which are found in both the RNA and WGS data (2+ samples, not found in RNAseq) 15.5 Filtering WGS data based on CD45 data Use the entire list for WGS Find mutations in CD45 (either) and remove ## quartz_off_screen ## 2 ## quartz_off_screen ## 2 "],["mutations-in-progression-cohort.html", "Chapter 16 Mutations in progression cohort 16.1 Summary of common mutations: 16.2 Look at the common mutations (cosmic ones) 16.3 Also look at the top RNA-mutations with are Ep/DN specific 16.4 Mutation load?", " Chapter 16 Mutations in progression cohort 16.1 Summary of common mutations: look at topCOSMIC: ## quartz_off_screen ## 2 16.2 Look at the common mutations (cosmic ones) 16.3 Also look at the top RNA-mutations with are Ep/DN specific 16.4 Mutation load? Any associations with "],["associating-expression-with-mutations.html", "Chapter 17 Associating expression with Mutations 17.1 Expression of genes in common 17.2 Expression of genes with key mutations 17.3 Expression of common mutations? 17.4 Expression of immune related genes in the CD45 population 17.5 Cancer Specific Pathways", " Chapter 17 Associating expression with Mutations Also plot the expression of the corresponding genes here, if the epithelial RNA data is present. Note, with this early batch, the DN population was not sorted by FACS nor sequenced. The following samples have matching WGX data: C2N__CD45, C2N__Ep, NMU12_RL_Ep, NMU12_LA_Ep, NMU14__Ep, NMU12_LA_CD45, NMU13_RAU_CD45, NMU14__CD45 from samples C2N_, NMU12_LA, NMU12_RL, NMU13_RAU, NMU14_ 17.1 Expression of genes in common Compare RNA mut freq &amp; expression values ## C2N__Ep C2R__Ep C5R__Ep NMU10_LL_Ep NMU12_LA_Ep NMU12_RL_Ep ## Ctgf 21854360 2 2 0 0 0 0 ## Dsc2 11829313 0 0 2 0 0 0 ## Enpep 233713639 1 1 1 0 0 0 ## Hps4 50293000 0 0 0 0 0 2 ## Igsf3 203832077 0 0 0 0 0 0 ## Klhl22 87693945 0 0 0 0 0 0 ## NMU13_LLU_Ep NMU14__Ep NMU7_RLU_Ep NMU13_LAU_Ep ## Ctgf 21854360 0 0 0 0 ## Dsc2 11829313 0 0 0 0 ## Enpep 233713639 0 0 0 0 ## Hps4 50293000 0 0 0 0 ## Igsf3 203832077 2 0 0 0 ## Klhl22 87693945 2 0 2 0 17.2 Expression of genes with key mutations We can still look at expression of genes of interest. Eg. C2N may be enriched in kalikrein systen, connective tissue degradation NMU12_LA in endothelium_leukocyte interactions, IL6 signalling NMU12 RL in NOTCH signalling? ## quartz_off_screen ## 2 ## quartz_off_screen ## 2 17.3 Expression of common mutations? Run the following to plot this for both the cd45 fraction as well as the epithelial fraction: 17.3.1 Look at cancer specific pathways ## quartz_off_screen ## 2 17.4 Expression of immune related genes in the CD45 population Initially do a search for the mutations shown before, also can do immune specific mutations Immune specific mutations 17.4.0.1 Combine the two fractions together 17.5 Cancer Specific Pathways Also separate out the TS and OG: change the first two lines of this to list this informaiton 17.5.1 Compute co-occurence matrices Use all genes in WGS coding Firstly by genomic location: pull out the top mutations occurring in at least 5 samples: this gives approximately 7000 loci. "],["haplotype-caller-1.html", "Chapter 18 haplotype caller", " Chapter 18 haplotype caller "],["trichrome-staining.html", "Chapter 19 Trichrome staining 19.1 Associations with cellular fraction (wsi) 19.2 Associations with growth and spatial patterns", " Chapter 19 Trichrome staining Quantification of trichrome staining was performed in Qupath using the following steps: image is loaded as a “DAB” image using “gold standard” trichrome-stained images with good stroma and epithelial content, estimate the stain vectors The output matrix was: XXX Perform color deconvolution A pixel classifier was used to estimate trichrome content A pixel classifier was used to estimate tumor content A snippet of the qupath script is shown below: 19.1 Associations with cellular fraction (wsi) ## knn.EpCAM knn.EpCAM..SMA knn.SMA knn.Unclass knn.EpMIN knn.EpStrRatio1 ## 10LB 39.96193 52.72253 16.94935 28.07623 39.96193 0.5735732 ## 10LC 32.12258 34.57734 17.87345 24.28626 32.12258 0.6124326 ## 10LD 34.33110 30.18133 15.97086 35.99495 30.18133 0.7438671 ## 10NA 23.80977 NA 27.49276 48.19205 23.80977 0.8660376 ## 10ND 26.20801 NA 30.06210 40.01762 26.20801 0.8717958 ## 10RBL 44.92703 67.36295 18.22774 26.07893 44.92703 0.5249056 ## knn.EpStrRatio2 knn.EpStrRatio3 knn.EpStrRatio4 IF.CD8 IF.EpCAM ## 10LB 2.3577258 1.3302993 5.4683183 0.20538263 0.2236555 ## 10LC 1.7972227 1.2716665 3.7317865 0.07842574 0.3168630 ## 10LD 2.1496080 1.3978193 4.0393825 0.28162217 0.2944373 ## 10NA 0.8660376 0.8660376 0.8660376 0.35915415 0.4808547 ## 10ND 0.8717958 0.8717958 0.8717958 0.30086657 0.4408878 ## 10RBL 2.4647619 1.3119416 6.1603904 0.12791040 0.2213380 ## IF.EpCAM..SMA IF.SMA IF.Unclass IF.EpMIN IF.EpStrRatio1 ## 10LB 0.08038836 0.5905018 0.3010823 0.08038836 0.3333713 ## 10LC 0.23757541 0.4768745 0.3714450 0.23757541 0.4435062 ## 10LD 0.25637789 0.5786730 0.1450209 0.25637789 0.3525981 ## 10NA NA 0.3207166 0.1112743 0.48085466 1.4993132 ## 10ND NA 0.1738438 0.1426298 0.44088779 2.5361139 ## 10RBL 0.20394931 0.5758915 0.4544651 0.20394931 0.2838246 ## IF.EpStrRatio2 IF.EpStrRatio3 IF.EpStrRatio4 MH.EpCAM MH.EpCAM..SMA ## 10LB 0.3787550 0.4531947 0.5148906 0.4189067 0.4131540 ## 10LC 0.6644578 0.7760354 1.1626506 0.4097456 0.4514649 ## 10LD 0.5088147 0.6596187 0.9518592 0.6622844 0.5987199 ## 10NA 1.4993132 1.4993132 1.4993132 0.4314681 NA ## 10ND 2.5361139 2.5361139 2.5361139 0.3700572 NA ## 10RBL 0.3843398 0.5453515 0.7384852 0.5503682 0.4903183 ## MH.SMA MH.Unclass MH.EpMIN MH.EpStrRatio1 MH.EpStrRatio2 ## 10LB 0.5718496 0.5168234 0.4131540 0.4252844 0.7325470 ## 10LC 0.4699867 0.5056881 0.4097456 0.4446740 0.8718238 ## 10LD 0.6967903 0.5894954 0.5987199 0.5112151 0.9504787 ## 10NA 0.4720285 0.3768075 0.4314681 0.9140722 0.9140722 ## 10ND 0.3088513 0.2854604 0.3700572 1.1981728 1.1981728 ## 10RBL 0.6513715 0.5568501 0.4903183 0.4820645 0.8449375 ## MH.EpStrRatio3 MH.EpStrRatio4 Treatment Growth Infil CD8frac ## 10LB 0.8447286 1.4550342 PDL1 growing Infiltrating 0.02289774 ## 10LC 0.9346237 1.8324147 PDL1 growing Infiltrating 0.01003407 ## 10LD 0.9733650 1.8097328 PDL1 stable Infiltrating 0.06810877 ## 10NA 0.9140722 0.9140722 PDL1 &lt;NA&gt; restricted 0.04656271 ## 10ND 1.1981728 1.1981728 PDL1 stable restricted 0.02271949 ## 10RBL 0.9115317 1.5976850 PDL1 growing restricted 0.02027148 ## GrowthRate TumSize knn.EpCAMcut MH.EpCAMcut IF.EpCAMcut CD8Fraccut ## 10LB 6.2285714 35 &lt;NA&gt; high low low ## 10LC 5.3571429 25 high low high low ## 10LD 1.9729730 10 high high high high ## 10NA NA 12 high high high high ## 10ND 0.3930533 15 high low high low ## 10RBL 4.9761905 40 &lt;NA&gt; high low low ## CD8 EpCAM EpCAM: SMA SMA Unclass CD8 EpCAM ## 10LB 0.02289774 0.2663149 0.1200304 0.3936498 0.1971072 0.02289774 0.2663149 ## 10LC 0.01003407 0.2960411 0.1672355 0.3081967 0.2184926 0.01003407 0.2960411 ## 10LD 0.06810877 0.1948931 0.2063845 0.4066703 0.1239434 0.06810877 0.1948931 ## 10NA 0.04656271 0.5554448 0.0000000 0.2855199 0.1124726 0.04656271 0.5554448 ## 10ND 0.02271949 0.4651478 0.0000000 0.2837204 0.2284123 0.02271949 0.4651478 ## 10RBL 0.02027148 0.3478534 0.1505455 0.2547647 0.2265650 0.02027148 0.3478534 ## EpCAM: SMA SMA Unclass Trichrome ## 10LB 0.1200304 0.3936498 0.1971072 0.1266438 ## 10LC 0.1672355 0.3081967 0.2184926 0.1500257 ## 10LD 0.2063845 0.4066703 0.1239434 0.1766188 ## 10NA 0.0000000 0.2855199 0.1124726 NA ## 10ND 0.0000000 0.2837204 0.2284123 NA ## 10RBL 0.1505455 0.2547647 0.2265650 NA ## quartz_off_screen ## 2 19.2 Associations with growth and spatial patterns ## [1] &quot;GrowthRate&quot; &quot;MH.EpCAM&quot; &quot;IF.EpCAM&quot; &quot;knn.EpCAM&quot; ## PDL1 LY PDL1+LY ## 0.50800711 0.96795666 0.03089095 ## knn.EpCAM knn.EpCAM..SMA knn.SMA knn.Unclass knn.EpMIN knn.EpStrRatio1 ## 10LB 39.96193 52.72253 16.94935 28.07623 39.96193 0.5735732 ## 10LC 32.12258 34.57734 17.87345 24.28626 32.12258 0.6124326 ## 10LD 34.33110 30.18133 15.97086 35.99495 30.18133 0.7438671 ## 10NA 23.80977 NA 27.49276 48.19205 23.80977 0.8660376 ## 10ND 26.20801 NA 30.06210 40.01762 26.20801 0.8717958 ## 10RBL 44.92703 67.36295 18.22774 26.07893 44.92703 0.5249056 ## knn.EpStrRatio2 knn.EpStrRatio3 knn.EpStrRatio4 IF.CD8 IF.EpCAM ## 10LB 2.3577258 1.3302993 5.4683183 0.20538263 0.2236555 ## 10LC 1.7972227 1.2716665 3.7317865 0.07842574 0.3168630 ## 10LD 2.1496080 1.3978193 4.0393825 0.28162217 0.2944373 ## 10NA 0.8660376 0.8660376 0.8660376 0.35915415 0.4808547 ## 10ND 0.8717958 0.8717958 0.8717958 0.30086657 0.4408878 ## 10RBL 2.4647619 1.3119416 6.1603904 0.12791040 0.2213380 ## IF.EpCAM..SMA IF.SMA IF.Unclass IF.EpMIN IF.EpStrRatio1 ## 10LB 0.08038836 0.5905018 0.3010823 0.08038836 0.3333713 ## 10LC 0.23757541 0.4768745 0.3714450 0.23757541 0.4435062 ## 10LD 0.25637789 0.5786730 0.1450209 0.25637789 0.3525981 ## 10NA NA 0.3207166 0.1112743 0.48085466 1.4993132 ## 10ND NA 0.1738438 0.1426298 0.44088779 2.5361139 ## 10RBL 0.20394931 0.5758915 0.4544651 0.20394931 0.2838246 ## IF.EpStrRatio2 IF.EpStrRatio3 IF.EpStrRatio4 MH.EpCAM MH.EpCAM..SMA ## 10LB 0.3787550 0.4531947 0.5148906 0.4189067 0.4131540 ## 10LC 0.6644578 0.7760354 1.1626506 0.4097456 0.4514649 ## 10LD 0.5088147 0.6596187 0.9518592 0.6622844 0.5987199 ## 10NA 1.4993132 1.4993132 1.4993132 0.4314681 NA ## 10ND 2.5361139 2.5361139 2.5361139 0.3700572 NA ## 10RBL 0.3843398 0.5453515 0.7384852 0.5503682 0.4903183 ## MH.SMA MH.Unclass MH.EpMIN MH.EpStrRatio1 MH.EpStrRatio2 ## 10LB 0.5718496 0.5168234 0.4131540 0.4252844 0.7325470 ## 10LC 0.4699867 0.5056881 0.4097456 0.4446740 0.8718238 ## 10LD 0.6967903 0.5894954 0.5987199 0.5112151 0.9504787 ## 10NA 0.4720285 0.3768075 0.4314681 0.9140722 0.9140722 ## 10ND 0.3088513 0.2854604 0.3700572 1.1981728 1.1981728 ## 10RBL 0.6513715 0.5568501 0.4903183 0.4820645 0.8449375 ## MH.EpStrRatio3 MH.EpStrRatio4 Treatment Growth Infil CD8frac ## 10LB 0.8447286 1.4550342 PDL1 growing Infiltrating 0.02289774 ## 10LC 0.9346237 1.8324147 PDL1 growing Infiltrating 0.01003407 ## 10LD 0.9733650 1.8097328 PDL1 stable Infiltrating 0.06810877 ## 10NA 0.9140722 0.9140722 PDL1 &lt;NA&gt; restricted 0.04656271 ## 10ND 1.1981728 1.1981728 PDL1 stable restricted 0.02271949 ## 10RBL 0.9115317 1.5976850 PDL1 growing restricted 0.02027148 ## GrowthRate TumSize knn.EpCAMcut MH.EpCAMcut IF.EpCAMcut CD8Fraccut ## 10LB 6.2285714 35 &lt;NA&gt; high low low ## 10LC 5.3571429 25 high low high low ## 10LD 1.9729730 10 high high high high ## 10NA NA 12 high high high high ## 10ND 0.3930533 15 high low high low ## 10RBL 4.9761905 40 &lt;NA&gt; high low low ## CD8 EpCAM EpCAM: SMA SMA Unclass CD8 EpCAM ## 10LB 0.02289774 0.2663149 0.1200304 0.3936498 0.1971072 0.02289774 0.2663149 ## 10LC 0.01003407 0.2960411 0.1672355 0.3081967 0.2184926 0.01003407 0.2960411 ## 10LD 0.06810877 0.1948931 0.2063845 0.4066703 0.1239434 0.06810877 0.1948931 ## 10NA 0.04656271 0.5554448 0.0000000 0.2855199 0.1124726 0.04656271 0.5554448 ## 10ND 0.02271949 0.4651478 0.0000000 0.2837204 0.2284123 0.02271949 0.4651478 ## 10RBL 0.02027148 0.3478534 0.1505455 0.2547647 0.2265650 0.02027148 0.3478534 ## EpCAM: SMA SMA Unclass Trichrome ## 10LB 0.1200304 0.3936498 0.1971072 0.1266438 ## 10LC 0.1672355 0.3081967 0.2184926 0.1500257 ## 10LD 0.2063845 0.4066703 0.1239434 0.1766188 ## 10NA 0.0000000 0.2855199 0.1124726 NA ## 10ND 0.0000000 0.2837204 0.2284123 NA ## 10RBL 0.1505455 0.2547647 0.2265650 NA ## quartz_off_screen ## 2 Update the metadata file "]]
